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Abstract 
The very old (aged 85 and over) are the fastest growing age group in the UK and most 
western societies. High incidence of disability and chronic diseases, financial constraints, 
polypharmacy, hospitalisation, body composition, sensory and gastrointestinal changes 
place very old adults at increased risk of malnutrition. However, very little is known about 
the dietary habits and health trajectories in this age group. Further, because one-carbon (1-
C) metabolism biomarkers are largely modifiable and have been associated with cognition, 
cardiovascular disease (CVD) and all-cause mortality, its modulation is of special interest. The 
overall aim of this PhD thesis was to provide an accurate snapshot of the dietary habits of 
the very old and examine health trajectories with respect to 1-C metabolism biomarkers in a 
unique cohort such as the Newcastle 85+ Study. Specifically, we aimed to explore the dietary 
habits of the very old; to investigate the association between folate, vitamin B12 and its 
status; and to investigate the cognitive decline and mortality trajectories with respect to 1-C 
metabolism biomarkers. The Newcastle 85+ Study is a longitudinal population-based study 
of health trajectories and outcomes over 5 years in 845 eighty-five year olds in North East 
England. Dietary intake was assessed at baseline on two non-consecutive occasions by a 24 
hour Multiple Pass Recall. Baseline red blood cell folate (RBC folate), plasma vitamin B12 and 
total homocysteine (tHcy) concentrations were determined by immunoassays. Cognitive 
function was assessed at baseline, 1.5, 3 and 5 years with the standardized mini-mental state 
examination and a battery of attention tests. Mortality was obtained from the Health and 
Social Care Information Service, UK. A high percentage of the participants did not meet the 
dietary reference values for energy, non-starch polysaccharides and several micronutrients. 
Cereals and cereal products were the top contributors for energy, most macronutrients and 
several micronutrients, including folate. RBC folate and tHcy were associated with better 
global cognition at baseline but were not predictive of the rate of decline over 5 years. 
Higher concentrations of tHcy in all participants and plasma vitamin B12 in women were 
associated with increased risk of all-cause and cardiovascular mortality. This thesis highlights 
the paucity of data and uncertainties in this age group. Furthermore, it demonstrates a link 
between 1-C metabolism biomarkers and age-related diseases.
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CHAPTER ONE 
 
1. Introduction 
1.1. Demographics of ageing 
The Western world is experiencing a major demographic shift and the United 
Kingdom (UK) does not escape this trend (1,2). Adults aged 65 and over comprise, on average, 
18% of the total population of the European Union (EU) (3). A similar figure to what is now 
observed in the UK, where the number of adults aged 65 and over increased by 17.3% in the 
last decade and now account for 17.4% of the 64.1 million people (4). As of 2014, there were 
22 countries in Europe with a life expectancy at birth higher than 80 years and 17 countries 
with a life expectancy at age 65 higher than 20 years (5). Life expectancy has not only been 
rising from birth but also at age 65. In the UK, since 1980-82, life expectancy at age 65 has 
increased from 13.0 years to 18.5 years for men and from 16.9 years to 20.9 years in women 
in 2013-2015 (6). This steady rise in life expectancy and decrease in later life mortality make 
very old people (those aged 85 and over) the fastest growing age segment of western 
societies (1,2). In the UK, there are now more than 1.5 million very old people (2.5% of total 
population) and the number is projected to rise to 3.3 million or 5% over the next 20 years 
(7).  
However, the increase in healthy life expectancy (number of years an individual can 
expect to live “disease free”) has not been as fast as life expectancy. UK’s life expectancy at 
birth increased by 6.2 years in men (from 72.9 to 79.1) and 4.3 years in women (from 78.5 to 
82.8) from 1990 to 2013 while healthy life expectancy increased by only 4.7 years for men 
(from 63.8 to 68.5) and 3.3 years for women (from 67.3 to 70.6) in the same period (8).  
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Maintaining health in old age is of utmost importance and lifestyle, which include 
dietary habits, might be responsible for some of the discrepancy between life expectancy 
and healthy life expectancy.  
Large cohorts of ageing from the Health and Retirement Study (HRS) (9) family of studies 
in Europe such as the Survey of Health, Ageing and Retirement in Europe (SHARE) with 
120000+ participants aged 50 and over from continental Europe and Israel (10), the English 
Longitudinal Study of Ageing (ELSA) which includes 10000+ individuals aged 50 and over (11), 
the Irish Longitudinal Study on Ageing (TILDA) with more than 8000 participants aged 50 and 
over (12), and the Northern Ireland Cohort for the Longitudinal Study of Aging (NICOLA) with 
more than 8000 adults aged 50 and over (13) are essential to better understand the ageing 
process and, its socioeconomic and psychobiological implications, as well as the societal 
demands. More specialized cohorts such as the Newcastle 85+ Study and the European 
Prospective Investigation into Cancer and Nutrition (EPIC) (14) can be of even greater 
importance to understand specific research questions, including nutritional, in older adults 
but also the very old.  
1.2. The role of nutrition in health and disease 
Food is central to the physical, psychological and social wellbeing at all life-stages, 
including in very old age. Diet is a major determinant in the development and 
management of a range of conditions and illnesses including type 2 diabetes, coronary 
heart disease (CHD), atherosclerosis, stroke, and cancer which are frequently the leading 
of causes of death in western societies and elsewhere (15,16).  
Obesity is primarily caused by an imbalance between energy intake and energy 
expenditure. Obesity is strongly associated with health complications such as 
cardiovascular disease (17), hypertension, hyperlipidaemia, type 2 diabetes, arthritis, 
urinary incontinence (18) and several types of cancer (19) in older adults (20). Dietary 
changes are important in all stages of life but also in older adults (21). An increase of 1-2 
portions of fruit and vegetables per day could cut cardiovascular diseases (CVD) risk by 
30% (22). The consumption frequency of foods or drinks high in sugar is a major causal 
factor for the development of dental caries in the absence of good dental hygiene (23). 
Further, high consumption of saturated and trans-fat increases low density lipoprotein 
(LDL) cholesterol and total cholesterol and decreases high density lipoprotein (HDL) 
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cholesterol, which is a risk factor for heart disease and may persist into very old age (24). 
Indeed, a 10% reduction in serum total cholesterol could reduce the risk of CHD by 25-
30% (25). Higher fat consumption is also associated with several types of cancer, mainly in 
the gastrointestinal tract (26). Several studies also point to a possible protective role of 
omega-3 fatty acids in relation to cardiovascular disease and dementia (27). High 
consumption of salt and alcohol are associated with high blood pressure (24). Indeed, a 
reduction of 6 mm Hg of systolic blood pressure is estimated to reduce the risk of heart 
attack by 15% and stroke by 40% (28). Micronutrient deficiencies have also been 
repeatedly associated with health and diseases. For example, a low vitamin D status may 
increase the risk of mortality (29), cognitive decline (30), several age-related diseases and 
low mood and depression (31); Low vitamin K intake and status was associated with low 
bone mass and increased fracture risk (32) and; low status of B vitamins, especially folate, 
B12 and B6 were associated with increased risk of stroke and cognitive decline (33). 
1.3. Nutritional guidelines and current challenges in very old age 
No specific nutritional guidelines for people aged 85 years and over are provided by 
major national authorities in the UK, EU (EFSA), USA or Australia. The Food and Nutrition 
Board, Institute of Medicine in the USA and the Scientific Advisory Committee on Nutrition 
(SACN) in the UK offer recommendations for those aged 70+ years and 75+ years, 
respectively, but only for specific aspects and, to a large extent, based on evidence from 
younger adults with unknown relevance for the very old (34,35). The British Nutrition 
Foundation (BNF) issued easy to follow health ageing tips for older adults that synthetize 
evidence-based recommendations (20,36):  
1) To diversify the diet and make it enjoyable; 
2) To frequently monitor weight and waist size;  
3) To maintain a good state of hydration by drinking 6-8 glasses (1.2L) of fluid per day 
on top of the water that is provided from food;  
4) To keep alcohol consumption to ≤14 units per week; 
5) To increase the dietary fibre intake with wholegrain cereals, legumes, vegetables and 
fruit;  
6) To reduce salt intake; 
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7) To reduce intake of saturated fatty acids and replace them, if needed, for mono and 
polyunsaturated fatty acids; 
8) To increase fish intake (two portions per week) and include oily fish, such as sardines, 
mackerel, tuna and salmon; 
9) To include calcium-rich foods in their diet; 
10) To maintain an optimum status of B vitamins; 
11) To take a vitamin D supplement per day if aged 65 and over; 
12) To stay physically (at least 150 minutes of moderate-intensity aerobic activity or 75 
minutes of vigorous intensity aerobic activity per week) and mentally active; 
13) To maintain a good dental health and;  
14) To avoid smoking. 
However, apart from the recommendation to take a daily vitamin D supplement, all 
other recommendations are applicable to the general population as well as older adults. This 
stresses the need to better understand the nutritional needs of older adults and the very 
old. 
The very old are a very heterogeneous population group ranging from healthy and 
active individuals with few disabilities to those with multiple diseases and multimorbidity (37). 
In the cross-sectional baseline assessment of the Newcastle 85+ Study, none of the 851 
participants were completely free of chronic diseases and the median number of diseases 
was 5 with an interquartile range (IQR) of 3-6 (37). This heterogeneity leads to both practical 
and conceptual difficulties in determining the nutritional needs of the very old and issuing 
public health recommendations with wide applicability. For example, there is limited 
understanding and agreement of the outcome measures that could be used to derive 
nutritional guidelines and nutritional adequacy in this age group. The vast majority of 
physical and cognitive functions tend to decline with age but the great inter-individual 
variability of when it happens and how rapid the decline is creates difficulties (but also 
opportunities) to assess biomarkers of healthy ageing (38,39). Further, the relationships 
between biomarkers and health outcomes are frequently considerably different between 
the very old and their younger counterparts. For example, whilst hypertension is a well-
established risk factor for cardiovascular disease (CVD) and mortality among younger adults, 
the same relationship was not observed in those aged 85 years and over (40). Indeed, among 
those aged 80 and over resident in nursing homes, low blood pressure was predictive of 
higher mortality (41). High blood pressure was also associated with greater cognitive 
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impairment in those younger than 75 but with better cognitive function in those aged 85 and 
over (42). Analyses of the Newcastle 85+ Study also found that low systolic blood pressure 
was associated with greater risk of cognitive impairment and disability count (43). Another 
good example is the relationship between telomere length and ageing. Several studies based 
on younger populations showed that telomeres shorten with age (44) and it was proposed 
that white blood cells’ telomere length acted as a biomarker of cumulative oxidative stress 
(45). However, the same relationship was not present in the very old as telomere length was 
not associated with morbidity and mortality in the Newcastle 85+ Study (43). Given the lack of 
data on dietary intake, nutritional status and associations with health trajectories in the very 
old, filling in this gap should take priority.  
1.4. Dietary assessment in the very old  
  To have an accurate record of the habitual food intake of an individual or group of 
individuals and understand nutrition-related outcomes, collection of robust dietary intake 
data is essential. Dietary assessment at any life stage presents challenges. Progress in the 
development of biomarkers could mean that, in the future, such challenges can be 
addressed by analysis of biological samples (46), but meanwhile dietary assessment remains 
labour intensive and costly. Methods at researchers’ disposal include weighed dietary 
intakes, estimated weight food diaries, food records and food frequency questionnaires 
(FFQ), with each method requiring varying levels of commitment, time and cognitive ability 
from the respondent, as well as the researcher’s time and skill. The question to be answered 
but also the population group to be assessed must be decisive factors when choosing the 
dietary assessment method.  
Assessing food choice and/or nutrient intake in older people, particularly in the very 
old (85 years and over), presents challenges. The respondent may have little or no 
involvement in food purchasing or preparation, cognitive impairment may restrict his/her 
ability to recall intake, and ability to record intake may be limited by physical limitations, 
sensory impairment and communication difficulties. The interviewer may need to rely on a 
carer as a proxy reporter of dietary intake which may then be compounded by the fact that a 
variable number of individuals or carers may be involved in the care of the respondent on 
any given day. Thus, in this age group, it is important that the chosen retrospective dietary 
assessment method is not dependent on self-recording of intake by participants. No 
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retrospective methods of dietary assessment had been used previously in this age group in 
the UK prior to the Newcastle 85+ Study (all the NDNS surveys used either 4 or 7 day 
weighed dietary intakes which is very resource intensive and imposes a large burden on 
subjects). A review of NDNS surveys showed that those of lower socio economic status and 
minority ethnic groups were under-represented (47). Therefore a survey to increase the 
response rate of those living on a low income was planned and a 24hr Multiple Pass Recall 
(24hr-MPR) method was used in the Low Income National Diet and Nutrition Survey (LIDNS) 
on 4 different occasions (48).  
 
1.5. Dietary intake in the very old in Europe 
Given the challenges that dietary assessment presents in the very old, it is not 
surprising that dietary intake data in this age group are scarce. Only a reduced number of 
population based studies have assessed dietary intake in the very old. However, some 
representative and non-representative studies have attempted to measure energy and 
nutrient intake of ≥80 or 85 year olds in Europe. The National Diet and Nutrition Survey 
(NDNS) of people aged 65 years old and over was carried out during 1994-95 in the United 
Kingdom and included two nationally representative samples drawn from adults aged 65 and 
over, free-living and institutionalised. Health background questionnaires, 4-d weighed diet 
record and blood/urine samples were collected. Four hundred and fifty nine free-living 
adults (172 men and 287 women) aged 85 and over completed the 4-d weighed diet record 
(49). The European Prospective Investigation into Cancer and Nutrition (EPIC)-Oxford study is 
a prospective cohort study that started in 1993 in Oxford, UK and was designed to 
investigate how diet influences the risk of cancer. A food frequency questionnaire (FFQ), 
lifestyle questionnaire and blood samples were collected. By the time of the third follow-up 
in 2010-2014, 1283 adults (411 men and 872 women) aged 80 and over had completed the 
FFQ (14). The Dutch National Food Consumption Survey of free-living older adults (DNFCS-
Older adults) was carried out in the Netherlands in 2010-2012 and included one nationally 
representative sample of ≥70 year olds. Two 24-hour recalls, anthropometric measures and 
background questionnaires were collected. In the DNFCS-Older adults, 225 adults ≥80 (103 
men and 122 women) completed both 24-hour recalls (50). The InCHIANTI Study was 
conducted in 1998 in Tuscany, Italy and included people aged 21–103 years old.  Data were 
collected on dietary intakes (FFQ), sociodemographic, lifestyle and functional characteristics. 
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Of the total 1436 that completed the FFQ, 170 (60 men and 113 women) were aged 85 and 
over (51). A German nationally-representative study was conducted on behalf of the German 
Ministry of Health in 1998 to describe the energy and nutrient intakes of older free-living 
adults. Sociodemographic, lifestyle and dietary assessment (3-d dietary record) were 
collected. Two hundred and eighty seven adults ≥85 (89 men and 198 women) had complete 
dietary records for the 3 days (52). The 2003 Austrian Nutrition Survey collected dietary data, 
using 3-d food records, on adults aged ≥85 and included 22 men and 93 women (53).  
Nutrient intake comparisons between these studies should be done cautiously as the 
dietary assessment methods, data collection period, sample size, food composition tables 
used and nutrient definitions are seldom the same. Of the six European studies with 
considerable numbers of ≥80 or 85 older adults, one used 24h recalls, two used FFQs and 
three used different forms of diet records. EPIC-Oxford had the largest number of ≥80 
(n=1283) of the six. The energy and selected nutrient intakes in European very old adults 
(≥80 or 85) is shown in Table 1.1. Men and women of the German Nutrition Survey and EPIC-
Oxford had the highest energy intakes (> 9.25 for men and 8.0 MJ for women). Overall, 41-
50% of the energy intake came from carbohydrates, 31-40% from fat and 14-16% from 
protein. Dietary fibre intake varied considerably between country and study and depended 
largely on the dietary assessment method (FFQ vs 24h recall) and analysis method [Englyst 
or the Association of Official Agricultural Chemists (AOAC)]. Vitamin and mineral intakes in 
the EPIC-Oxford were generally higher than in any other study but the choice of dietary 
assessment method and participants’ age have to be taken into account. The very old adults 
participating in the Dutch National Food Consumption Survey (DNFCS) had higher intakes of 
vitamin B12 and calcium than others (except EPIC-Oxford) (50). This was likely a reflection of 
the higher contribution of dairy products to calcium and vitamin B12 (50).
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Table 1.1. Intake of energy and selected nutrients intake in very old Europeans. 
 
Cohort 
Men Women 
Energy 
MJ/d 
Carb 
% 
Fat 
% 
Protein 
% 
Fibre 
g/d 
Folate 
µg/d 
B12 
µg/d 
D 
µg/d 
Ca 
mg/d 
Iron 
mg/d 
Energy 
MJ/d 
Carb 
% 
Fat 
% 
Protein 
% 
Fibre 
g/d 
Folate 
µg/d 
B12 
µg/d 
D 
µg/d 
Ca 
mg/d 
Iron 
mg/d 
NDNS 65+(49) 6.992 48.5 36.3 15.2 11.43 219 3.8 2.8 717 9.7 5.602 48.4 36.8 14.5 9.43 170 2.9 2.0 619 7.5 
EPIC1 (14) 9.84 49.7 31.4 15.5 24.53 466 7.5 4.2 1157 18.1 9.02 50.3 31.5 16.3 24.03 461 7.5 4.0 1147 17.0 
DNFCS(50) 7.40 41.4 34.0 16.4 20.0 464 4.9 3.9 1016 9.6 7.30 41.0 35.0 15.6 16.2 344 4.4 2.9 2030 8.3 
InCHIANTI1 (51) 7.38 50.0 29.0 16.0 17.2 228 - - 778 11.5 6.36 50.0 32.0 16.0 15.3 200 - - 701 9.6 
German Nutrition 
Survey(52) 
9.34 44.2 33.2 16.3 23.7 1235 - 3.8 721 13.3 8.07 42.6 35.0 16.2 19.9 1065 - 2.7 729 12.6 
Austrian Nutrition 
Survey1 (53) 
7.40 44.0 40.0 14.0 15.0 1745 4.0 3.4 642 10.0 7.10 43.0 40.0 16.0 16.0 1665 3.9 3.1 649 11.1 
Values are medians unless stated otherwise. NDNS 65+, National Diet and Nutrition Survey of people aged 65 years old and over; EPIC, European Prospective Investigation into Cancer and Nutrition; 
DNFCS, Dutch National Food Consumption Survey; InCHIANTI, Ageing in Chianti; Carb, Carbohydrates; B12, Vitamin B12; D, Vitamin D; Ca, Calcium. 
1 Values are means. 
2 Does not include alcohol. 
3 Non-starch polysaccharides. 
4 Only folic acid. 
5 Dietary folate equivalents (1 µg DFE = 1 µg food folate = 0.5 µg folic acid supplement on empty stomach = 0.6 µg folic acid from fortified food or as a supplement taken with meals). 
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1.6. Nutritional deficiencies - folate and vitamin B12 
In the UK, over 10% of older adults (aged 65 and over) and 18% of those aged 85 and 
over are at medium or high risk of malnutrition (54). Public expenditure on disease-related 
malnutrition is estimated to exceed £13 billion per year and over half is expended on older 
adults (55). The very old are at increased risk of nutritional deficiencies due to inherent 
biological ageing changes but also due to higher prevalence of chronic diseases and its 
treatments, polymedication, increased hospitalization and financial restrains, reduced 
mobility, social isolation and increased dependence on others (56). These health and social 
factors are coupled with loss of lean mass, relative increase in fat mass, loss of bone density, 
fluid and electrolyte regulation, decline in taste sensitivity and malabsorption (57). Further, 
age per se and some widely used drugs in this age group, have adverse effects on the sense 
of taste (58,59), on appetite (60) or on nutrient use by the body (61). For instance, poor appetite 
(62) may lead to inadequate protein intake, which is a risk factor for the development of 
sarcopenia (loss of muscle mass and function) and physical frailty (63). Although 
micronutrient malabsorption is not an inherent consequence of ageing, the absorption of 
pH-dependent vitamins and minerals, such as folate, vitamin B12, calcium, iron and β-
carotene might be partially compromised (64,65). For example, about 10-30% of older adults 
have atrophic gastritis (caused by Helicobacter pylori infection, long-term use of proton 
pump inhibitors, H2 receptor antagonists and biguanides) which leads to hypochlorhydria (64). 
This has a detrimental effect on acid-pepsin digestion and favours small bowel bacterial 
growth resulting in impaired vitamin B12 absorption (66). In addition, those with autoimmune 
atrophic gastritis produce antibodies against intrinsic factor which can lead to pernicious 
anaemia (66). Very old adults are also at higher risk of vitamin D deficiency due to reduced 
skin stores of 7-dehydrocholesterol (provitamin D) (coupled with reduced sun exposure), 
renal impairment and reduced renal conversion of its biologically inert to active form (i.e. 
25-hydroxyvitamin D to calcitriol), immobility, malnutrition and environmental factors 
[reviewed in Hill et al. (67)]. Micronutrient deficiencies contribute to disability, frailty and 
impaired physical function in very old adults (68).  
Energy requirements are largely dependent on energy expenditure so that the 
decrease in energy needs in later life mirrors the age-dependent fall in physical activity, 
through frailty, disability or disease. While energy requirements generally decrease with age 
there is currently no convincing evidence that vitamin and mineral requirements decrease as 
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well. In 2011, the Scientific Advisory Committee on Nutrition (SACN) released new energy 
dietary reference values (DRVs) for the UK. Energy DRVs were set at 11.5 MJ for men and 9.1 
MJ for women aged 25-34 and; 9.6 MJ for men and 7.7 MJ for women aged 75 and over 
(decrease of ~2MJ) (34). However, folate and vitamin B12 DRVs remain constant throughout 
adulthood according to the Committee on Medical Aspects of Food Policy (COMA) 1991 
report (69). This difference in requirements between energy and micronutrients adds to the 
potential risk for folate and vitamin B12 deficiencies in this age group.  
A review of micronutrient deficiencies in community-dwelling older adults (aged 65 
and over) living in western countries reported that 29% and 16% of men and, 30% and 19% 
of women had intakes below the Nordic Nutrition Recommendations (NRR) estimated 
average requirement (EAR) for folate (200 µg/d) and vitamin B12 (1.4 µg/d), respectively (70). 
Another review found out that 17-34% of older men and 18-46% of older women living in 
Europe had folate intakes below the EAR and 0-20% of older men and 0-21% of older women 
had vitamin B12 intakes below the EAR (71).  
Seventeen percent of free-living older adults participating in the National Diet and 
Nutrition Survey (NDNS) of people aged 65 and over were below the UK EAR for folate of 
150 µg/day (69,72) and 2% had vitamin B12 intakes below the EAR of 1.25 µg/day (69,72). Intake 
of most micronutrients was approximately 10% lower in those aged 85 and over than those 
aged 65-74 years old (49). The NDNS of people aged 65 and over concluded that the great 
majority of vitamin and mineral deficiencies increased with age and fall with socioeconomic 
status (72,73). The current NDNS rolling programme estimated that 1% of older adults (aged 65 
and over) were below the UK lower reference nutrient intake (LRNI) for folate (100 µg/d) 
and vitamin B12 (1.0 µg/d) and that 7.3% of men and 10.8% of women had red blood cell 
folate (RBC) concentrations below 340 nmol/L and 5.9% of men and women had serum 
vitamin B12 concentrations below 150 pmol/L (74). 
1.7. The role of folate and vitamin B12 in one-carbon metabolism and fatty 
acid synthesis 
The involvement of folate and vitamin B12 on 1-C metabolism and fatty acid 
synthesis is shown in Figure 1.1 Methionine synthase requires a form of vitamin B12, 
methylcobalamin (MeCbl) to convert 5-methylTHF to tetrahydrofolate (THF) (folate cycle) 
and homocysteine to methionine (methionine cycle). Methionine is further converted to S-
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adenosylmethionine (SAM), the main methyl donor in the brain. Another form of vitamin 
B12, adenosylcobalamin acts as a co-factor for methylmalonyl-CoA mutase and without it 
methylmalonyl-CoA would accumulate and not be converted to succinyl-CoA. For example, a 
build-up of methylmalonyl-CoA would have negative effects on the membranes of the 
neuronal tissue by two possible mechanisms: methylmalonyl-CoA would inhibit malonyl-CoA 
and result in decreased fatty acid synthesis and; be converted back to proprionyl-CoA (can 
substitute acetyl-CoA in fatty acid synthesis), resulting in the incorporation of odd chain fatty 
acids in the myelin sheath. Within the folate cycle, 10-formylTHF provides 1-C units for 
purine synthesis (guanine and adenine) and 5,10-methyleneTHF acts as a cofactor in the 
reaction leading to thymidylate synthase that will eventually synthesize pyrimidines 
(thymidine). Another intermediate in the 1-C metabolism, 5-methylTHF, acts as a co-
substrate in the conversion of homocysteine to methionine by methionine synthase. Vitamin 
B12 and folate deficiency also lead to hyperhomocysteinemia, reduced synthesis of 
neurotransmitters (dopamine, epinephrine and serotonin) and decreased synthesis of 
purines/pyrimidines.
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 Figure 1.1. Folate and vitamin B12 in one-carbon metabolism and fatty acid synthesis. 
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TCA, tricarboxylic acid cycle; THF, tetrahydrofolate; AdoCbl, adenosylcobalamin; FAS, fatty acid synthase; TS, thymidylate synthase; MeCbl, 
methylcobalamin; MAT, methionine adenyltransferase; SAH, S-adenosyl homocysteine.
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1.8. Folate 
Folate is essential in 1-C transfer reactions as the 1-C units are used for de novo 
biosynthesis of purines and pyrimidines, remethylation of homocysteine to methionine and 
interconversions of serine and glycine. Therefore it is no surprise that, besides the classic 
symptom of over folate deficiency, megaloblastic anaemia (75), folate deficiency/ 
insufficiency has been associated with neural tube defects (76), stroke (77,78), bone health  
(79,80), cognitive impairment (81-83), certain types of cancer (84-86) and all-cause mortality (87). 
Folate or vitamin B9 is a general term to describe water-soluble tetrahydrofolate 
(THF) derivatives belonging to the group of B vitamins. Folate is composed of a mixture 
between monoglutamates and polyglutamates and is naturally present in foods such as 
spinach, asparagus, kale, brussel sprouts, black-eyed peas and liver (88). Folic acid is the 
synthetic fully oxidized monoglutamate used in fortified foods and dietary supplements and 
it is more stable than folate (89) (Figure 1.2.). Naturally occurring folate is unstable and a 
variable degree of losses occur when light or oxygen or high temperatures are present (89).  
The UK has set the dietary reference value (DRV) for folate at 100, 150 and 200 µg/day for 
lower reference nutrient intake (LRNI), estimated average requirement (EAR) and reference 
nutrient intake (RNI), respectively for adults aged 50 and over (69). 
Intestinal and tissue absorption 
Ingested polyglutamated folate is hydrolyzed to a monoglutamated form and 
absorbed in the jejunum by an active and pH-dependent mechanism with the aid of the 
proton-coupled folate transporter (PCFT1) (90). Folates that are not initially absorbed are 
later absorbed in the ileum by passive diffusion (91,92). Once the folate monoglutamates have 
gone through the jejunal brush border membrane, these are transported to the liver via 
portal circulation where they are stored and released to peripheral tissues when needed. 
Tissue absorption is cell-specific but generally also occurs through active transport with the 
presence of folate transporters (folate receptors, reduced folate carrier and PCFT1). 
Bioavailability  
Folate bioavailability is dependent on the food matrix, stability of labile folates, 
presence of vitamin C and folate-binding proteins and folate pool sizes (89,93,94). Nonetheless, 
there is a consensus that folic acid is better absorbed than dietary folate (95). The US Institute 
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of Medicine estimated that the absorption efficiency of folic acid from supplements (if taken 
with food) or from fortified food was 85% and 100% from supplements taken on an empty 
stomach (89) whilst dietary folate absorption efficiency was 50% (89,94). In an attempt to 
overcome the different bioavailabilities of folate and folic acid in different conditions, 
dietary folate equivalents (DFE) were introduced where 1 µg DFE equals 1 µg of dietary 
folate or 0.6 µg folic acid from fortified foods/ supplements on a full stomach or 0.5 µg folic 
acid consumed while fasting (89).  
Biomarkers of status 
Folate status can be assessed by measuring plasma/ serum folate or by measuring 
folate in erythrocytes with red blood cell (RBC) folate. Plasma folate concentrations can be 
analysed by high-performance liquid chromatography (HPLC), by liquid chromatography–
mass spectrometry (LC-MS), by liquid chromatography-tandem mass spectrometry (LC/MS-
MS), or, far more frequently, by microbiological assay or folate-binding protein assays (such 
as chemiluminescence assays, radioassays and ion-capture assays) (96). The chromatography 
methods have the added advantage that they are able to measure different folate species 
while the microbiological assay and protein-binding assays only measure total folate (97). 
However, the chromatography methods are often costly, need time-consuming extraction 
procedures or large volumes of plasma (97). Folate concentrations obtained from the protein-
binding assays are lower than those from microbiological assays and show a wide variation 
between different kits (98). The Microbiological assay [using a strain of Lactobacillus 
rhamnosus (formerly Lactobacillus casei), Streptococcus faecium or Pediococcus cerevisiae] is 
generally considered to be the “gold standard” (99).  
Folate measured in plasma/ serum reflects short-term folate intake and folate 
measured in erythrocytes is a sensitive indicator of long-term status (preceding 120 days) 
and reflects tissue folate stores (33,100). A serum folate concentration <10 nmol/L or a RBC 
folate concentration <340 nmol/L is broadly considered as deficient (89).  
Genetic variation in folate status 
Several polymorphisms of genes coding for enzymes and transport proteins involved 
in 1-C metabolism have been identified and reported to have a detrimental effect on folate 
status. The C677T methylenetetrahydrofolate reductase (MTHFR) single nucleotide 
polymorphism (SNP) (rs1801133) is the most widely studied. The MTHFR gene encodes an 
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enzyme of the same name that is responsible for the reduction between 5,10-methylene-
tetrahydrofolate and 5-methyltetrahydrofolate (the major form of folate in plasma) 
providing 1-C unit in the process. Homozygosity for the T allele equates to a reduction of 
~70% in the MTHFR enzyme activity which is translated to 20-25% lower serum folate 
concentrations than in those with the CC genotype. The reduction in MTHFR enzyme activity 
is less dramatic for the A1298C mutation (rs1801131) in the same gene. However, a 
synergistic effect may exist between the two SNPs where individuals with both mutations 
have the highest tHcy and lowest RBC folate concentrations (101). The 19-bp deletion of 
dihydrofolate reductase (DHFR) was associated with a modest increase in folate status in 
women but not in men (102) and not in all studies (103). A SNP in the solute carrier family 19 
member 1 (which encodes the reduced folate carrier 1 enzyme) from the G allele to the A 
allele (rs1051266) was associated with lower RBC folate concentrations (104).   
Other SNPs such as methionine synthase reductase A66G (rs1801394), glutamate 
carboxypeptidase II C1561T (rs61886492), MTR A2756G (rs1805087) and MTRR A66G 
(rs1801394) may also influence folate status (89).  
Figure 1.2. Chemical structure of folic acid (C19H19N7O6).  
 
C, carbon; H, hydrogen; N, nitrogen O, oxygen. 
1.9. Vitamin B12 
Vitamin B12 acts as a coenzyme for methionine synthase (MS) and methylmalonil-
CoA mutase. Vitamin B12 is closely interlinked with folate through the MS co-enzyme, 
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having been associated to many of the same diseases, i.e. megaloblastic anaemia (105), 
neuropathy (106), cognitive impairment (107), CVD (108) and bone health (109). 
Vitamin B12 or cobalamin is a water-soluble vitamin belonging to the B vitamins 
group. All compounds with vitamin B12 activity are generally called cobalamins due to the 
cobalt-containing chemical structure (Figure 1.3) but only two act as co-enzymes in human 
metabolism; methylcobalamin and 5-deoxyadenosylcobalamin (110). Hydroxocobalamin is 
considered an intermediate and cyanocobalamin is a synthetic compound used in dietary 
supplements and food fortification (110). Humans, animals, plants and fungi cannot synthesize 
vitamin B12, only bacteria and archaea are able to do so. However, due to bacterial 
symbiosis, some foods are natural sources of B12 such as dairy products (milk, yogurt, and 
cheese), organ meat (liver, kidneys, giblets, and pate), meat (beef, pork), fish and seafood 
(clams, oysters, mackerel and herring). Vitamin B12 is not known to be destroyed by heat 
but can be destroyed by light. Strict vegetarians and vegans may have to resort to fortified 
foods such as soy milk and breakfast cereals to achieve the recommended daily intake of 
vitamin B12 (88,111). DRVs for vitamin B12 vary depending on the authority setting them but 
they have been set for adults older than 50 years at 1.0, 1.25 and 1.5 µg/day for the lower 
reference nutrient intake (LRNI), estimated average requirement (EAR) and reference 
nutrient intake (RNI) in the UK, respectively (69). 
Intestinal and tissue absorption 
Vitamin B12 has to undergo a complex process in order to be absorbed in the distal 
ileum. Bound to protein in food, vitamin B12 has to be released by pepsin and hydrochloric 
acid in the stomach (vitamin B12 in fortified foods does not have to go through these steps 
as it is already in the free form). The ensuing free form of vitamin B12 binds to haptocorrin, 
forming a B12-haptocorrin complex. This complex is later broken down in the duodenum by 
pancreatic proteases which enable vitamin B12 to bind to the glycoprotein intrinsic factor 
(IF), be recognized (by cubilin) and absorbed by endocytosis in the enterocytes of the distal 
ileum (66,112).  
Once absorbed, most of the vitamin B12 binds to haptocorrin (70-90%) while the 
remaining 10-30% bind to transcobalamin II and III forming holotranscobalamin (66,113). Only 
holotranscobalamin can be taken up by tissue cells by an endocytosis mechanism through 
specific calcium-dependent transcobalamin receptors (114). The haptocorrin-bound vitamin 
B12 acts as a circulating storage but most of the vitamin B12 is stored in the liver (around 5 
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mg or 50% of total body stores). Adenosylcobalamin is the major form of vitamin B12 
present in the liver but hydroxocobalamin and methylcobalamin are present as well. Other 
organs such as the kidney, brain and spleen can also store a relatively high amount of 
vitamin B12. Around 1.4 µg per day of vitamin B12 is believed to be secreted by the liver into 
the bile but because of the enterohepatic circulation, once the bile enters the small 
intestine, vitamin B12 will once again bind to IF and be reabsorbed in the ileum (up to 90%). 
Even so, the highest loss of vitamin B12 occurs through faeces and whenever circulating 
vitamin B12 exceeds blood’s capacity, the excess is also secreted in urine (115). Since intake of 
vitamin B12 is small relative to its body stores, vitamin B12 deficiency can take years to 
manifest (116).  
Bioavailability 
Ileal receptors saturate with intakes of 1.5 and 2.5 µg of vitamin B12 per meal. It is 
estimated that only 50% and 5% of vitamin B12 is absorbed with intakes of ~1 and 25 µg, 
respectively, and only ~1% is be absorbed by passive diffusion if IF is not present. The 
bioavailability of vitamin B12 in any form or dose is estimated to be roughly 40% in healthy 
adults with intact IF secretion (112).  
Biomarkers of status and function 
Vitamin B12 status can be assessed by vitamin B12 measured in plasma/ serum, 
holotranscobalamin or by methylmalonic acid (MMA) which is a functional biomarker. While 
plasma/ serum vitamin B12 measures all forms of vitamin B12, holotranscobalamin only 
measures the metabolically active fraction of vitamin B12. MMA concentrations are elevated 
with deficient vitamin B12 levels because the conversion of methylmalonyl-CoA to succinyl-
CoA is a vitamin B12-dependent process. Deficiency of vitamin B12 leads to accumulation of 
methylmalonyl-CoA which is further metabolised to MMA (33,100). The European Food Safety 
Authority (EFSA) and other authorities have broadly classified plasma vitamin B12 deficiency 
in adults as a concentration <148 pmol/L (112). 
Genetic variation in vitamin B12 status 
FUT2 encodes galactoside 2-alpha-L-fucosyltransferase 2 which is involved in the 
regulation of the H antigen (117). FUT2 GG genotype was associated with higher vitamin B12 
status, especially in women (118). Transcobalamin 1 and transcobalamin 2 are circulating 
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vitamin B-12 binding proteins and rs526934 and rs757874, respectively were associated with 
lower vitamin B-12 status (117). Several other genes polymorphisms affect vitamin B12 status, 
such as CBS (rs2124459), CD320 (rs2336573), CUBN (rs11254363), DNMT2 (rs2295809) and 
PON1 (rs3917577). CBS encodes cystathionine β-synthase which converts homocysteine to 
cystathionine, the CD320 receptor binds to holotranscobalamin and internalises it by 
endocytosis, CUBN encodes cubilin which is the receptor for the vitamin B12-IF complex, 
DNMT21 is a RNA methyltransferase and PON1 is an esterase that can remove detrimental 
oxidised-lipids (117,119). Zinck et al. reported that individuals with SNPs in CBS (rs2124459), 
CD320 (rs2336573), CUBN (rs11254363), DNMT2 (rs2295809), and PON1 (rs391757) were 
less likely to have inadequate plasma vitamin B12 concentrations (<220 pmol/L) than the 
reference major allele (117). 
Figure 1.3. Chemical structure of vitamin B12 (cyanocobalamin) (C63H88CoN14O14P).  
 
C, carbon; Co, cobalt; H, hydrogen; N, nitrogen O, oxygen; P, phosphorus. 
1.10. Homocysteine 
Elevated homocysteine concentrations have been associated with cardiovascular 
diseases(120,121), fracture risk (122) and impaired cognition (33,107,123). Although the meaning of 
elevated homocysteine and whether it is a cause, an intermediate or a consequence of 
disease severity is still debatable, reduction of hyperhomocysteinemia is frequently pointed 
out as a potential explanation for the association between B vitamins and health outcomes. 
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Homocysteine is a potentially cytotoxic non-protein sulphur-containing α-aminoacid derived 
from methionine catabolism (Figure 1.4.). Homocysteine is central to two pathways: the 
methionine or remethylation cycle and the transsulfuration pathway. In the methionine 
cycle, homocysteine is remethylated to methionine by methionine synthase, this is further 
converted to S-adenosylmethionine (SAM) which donates methyl groups by being 
demethylated to S-adenosylhomocysteine which is then hydrolysed back to homocysteine 
(Figure 1.1). In liver and kidneys, homocysteine is converted to cystathionine and further 
hydrolysed to cysteine in the transsulfuration pathway. Because of the involvement of B 
vitamins but especially folate and vitamin B12 in the remethylation of homocysteine, dietary 
intakes of these vitamins are inversely associated with total homocysteine concentrations. In 
fact, supplementation with folic acid typically lowers homocysteine concentrations by 13-
25% with a further reduction of 7% with the addition of vitamin B12 (124), making it a 
functional marker of folate and vitamin B12. Homocysteine can be assessed by measuring 
the concentration of plasma total homocysteine (tHcy). Hyperhomocysteinemia is frequently 
defined as a tHcy concentration >15 μmol/L (125).   
Figure 1.4. Chemical structure of homocysteine (C4H9NO2S). 
 
C, carbon; H, hydrogen; O, oxygen; S, sulfur. 
1.11. Relationship between folate and vitamin B12 intake, and status 
The complexity of the dose-response relationships between intake and status are 
influenced by limitations in dietary assessment, food composition data, choice of 
biomarkers, genotypic variation, bioavailability and complex metabolic pathways. In 
addition, several single nucleotide polymorphisms (SNP) modulate folate and vitamin B12 
status. For example, homozygosity of the T allele (measured in the forward orientation) 
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(rs1801133) of the MTHFR gene (which encodes methylenetetrahydrofolate reductase) is 
associated with low folate status (117).  
There is conflicting evidence about relationships between folate and vitamin B12 intake 
and, folate and vitamin B12 status, respectively, in older adults. Some studies report a 
significant association between folate and vitamin B12 intake and status in older adults 
(83,126-130) while others do not (131-133). Differences in folate and vitamin B12 bioavailability 
from total diets and specific food sources may provide a partial explanation for the observed 
discrepancies. Folate bioavailability from foods is substantially lower than that from 
supplements or from foods fortified with folic acid with estimated bioavailability of 50 and 
85%, respectively (89). If intrinsic factor (IF) secretion is intact, approximately 40% of vitamin 
B12 is absorbed (112).  
1.12. One-carbon metabolism and cognition 
There are now 46.8 million people with dementia worldwide and that number is 
predicted to reach 74.7 million by 2030 (134). The Cognitive Function and Ageing Study (CFAS) 
II estimated that there were 670,000 older adults with dementia in 2011 in England alone 
(135). Despite some evidence of reduction in the prevalence and incidence of dementia 
(135,136), it is predicted that cases of dementia will increase primarily for the following 
reasons: (a) dementia incidence doubles every 6.3 years after 60 years old (134); (b) the 
population is ageing worldwide due predominantly to the rise in the numbers of  the very 
old (aged 85 years and over), the fastest growing age segment in the United Kingdom and 
most western societies (7). Dementia is one of the most important predictors of disability and 
poses a major societal challenge (137). Since cognitive decline and dementia impact quality of 
life detrimentally and are currently not treatable, research priorities have focused on 
preventing or delaying the onset of dementia through modifiable risk factors, such as 
nutrition (138). 
Folate and vitamin B12 are central to one-carbon (1-C) metabolism. Inadequate or 
aberrant 1-C metabolism may be associated with cognitive function through mechanisms 
such as hyperhomocysteinemia (139), reduced synthesis of neurotransmitters, 
phosphatidylcholine and pyrimidines (140), altered DNA methylation patterns (141), reduced 
fatty acid synthesis and incorporation of odd chain fatty acids into the myelin sheath (142).  
Although the biological rationale for associations between folate, vitamin B12 and 
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homocysteine with cognitive function seem plausible, conflicting results have been reported. 
Folate, vitamin B12 and homocysteine have been associated with cognitive decline in some 
longitudinal studies (82,123,143) but not all (144-146), in some randomized controlled trials (RCTs) 
(83,147), for one vitamin but not for the other or only for certain cognitive domains. 
1.13. One-carbon metabolism and mortality 
Folate provides 1-C units for de novo biosynthesis of purines and pyrimidines, 
transmethylation of homocysteine to methionine and interconversions of serine and glycine 
(148). Vitamin B12 acts as a coenzyme for methionine synthase (MS), responsible for the 
transmethylation of homocysteine to methionine and consequent production of S-
adenosylmethionine (SAM) and methylmalonyl-CoA mutase, which converts 
methylamalonyl-CoA to succinyl-CoA in the fatty acid synthesis pathway (148). SAM is the 
universal methyl donor for methylation of all cellular macromolecules, including DNA and 
histones, and therefore plays a critical role in regulation of gene expression (148). Given the 
close involvement in 1-C metabolism, it is no surprise that folate and vitamin B12 have been 
associated with CVD, cancer and all-cause mortality. A recent meta-analysis pooling data 
from 30 randomized controlled trials (RCTs) reported that folic acid supplementation 
reduced CVD risk by 4% and the risk of stroke by 10% (149). Systematic reviews and meta-
analyses have shown that raised homocysteine concentration and low folate status are 
associated with increased cancer risk whilst (150) higher folate intake or status is associated 
with lower risk at some cancer sites (85,86). However, randomised controlled intervention 
studies show no effect of supplemental folic acid on cancer risk (151). The picture is similar for 
vitamin B12. Some have found that high concentrations of vitamin B12 are associated with 
all-cause mortality (152,153) and cancer (particularly haematological and smoking and alcohol 
related cancers) (154,155) while others did not (156-159). It is hypothesized that “very high” 
vitamin B12 concentrations may be due to i) increased release of vitamin B12 from storage 
ii) upregulation of haptocorrin and transcobalamin synthesis, iii) decreased clearance of 
vitamin B12 from plasma and/or iv) diminished binding affinity of vitamin B12 for 
transporter proteins (all of which may be associated with disease development) but no clear 
mechanism has been determined (114,160). 
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1.14. Objectives 
There is a dearth of data exploring the dietary intake and nutritional status of very old 
adults and its association with health outcomes. Therefore, the overall objective of this PhD 
thesis was to provide an accurate snapshot of the dietary habits of the very old and examine 
health trajectories with respect to 1-C metabolism biomarkers in a unique cohort such as the 
Newcastle 85+ Study. More specifically, this PhD aimed to: 
 CHAPTER 3 and 4 
1) Describe the daily intake of energy, macronutrients, non-starch polysaccharides, 
vitamins and minerals in the very old at baseline; 
2) Determine the principal food sources of macro and micronutrients; 
3) Investigate how dietary intakes compare against the current UK DRVs; 
4) Explore socioeconomic and lifestyle influences on dietary intake.  
 CHAPTER 5 
1) Determine the prevalence of “inadequate” folate and vitamin B12 intake and 
status; 
2)  Examine the associations between the top contributing dietary sources of folate 
and vitamin B12, and status; 
3) Investigate whether high dietary intakes of folate and vitamin B12 are associated 
with reduced risk of “inadequate” status. 
 CHAPTER 6 
1) Investigate the association between red blood cell folate (RBC folate) 
concentrations and cognitive impairment and the rate of cognitive decline in 
global and attention-specific cognition over 5 years; 
2) Examine the association between plasma vitamin B12 concentrations and 
cognitive impairment and the rate of cognitive decline in global and attention-
specific cognition over 5 years; 
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3) Explore the association between total homocysteine (tHcy) concentrations and 
cognitive impairment and the rate of cognitive decline in global and attention-
specific cognition over 5 years. 
 CHAPTER 7 
1) Determine the association between RBC folate concentration and all-cause and 
cardiovascular specific mortality over a 9-year period; 
2) Explore the association between plasma vitamin B12 concentration and all-cause 
and cardiovascular specific mortality over a 9-year period; 
3) Investigate the association between tHcy concentrations and all-cause and 
cardiovascular specific mortality over a 9-year period. 
1.15. Summary 
The very old are now the fastest growing age group of western societies. However, 
very little is known about the dietary habits in this age group. Many studies arbitrarily 
exclude very old people for no reason other than age (161), whilst others only include a small 
number, resulting in a lack of statistical power. Further, healthy life expectancy has not seen 
such a rapid rise as life expectancy, which raises the need for new strategies to postpone the 
age-related morbidity. Modulation of modifiable risk factors, such as nutrition and 1-C 
metabolism biomarkers is of special interest. Given the close involvement in 1-C metabolism, 
it is no surprise that folate, vitamin B12 and homocysteine have been associated with 
cognition, cardiovascular disease (CVD) and all-cause mortality. However, the current 
evidence is inconclusive and most is based on studies in younger populations. 
Chapter 2 will describe general methods that are common to two or more 
experimental chapters throughout this thesis. Chapter 2 will describe the Newcastle 85+ 
Study database which was used for all analyses, the study’s recruitment and cohort 
retention profile and general strengths and weaknesses; the dietary assessment and food 
group allocation; blood collection, 1-C metabolism biomarkers and genotyping; and general 
statistical analysis.
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CHAPTER TWO 
 
2. General Methods 
2.1. The Newcastle 85+ Study 
The Newcastle 85+ Study is a longitudinal population-based study of health 
trajectories and outcomes in the very old. All people turning 85 in 2006 (born in 1921) who 
were permanently registered with the 64 general practices within Newcastle upon Tyne or 
North Tyneside primary care trusts (North East England) were approached. The study’s initial 
aim was to provide a comprehensive snapshot of the very old and investigate their health 
trajectories and outcomes at different phases of follow-up in the hope of better 
understanding the different aspects of the ageing process.  
Recruitment profile 
Most (83%) of the 64 general practices agreed to participate (n=53). Participating 
general practitioners were asked to exclude people with an end-stage terminal illness and 
individuals who were deemed unsafe for a research nurse to visit alone (37). Cognitively 
impaired or institutionalized participants were not excluded. All eighty-five year olds 
remaining (who were not excluded) were sent a letter of invitation. In total, 1459 people 
were invited to participate, 1042 were recruited and 845 (319 men and 526 women) had 
multidimensional health assessment and GP record review data. A detailed flowchart with 
the recruitment profile and the sample available for the most important exposures and 
outcomes of interest used in this thesis is shown in Figure 2.1. 
The multidimensional health assessments were carried out by one of the eleven 
trained research nurses at the participant’s usual residence, including home or institution. 
Three interviews lasting ≈90 min, including questionnaires (socioeconomic, health, diet 
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intake and lifestyle variables), measurements and functional tests (anthropometry, 
cognition, physical function, pulmonary and cardiovascular) were completed at each phase 
(for study questionnaires visit http://research.ncl.ac.uk/85plus). A fourth visit was done to 
collect a fasting blood sample (nutrition, health and ageing biomarkers). The mean duration 
of the multidimensional health assessment (excluding blood collection and body weight 
measurement) was 206 minutes over 25 days (37). An overview of the variables collected in 
the Newcastle 85+ Study from baseline to phase 4 is shown in Appendix E. All computerized 
and paper GP records, including hospital correspondence and the results of investigations, 
were reviewed by a research nurse for diseases, medication use and recent use of general 
practice services (last 12 months). Inter-rater agreement of GP record data extraction was 
examined for 24 randomly selected records. Intra-class correlations for a core set of diseases 
(angina, myocardial infarction, heart failure, hypertension, and stroke) ranged from 0.45 to 
0.79 which indicated a moderate or good agreement between research nurses (37). Only total 
number of prescribed medications showed some disagreement between the research nurses 
but not type of medication and number of consultations with a GP/ practice nurse and in 
which setting (37).  
Assessment and retention profile 
Data were collected at baseline (phase 1, 2006/2007), 18 (phase 2, 2007-2009) (GP 
records were not reviewed on this phase), 36 (phase 3, 2009/2010) and 60 months later 
(phase 4, 2011/2012). The final analytical sample with complete baseline (phase 1) 
multidimensional health assessment and GP record review (minus 2 participants who 
withdrew from the study) was 845 (81% of the original 1042 that were recruited). The 
recruited cohort was socio-demographically representative of the general UK population (37). 
From phase 1 to phase 2, 25% (n=215) of the participants withdrew or died, from phase 2 to 
phase 3 23% (n=147) and from phase 3 to phase 4 29% (n=139) (Figure 2.1).  
This study was conducted according to the guidelines laid down by the Declaration of 
Helsinki and all procedures involving human subjects were approved by the Newcastle and 
North Tyneside local research ethics committee (06/Q0905/2). Written informed consent 
was obtained from all participants, and when unable to do so, consent was obtained from a 
carer or a relative according to the UK Mental Capacity Act 2005.  
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General health characterization at baseline 
At baseline, most participants were community-dwelling while 10% lived in care 
homes (37). Hypertension, atherosclerotic disease, osteoarthritis, and cataracts were very 
prevalent in the participants of the Newcastle 85+ Study, with each close to 50% (37). No 
participant was completely free of chronic diseases and almost 90% had at least three 
diagnosed diseases (37). The median number of chronic diseases was 5 (interquartile range: 3-
6). Women had a higher disease count than men. Sixty percent reported to have hearing 
impairment, 38% to be visually impaired, 38% had had a fall in the last year and 21% had 
severe or profound urinary incontinence (37). Despite the relatively high number of diseases 
and conditions, almost 80% rated their health as good, very good or excellent compared to 
others of the same age (37).  Further details of the study have been reported elsewhere 
(35,37,161).   
Strengths and weaknesses of the Newcastle 85+ Study 
The Newcastle 85+ Study is a unique cohort owing to the age group, the large 
number of participants and the extensive multidimensional health data. The high response 
rate achieved in recruitment and retention is also an important strength, especially 
considering the age group and extensive assessment involved (161). A single-aged cohort 
offers several advantages such as minimizing the effect of age variability but it limits 
generalizations. In 1921 life expectancy was 56.2 years for men and 60.0 years for women 
and only 18% of men and 33% of women were expected to reach 85 years old. Cohort life 
expectancy (which take into account mortality rates in later years) set it at 61.3 for men and 
68.0 for women (162). It is impossible to fully exclude any survival or length bias that arose 
due to selective survivability as all participants were 85 or turned 85 at recruitment (~20 
years beyond cohort life expectancy), an age where mortality rates are high (163).  
The Newcastle 85+ Study cohort was socio-demographically representative of the UK 
(comparison between sociodemographic status of the Newcastle 85+ Study and the 2001 
national census) and included institutionalised and cognitively impaired very old (two 
commonly excluded characteristics in other cohorts). The participants were all from 
Newcastle-upon-Tyne and North Tyneside (mainly urban areas) and of a predominantly 
white background. Generalisations to other geographical locations and to populations with 
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different ethnic makeup should be undertaken with caution. The rapid processing of blood 
samples after venipuncture is another strength of this study.  
2.2. Dietary intake assessment and food group allocation 
A pilot study conducted between 2003 and 2004 in 171 eighty five year old 
Newcastle-upon-Tyne residents informed the choice of the dietary assessment method to be 
used (Food Frequency Questionnaire (FFQ) or repeated Multiple Pass 24h Recall (24hr-MPR)) 
in the Newcastle 85+ Study (164). Four criteria were used: i) Energy intake (EI) relative to 
estimated basal metabolic rate (BMR), ii) EI and daily intake of selected nutrients vs. the 
1994-95 UK National Diet and Nutrition Survey (NDNS) dietary intake data for community-
dwelling 85 and older adults (49), iii) time burden for research nurses/ nutrition researchers 
and iv) utility and acceptability of each method by the participants and research nurses. 
Against these four criteria, the repeated 24hr-MPR was superior to the FFQ quantitatively 
and qualitatively (164). The 24hr-MPR provides detailed retrospective information on food 
eaten while only requiring short-term memory. Participant burden is also minimal (especially 
against weighed or unweighed food diaries) (165), it is completed by an interviewer and not 
the responder (166), and the conversational nature of the process reduces the risk of 
overlooking details. However, the 24hr-MPR also presents disadvantages such as still relying 
on memory, having to estimate portion size, requiring trained interviewers and tiresome 
data preparation/coding. From the available options at the time of dietary assessment in the 
Newcastle 85+ Study, the 24hr-MPR was an acceptable, and potentially preferred method, of 
dietary assessment in this age group (164).  
Dietary intake was assessed by 24 hour Multiple Pass Recall (24hr-MPR) on two non- 
consecutive occasions (one week apart and on different days of the week) by trained 
research nurses and portion sizes estimated using the “Photographic Atlas of Food Portion 
Sizes” (167). The repeated 24hr-MPR assesses dietary intake in the previous 24 hours and 
includes 3 passes to ensure that every detail is recorded. Pass 1/ quick list: the participant 
was asked to recall the food and drink they had consumed in the previous 24 hours, while 
thinking of what they had done. An initial prompt was given for commonly omitted foods, 
such as snacks and sweets, and the whole intake was recorded without interruption. Pass 2/ 
detailed record: the interviewee was asked to provide more detail, including the time and 
occasion of everything recorded in the quick list. Portion sizes were also estimated during 
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this pass. Pass 3/ review: all the recorded food and drink, portion sizes, time of meals and 
method of confection (if appropriate) were reviewed by the interviewer and participant. 
Mean time to complete a single 24h-MPR was 22 minutes. Dietary assessment of 
participants in residential care and those requiring proxy respondents were included 
successfully (168). Eighty five percent and 90% of the participants believed that the 24hr-
MPRs reflected their usual food and drink intake, respectively. All dietary intake data were 
independently double entered. Any discrepancies were identified, checked against original 
records and corrected prior to data analysis. Individual foods were coded and allocated to 15 
first level food groups [cereals and cereal products (grains), milk and milk products, eggs and 
egg dishes, oils and fat spreads, meat and meat products, fish and fish dishes, vegetables, 
potatoes, savoury snacks, nuts and seeds, fruit, sugar, preserves and confectionery, non-
alcoholic beverages, alcoholic beverages and miscellaneous (soups, sauces and remaining 
foods that did not belong in other food groups)], 48 second level and 132 third level food 
groups with increasing specificity (Appendix A). Use of the 24-MPR was consented by 805 
participants and complete dietary intake data (without protocol violation and 2x24hr-MPRs) 
were available for 793 participants. 
2.3. Blood collection, one-carbon metabolism biomarkers and genotyping 
Blood samples were taken after an 8h overnight fast at baseline. Forty mL of blood 
was drawn from the antecubital vein between 7:00 a.m. and 10:30 a.m., placed on 
ethylenediamine tetraacetic acid (EDTA) tubes and taken immediately to the laboratory 
(95% of the samples reached the laboratory within 1 h) (43). 778 participants had blood taken 
and 95% provided fasting samples (37). As part of the full blood count, red blood cell count, 
white blood cell count and platelets were analysed and haematocrit calculated. RBC folate 
concentration analysis required an extra manual pre-treatment where blood samples were 
treated with a folate lysis reagent (ascorbic acid) and incubated for 90 min. Red blood cell 
folate (RBC folate) and plasma vitamin B12 concentrations were determined by a two-step 
assay using a chemiluminescence microparticle immunoassay on an Abbott ARCHITECT 
analyser and data were available for 752 and 753 participants, respectively. RBC folate was 
further adjusted for haematocrit. tHcy concentration was measured by an Abbot IMx 
immunoassay at baseline and available for 766 participants (169). All biochemical analyses 
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were done by the department of clinical biochemistry at Newcastle Royal Victoria Infirmary 
(Newcastle-upon-Tyne, UK) (170). 
Whole blood DNA was extracted by means of QiaGEN Amp Maxi DNA Purification Kit. 
As part of the EU Longevity Genetics Consortium, genome-wide association studies (GWAS) 
were performed on 765 participants from the Newcastle 85+ Study using Illumina Omni 
genotyping arrays. Data were obtained from 710 individuals and after quality control, 642 
individuals were retained for the final analysis (171). 
2.4. Other socioeconomic, health and lifestyle variables 
Socioeconomic 
 Multidimensional health questionnaires recorded sex (male/ female), housing type 
[standard, sheltered (self-contained housing with communal areas such as a lounge, laundry 
or garden and on-call support) or institutional], living arrangements (living alone, with 
spouse or with others), years of full time education, social class according to the National 
Statistics Socio-Economic Classification (NS-SEC) three class scheme [Higher managerial, 
administrative and professional occupations (Class 1); intermediate occupations (Class 2); 
and routine and manual occupations (Class 3) (172)] based on past main occupation (37). Meal 
provision included meals provided by the social services, voluntary services or other private 
help in the previous 4 weeks, and luncheon club attendance was defined as at least one visit 
in the previous 4 weeks. 
Health 
Medical records held by the general practitioner were reviewed by research nurses 
for diagnosed dementia/Alzheimer’s disease, diabetes type 1 and 2, hypertension and 
cardiac disease (heart failure, angina, myocardial infarction, coronary artery bypass graft, 
coronary angioplasty/stent, pacemaker, atrial flutter/fibrillation), cerebrovascular disease 
(stroke, transient ischaemic attack, carotid endarterectomy), peripheral vascular disease, 
arthritis, respiratory disease, and cancer diagnosed within the previous 5 years excluding 
non-melanoma skin cancer. A disease count was created by scoring these diseases as either 
present or absent (173). Glomerular filtration rate (GFR) was estimated by the chronic kidney 
disease epidemiology collaboration (CKD-EPI) guidelines using sex, ethnicity, serum 
creatinine and age; and a GFR  < 30 ml/minute/1.73m2 was defined as renally impaired (174). 
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Depression was assessed by the 15-item geriatric depression scale [no depression (0-5), mild 
or moderate (6-7) and severe depression (≥8 points)]. Self-rated health compared to others 
of the same age was categorised into excellent or very good, good, fair or poor. Being able to 
cook a hot meal and being able to go shopping for groceries was categorized into no 
difficulty, able to but with help or an aid, and unable to do this by him/herself. High 
sensitivity C-reactive protein (hs-CRP) was measured with a Dade Behring Cardiophase 
hsCRP immunoassay. Alanine transaminase (ALT), alkaline phosphatase and bilirubin were 
measured as part of the liver panel.  
Lifestyle 
Weight and height were measured and used to calculate body mass index (BMI). 
Participants were categorised into those with low (scores 0-1), medium (scores 2-6) and high 
(scores 7-18) physical activity based on a validated and purpose designed physical activity 
questionnaire (175). Supplement use was divided into three categories viz. no supplements, 
one supplement and, two or more supplements. Information on supplement use was limited 
to type and brand, therefore micronutrient-containing supplements were assumed to be 
taken according to manufacturer’s specifications. 
2.5. General statistical analysis  
Statistical analysis was conducted using the IBM statistical tool SPSS v22.0 (IBM, New 
York, USA) unless otherwise mentioned. The Shapiro-Wilk test, quantile-quantile plots and 
histograms were used to assess normality. Normally distributed continuous data are 
presented as means and standard deviations (SD), and non-Gaussian distributed variables as 
medians and interquartile ranges (IQR). Categorical data are presented as percentages (with 
corresponding sample size). Sex differences (or other differences between two groups) were 
assessed with the Chi-squared test (χ2) for categorical variables and, by independent t-test 
and Mann-Whitney U test for parametric and non-parametric continuous data, respectively. 
Differences between 3 or more groups (e.g. quartiles) were assessed by the Chi-squared test 
(χ2) for categorical variables and, ANOVA and Kruskal-Wallis test for parametric and non-
parametric continuous data, respectively.  Values of p<0.05 were considered broadly 
statistically significant. Specific statistical methods will be reported in each experimental 
chapter.
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Figure 2.1 Flowchart of recruitment and cohort retention profiles of the Newcastle 85+ 
Study. 
 
 
CoA, continuity of attention; GP, general practitioner; mo, months; PoA, power of attention; tHcy, RBC folate, 
red blood cell folate; RTV, reaction time variability; SMMSE, standardised mini-mental state examination; total 
homocysteine; vit., vitamin. 
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2.6. Summary 
The Newcastle 85+ Study is a longitudinal cohort study of health trajectories and 
outcomes in the very old (all 85 years at baseline). Data were collected at baseline, 18, 36 
and 60 months later. GP records review and multidimensional health assessment were 
performed at each collection phase by research nurses and the final analytical sample was of 
845 participants at baseline. Dietary intake was assessed by 24hr-MPR on two non-
consecutive occasions and was available for 793 participants. Blood samples were taken 
after an 8h overnight fast at baseline and taken to the laboratory within 1h. RBC folate and 
plasma vitamin B12 concentrations were determined by a chemiluminescence microparticle 
immunoassay on an Abbott ARCHITECT analyser and tHcy concentration was measured by 
an Abbot IMx immunoassay. 
Food and nutrient intake data are scarce in very old adults – the fastest growing age 
segments of most western societies, including the UK. Chapter 3 is the first experimental 
chapter of this thesis and will cover the macronutrient intake and food sources in the very 
old. Besides determining dietary intake of energy, carbohydrate, fat, protein and non-starch 
polysaccharide (NSP), and corresponding food sources according to 15 major food groups, it 
will assess nutrient “adequacy” and investigate associated factors. 
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CHAPTER THREE 
 
 
3. Macronutrient intake and food sources in the 
very old 
 
[Mendonça N et al. (2016) Macronutrient intake and food sources in the very old: Analysis of 
the Newcastle 85+ Study. Br J Nutr. 115(12):2170-80.] 
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3.1. Abstract 
Food and nutrient intake data are scarce in very old adults (85 years and older) – one 
of the fastest growing age segments of Western societies, including the UK. Our primary 
objective was to assess energy and macronutrient intakes and respective food sources in 793 
85-year-olds (302 men and 491 women) living in North-East England and participating in the 
Newcastle 85+ cohort Study. Dietary information was collected using a repeated multiple-
pass recall (2 × 24 h recalls). Energy, macronutrient and NSP intakes were estimated, and the 
contribution (%) of food groups to nutrient intake was calculated. The median energy intake 
was 6·65 (interquartile ranges (IQR) 5.49–8.16) MJ/d – 46.8% was from carbohydrates, 
36·8% from fats and 15.7% from proteins. NSP intake was 10·2 g/d (IQR 7.3–13.7). NSP 
intake was higher in non-institutionalised, more educated, from higher social class and more 
physically active 85-year-olds. Cereals and cereal products (grains) were the top contributors 
to intakes of energy and most macronutrients (carbohydrates, non-milk extrinsic sugars, NSP 
and fat), followed by meat and meat products. The median intakes of energy and NSP were 
much lower than the estimated average requirement for energy (9.6 MJ/d for men and 7.7 
MJ/d for women) and the dietary reference value (DRV) for NSP (≥18 g/d). The median SFA 
intake was higher than the DRV (≤11% of dietary energy). This study highlights the paucity of 
data on dietary intake and the uncertainties about DRV for this age group. 
3.2. Introduction  
Although the population is ageing and very old adults are at increased risk of 
nutritional deficiencies, very little is known about the dietary habits in this age group. Many 
studies arbitrarily exclude very old people for no reason other than age (161), whilst others 
only include a small number, resulting in a lack of statistical power. For example, a Europe-
wide multi-centre study of food intake in older adults (SENECA: Survey in Europe on 
Nutrition and the Elderly: a Concerted Action) had an upper age limit of 79 years (176). Out of 
the current (years 1-4) 4156 participants (sample size was weighted for unequal selection 
and non-response) in the UK’s National Diet and Nutrition Survey (NDNS) rolling programme, 
only 15 men and 23 women were aged 85 and over (177). Twenty years ago, the 1994-95 
NDNS of people aged ≥65 years was the first representative dietary survey in the UK to 
include significant numbers of adults aged 85 and over (172 men and 287 women) but this 
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survey has not been repeated (49). This survey reported that dietary intakes for most 
nutrients in the very old did not meet the Dietary Reference Values (DRV) (49). The UK’s DRVs 
for “older people” add further to the evidence of how frequently very old people are 
overlooked. Apart from the Estimated Average Requirement (EAR) for energy intake and the 
Reference Nutrient Intake (RNI) for protein which sets a DRV for individuals aged 75 and 
over and 50 and over, respectively, all other DRVs include everyone aged ≥18 in the same 
category (34,69). In summary, there is a need for more reports of dietary intake data for those 
aged ≥85.  
The chapter aimed to describe the intake of energy, macronutrients and non-starch 
polysaccharides (NSP) by participants in the Newcastle 85+ Study, and to determine their 
principal food sources. Further, intakes are compared against the current UK DRVs and, 
socioeconomic and lifestyle influences on dietary intake are explored.  
3.3. Methods  
Participants 
This chapter uses data from the Newcastle 85+ Study and details were reported in 
Chapter 2, General Methods -  2.1 The Newcastle 85+ Study.  
 
Estimation of energy and macronutrients intake and, food group contributions 
Dietary intake assessment and food allocation to tertiary food groups was described 
on Chapter 2, General Methods - 2.2 Dietary assessment and food group allocation. Energy 
and macronutrient [alcohol, total carbohydrate, non-milk extrinsic sugars (NMES), non-
starch polysaccharides (NSP), fat, total, saturated (SFA), polyunsaturated (PUFA) and 
monounsaturated (MUFA), and protein] intakes were estimated using 
McCance and Widdowson's sixth edition food composition tables (178) and a purpose-
designed Microsoft Office Access database. Food group contribution to total energy and 
macronutrient intake was calculated and sources of at least 85% of each nutrient intake are 
reported.  In addition, consumed foods were also disaggregated into five groups (bread, rice, 
potatoes, pasta and other starchy foods; milk and dairy foods; food and drinks high in fat 
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and/or sugar; meat, fish, eggs, beans and other non-dairy sources of protein and; fruit and 
vegetables) and compared with the Eatwell Plate (Balance of Good Health) (179).  
Estimation of misreporting  
Dietary misreporting is an acknowledged limitation of all dietary assessment 
methods. Goldberg et al. tried to address this problem by introducing cut-off values to 
identify misreporters (180). The cut-offs are derived from estimations of energy intake (EI) 
divided by the estimated basal metabolic rate (BMRest) (EI:BMRest) (181). Fredrix equations 
have been shown to be the most accurate in older subjects (182) and were used to calculate 
each participant’s BMRest. Under-reporters and over-reporters were defined as having an 
EI:BMRest below 1.05 and over 2.0, respectively. A 17% within subject variation for energy 
intake, 15% between-subject variation for physical activity level (PAL) (181) and 3.5% within-
subject variation for BMR measurements (183) were assumed. The individual limits were 
calculated assuming a PAL value of 1.55, the World Health Organization (WHO) value for 
“light activity” and a 95% confidence interval (181). As a sensitivity analysis, nutrient intakes 
with the cut-offs applied were calculated and compared to the nutrient intakes of all 
participants (without the cut-offs).  
Socioeconomic, health and lifestyle factors 
Details of variables used were described in Chapter 2, General Methods - 2.4 Other 
socioeconomic, health and lifestyle variables.  
Statistical analysis 
Case selection and simple descriptive analysis were used to identify the baseline 
characteristics, dietary intake and population below or above the DRVs. Energy and nutrient 
intakes were compared across housing, living arrangements (with whom participants live), 
years of full-time education, past occupation (NS-SEC) and physical activity groups by 
multinomial logistic regression. All models were adjusted for sex and NSP was also adjusted 
for energy intake. General details are presented in Chapter 2, General Methods - 2.5 General 
statistical analysis. 
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3.4. Results  
 Characteristics of the Newcastle 85+ Study population 
Dietary intake data were available for 793 participants of the Newcastle 85+ Study 
(302 men and 491 women; female:male ratio of 1.6), who were all born in 1921 (aged 
85.5±0.4 years at the time of data collection). Health and sociodemographic characteristics 
of these 793 participants by sex are included in Table 3.1. The majority of participants lived 
in standard housing (78%), alone (61%) and had nine years or less of full time education 
(64%). Approximately half (51%) had had a routine or manual occupation (NS-SEC class 3) 
and 44% had a medium physical activity level. Using WHO adult body mass index (BMI) cut-
offs(184), 7% of participants were underweight while 10% were obese, suggesting the 
existence of a double burden of malnutrition. Participants with 2x24hr-MPR data and those 
without (n=40) or with only 1x24hr-MPR (n=12) did not differ with respect to sex, living 
arrangements (who participants live with), education, social class and BMI. However, people 
without complete dietary data were more likely to live in institutional housing, to be 
physically inactive, to be unable to cook a hot meal and unable to do grocery shopping 
independently compared with those with complete dietary data.  
Dietary intake 
Intakes of energy, EI:BMRest, macronutrients and NSP are reported in Table 3.3. 
Median energy intake was 6.65 (IQR: 5.49-8.16) MJ per day of which 46.8% was derived from 
carbohydrate, 36.8% from total fat and 15.7% from protein. EI:BMRest was 1.33 (IQR: 1.08-
1.60) for both men and women. As expected, men had significantly higher intakes of energy, 
macronutrients and NSP than women. However, when expressed as relative contribution to 
energy or per 1 MJ, only percent of energy from protein was significantly higher for men 
(p=0.010). Conversely, the percentage of energy from SFA was lower in men (p=0.012) 
whereas the PUFA: SFA ratio was higher in men than in women (p=0.017).  
Sensitivity analysis 
Sixty-two participants (13 men and 49 women) did not have records of weight and/or 
height and so were excluded from the analysis of effects of misreporting which was 
conducted for the remaining 731 participants. Using 1.05-2.0 EI:BMRest as a cut-off, 26.3% 
(n=192) of participants were identified as potential misreporters (30.4% men and 23.5% 
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women). Of the 731 very old, 21.6% (n=158) were defined as under-reporters (25.6% men 
and 19.0% women) and 4.7% (n=34) as over-reporters (4.8% men and 4.5% women). 
Cognitive impairment at baseline was associated with misreporting (OR: 1.61, 95% CI, 1.11-
2.33, p=0.012). Dietary intake of non-misreporters (n=607) and the differences between 
total reporters (n=731) are presented in Supplemental Table 3.2. Since there were more 
under-reporters than over-reporters, daily energy intake increased by 0.36 MJ or 86 Kcal 
when cut-offs were applied, marginally increasing intakes of all macronutrients and NSP. 
Data from all participants (n=793) were used in our primary analyses because of the 
uncertainty regarding the identification of misreporters.  
Contribution of food groups to dietary intake 
Cereals and cereal products (CCP) and non-alcoholic beverages were the only food 
groups consumed by all participants (Table 3.2). Since CCP includes macronutrient-rich foods 
such as bread, buns and breakfast cereals, CCP were frequent top contributors for 
macronutrients (Figure 3.1). One third of the 34.2% of energy intake that came from CCP 
came from bread (32.7%). Similarly, more than a third of the CCP contribution to 
carbohydrate intake (48.3%) was also from bread (38.7%). Non-alcoholic beverages 
contributed to 18.4% of NMES intake of which 60% was from fruit juice and the remaining 
40% from soft drinks. Added sugar was coded separately from tea/coffee if it was added. 
Therefore, tea and coffee contributed to 0% of NMES intake, even though these were 
ubiquitously consumed in this population. More than half of the 42.3% of NSP intake 
attributable to CCP came from bread (50.8%). Nearly half of the contribution of vegetables 
to NSP intake (22%) came from peas and cruciferous vegetables (49.7%). The biggest 
contributors to fat intake were CCP with 23.1% (38.5% of which was provided by buns, 
cakes, pastries and fruit pies), followed by meat and meat products (20.8%), and oils and fat 
spreads (19.9%). Meat and meat products were greater contributors to fat intake in men 
than in women (23.8% vs. 18.5%) while the opposite was true for oils and fat spreads (18.0% 
vs. 21.4%). There were similar sex differences in contributions to SFA intake. The large 
majority of SFA intake attributable to oils and fat spreads consumption (21.6%) came from 
butter (81.9%). Similarly, most of PUFA that came from oils and fat spreads (31.9%) came 
from fat spreads (87.4%). Meat and meat products were the main sources of protein 
(34.6%), followed by CCP (24.2%) and, milk and milk products (11.5%). Most sex differences 
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occurred when meat and meat products were a top contributor to macronutrient intake but 
the male: female ratio did not exceed 1.3.  
Comparison of food intake with the Eatwell Plate 
As a public health tool, the Eatwell Plate (Balance of Good Health) is intended to 
illustrate the recommended intake of five food groups (%). Foods and drinks high in fat 
and/or sugar (FS) accounted for 18% of the “Newcastle 85+ plate”, much higher than the 8% 
recommended by the Eatwell Plate (not the recently updated version), leading to lower than 
recommended proportion of fruit and vegetables, bread, rice, potatoes, pasta and other 
starchy foods and, albeit to a less extent, of meat, fish, eggs, beans and other non-dairy 
sources of protein in the Newcastle 85+ Study (Supplemental Figure 3.1). 
Nutrient adequacy 
Compliance of the Newcastle 85+ Study cohort with the UK DRVs is shown in 
Supplemental Table 3.1, while Figure 3.2 shows the distribution of energy, NMES, NSP and 
SFA intake compared with the corresponding DRVs. The median energy intakes were below 
the recently established EAR for dietary energy in the UK (34) and only 20% of the cohort met 
the 9.6 MJ and 7.7 MJ for men and women, respectively. Fifty per cent of men and 24% of 
women reported drinking alcohol and most of those were below the 32g and 24g advisable 
maximum limits of alcohol intake per day for men (77.5%) and women (90.8%), 
respectively(185). Because alcohol consumption was relatively low, the percentage of energy 
inadequacy decreased by only 5% in men (from 80.1% to 75.1%) and 3% in women (from 
80.2% to 77.2%) when alcohol was included in energy intake estimations. Median 
carbohydrate intake was also below the DRV for men and women and carbohydrate 
contributed ≥50% of food energy intake in one third (33%) of the population. Median NMES 
intake did not reach 11% energy from NMES per day but more than 40% of the group 
derived more energy from NMES than the dietary guidelines. In contrast, neither men nor 
women met the NSP intake DRV of 18g per day and only 9% of the cohort had higher intakes. 
Moreover, median NSP intake was also below 12g per day (66% of the population had lower 
intakes), the estimated lower end of the reference range(69). Median total fat and SFA 
contribution to energy intake was higher than 35% and 11%, respectively. Nearly 60% of the 
group exceeded the recommended contribution of fat to energy intake while this percentage 
rose to 72.1% for SFA. However, median protein intake was higher than the RNI of 0.75g/Kg 
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(69), reflecting that 78.1% and 67.4% of men and women, respectively, had higher protein 
intakes than the RNI.  
Dietary intake by housing, socioeconomic status and physical activity 
Table 3.4 reports daily energy, macronutrient and NSP intake stratified by housing, 
living arrangements, years of full time education, social class (NS-SEC) and physical activity. 
When adjusted for sex, participants in institutional housing were more likely to have higher 
intakes of energy, carbohydrate and higher percentage of energy from NMES than those 
who lived in standard housing. However, institutionalised participants were more likely to 
have lower intakes of NSP (also adjusted for energy intake) and percentages of energy from 
MUFA and PUFA. Participants living in sheltered housing were more likely to have lower NSP 
intakes than those living in standard housing. There were no statistically significant 
differences between those living with their spouse or with others compared to those living 
alone except for protein intake. Participants who lived with others were more likely to have 
a lower protein intake than those who lived alone (p=0.032). Adjusted for sex and energy, 
participants who experienced 12 years or more of full time education had higher NSP intakes 
than those with ≤ nine years of full time education (p=0.008). Similarly, those with previous 
higher managerial, administrative or professional (Class 1) and intermediate (Class 2) 
occupations (NS-SEC) had higher NSP intakes than those with routine or manual occupations 
(Class 3) (p=0.001 and p=0.018, respectively). Participants with high physical activity had 
higher intakes of NSP and, percentage of energy from MUFA, PUFA and protein than those 
with low physical activity. The same was true for NSP and percentage of energy from PUFA in 
those with medium physical activity.
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Table 3.1. Health and sociodemographic characteristics of the Newcastle 85+ Study 
participants with complete dietary data by sex.  
 All Men Women p-value1 
Sex - (793) 38 (302) 62 (491) - 
Age (mean±sd) 85.5±0.4 85.5±0.46 85.5±0.43 0.4722 
Housing    0.001 
Standard 78 (620) 85 (256) 74 (364)  
Sheltered 17 (137) 12 (37) 21 (100)  
Institutional 4 (34) 3 (8) 5 (26)  
Living Arrangements3    <0.001 
Alone 61 (437) 42 (119) 74 (318)  
With Spouse only 28 (204) 51 (145) 14 (59)  
With Others 11 (79) 8 (23) 13 (56)  
Year of full-time education    0.608 
≤9 years 64 (501) 61 (184) 66 (317)  
10-11 years 23 (183) 25 (75) 23 (108)  
12-20 years 12 (97) 13 (39) 12 (58)  
Past Occupation (NS-SEC)    <0.001 
Higher Managerial/ Administrative/ 
Professional (Class 1) 
34 (259) 40 (118) 31 (141)  
Intermediate (Class 2) 15 (109) 8 (23) 19 (86)  
Routine and manual (Class 3) 51 (385) 52 (155) 50 (230)  
Body Mass Index (Kg/m2)    0.125 
Underweight (<18.5) 7 (48) 5 (13) 8 (35)  
Eutrophic (18.5-24.9) 51 (374) 51 (146) 51 (228)  
Overweight (25.0-29.9) 32 (236) 36 (105) 30 (131)  
Obese (≥30.0) 10 (72) 9 (25) 11 (45)  
Physical Activity4    <0.001 
Low 22 (176) 20 (60) 24 (116)  
Medium 44 (343) 33 (99) 50 (244)  
High 34 (270) 47 (142) 26 (128)  
Diet Change in past year    0.082 
Yes 7 (53) 5 (15) 8 (38)  
No 93 (718) 95 (279) 92 (439)  
Food provision (Social Services + Private + Voluntary)    0.610 
No visit 94 (671) 94 (268) 93 (403)  
At least once in 4 weeks 6 (47) 6 (17) 7 (30)  
Luncheon Club    0.010 
Attended 7 (55) 4 (12) 9 (43)  
Not Attended 93 (734) 96 (289) 91 (445)  
Cook a Hot Meal independently   0.051 
No Difficulty 79 (624) 83 (251) 76 (373)  
Some Difficulty 7 (48) 5 (16) 7 (32)  
Unable 15 (118) 11 (34) 17 (84)  
Shopping for Groceries independently   <0.001 
No Difficulty 48 (378) 64 (191) 38 (187)  
Some Difficulty 13 (100) 12 (37) 13 (63)  
Unable 40 (313) 24 (73) 49 (240)  
Values are percentages (numbers) unless stated otherwise. 1 Chi-squared test (χ2) for no sex difference 2 
Independent t-test for no sex difference 3 Excludes participants in institutional care. 4 Purpose designed 
physical activity questionnaire (186). 
CHAPTER 3 
42 
 
Table 3.2. Percentage (%) of consumers and consumption (g/d) of major food groups in the Newcastle 85+ Study participants by sex. 
Food Groups 
All Men Women 
p-value1 
% 
Median 
(g/d) 
IQR % Median (g/d) IQR % 
Median 
(g/d) 
IQR 
Cereals and Cereal Products 100 211.0 141.6-307.0 100 265.6 190-382.8 100 186.6 125.6-263.6 <0.001 
Non-Alcoholic Beverages 100 1210 918-1528 100 1210 899-1549 100 1210 950-1518 0.876 
Meat and Meat Products 94 112.5 65.8-167.8 97 135 88.6-197.6 92 98 57.6-148.0 <0.001 
Oils and Fat Spreads 93 16.0 10.0-28.0 92 18 10.0-29.8 93 16.0 10.0-26.0 0.213 
Vegetables 91 103.8 60.5-159.5 91 114.6 70.0-169.0 91 96.6 54.0-147.6 0.006 
Milk and Milk Products 90 141.5 69.0-225.0 89 138.6 54.2-225 90 143.6 75.0-225.0 0.412 
Potatoes 82 99.0 66.0-153.5 83 131 78.6-178.2 81 90.6 49.8-140.0 <0.001 
Sugar, Preserves and Confectionery 80 20.0 10.8-36.0 83 25 13.0-43.4 78 17.6 10.0-32.0 <0.001 
Fruit 74 143.0 79.5-231.3 74 151 86.0-243.6 75 130.8 75.8-221.8 0.221 
Miscellaneous 73 55.8 22.8-142.0 75 55 22.0-145.4 73 57.6 25.0-140.8 0.962 
Eggs and Egg Dishes 39 30.0 25.0-60.0 40 50 25.0-60.0 38 30.0 25.0-60.0 0.102 
Fish and Fish Dishes  36 56.0 32.0-85.5 33 60 37.6-77.6 38 52.2 28.0-90.0 0.259 
Alcoholic Beverages 34 125.5 50.0-300.9 50 250 100.0-568.0 24 75.0 40.0-142.0 <0.001 
Savoury Snacks 11 14.0 7.0-14.5 11 14 7.0-20.2 10 14.0 7.0-14.0 0.730 
Nuts and Seeds 7 15.0 6.4-20.8 9 20 13.2-23.8 7 9.0 5.0-19.4 0.015 
%, Percentage of consumers throughout the 2x24hr-MPR; IQR, Interquartile Range. 
1 Mann-Whitney U test for no sex differences between consumption (g/d) of each food group (only consumers).  
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Table 3.3. Daily energy, EI:BMRest, macronutrient and NSP intakes in the Newcastle 85+ Study by sex. 
Macronutrients 
All Men Women 
p-value1 
Median IQR Median IQR Median IQR 
Energy (MJ)2 6.65 5.49-8.16 7.73 6.36-9.20 6.15 5.09-7.25 <0.001 
Energy (Kcal) 1588 1018-1949 1848 1519-2201 1471 1217-1733 <0.001 
EI:BMRest 1.33 1.08-1.60 1.33 1.04-1.57 1.33 1.11-1.61 0.287 
Alcohol (g)4 13.2 6.8-23.2 17.3 9.6-30.7 8.7 4.8-14.3 <0.001 
Carbohydrate (g) (% en) 193.9 (46.8) 156.9-238.1 228.3 (46.8) 180.9-271.9 177.3 (46.8) 147.2-218.6 <0.001 (0.7603) 
NMES (g) (% en) 42.7 (10.1) 25.4-63.8 50.2 (10.5) 32.5-78.2 38.0 (9.8) 23.2-56.7 <0.001 (0.055) 
NSP (g) 10.2 7.3-13.7 11.3 8.8-15.5 9.3 6.8-12.2 <0.001 
NSP (g) per 1 MJ 1.51 1.17-2.01 1.52 1.16-1.95 1.50 1.18-2.04 0.485 
Total Fat (g) (% en) 65.8 (36.8) 50.1-84.2 74.7 (36.4) 57.7-95.0 60.4 (37.2) 47.1-77.1 <0.001 (0.0933) 
SFA (g) (% en) 24.3 (13.6) 17.3-32.4 27.0 (12.9) 18.8-35.5 22.8 (13.7) 16.4-30.9 <0.001 (0.012) 
MUFA (g) (% en) 15.5 (8.8) 11.1-21.3 18.2 (8.6) 12.6-23.9 14.2 (8.9) 10.6-19.7 <0.001 (0.761) 
PUFA (g) (% en) 6.3 (3.4) 3.9-9.9 7.3 (3.6) 4.7-11.4 5.7 (3.4) 3.5-8.5 <0.001 (0.237) 
P:S ratio 0.25 0.15-0.42 0.28 0.17-0.43 0.23 0.14-0.41  0.017 
Protein (g) (% en) 61.3 (15.7) 48.9-75.7 73.0 (15.9) 57.9-90.1 54.5 (15.5) 45.1-67.2 <0.001 (0.010) 
Protein (g/Kg) 0.99 0.77-1.24 1.04 0.81-1.32 0.96 0.75-1.17 <0.001 
EI:BMRest, intake energy intake as a multiple for estimated basal metabolic rate (182); NSP, non-starch polysaccharides; IQR, interquartile range; % en, 
percentage of energy; NMES, non-milk extrinsic sugars; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty 
acids; P:S ratio, PUFA/SFA ratio. 
1 Mann-Whitney U test for no sex difference unless stated otherwise. 2 Does not include alcohol. 
3 Independent t-test for no sex difference. 4 Alcohol consumers only.
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Table 3.4. Daily energy, macronutrient and NSP intake of the Newcastle 85+ Study participants by demographic, socioeconomic and lifestyle 
characteristics. 
Macronutrients 
Housing Living Arrangements3 Education (years) Past-Occupation (NS-SEC) Physical Activity 
Standard 
(n=620) 
Sheltered 
(n=137) 
Institutional 
(n=34) 
Alone 
(n=437) 
Spouse 
(n=204) 
Others 
(n=79) 
≤9 
(n=501) 
10-11 
(n=183) 
≥12 
(n=97) 
Class 1 
(n=385) 
Class 2 
(n=109) 
Class 3 
(n=259) 
Low 
(n=176) 
Medium 
(n=343) 
High 
(n=270) 
Energy (MJ) 6.62 6.78 7.65* 6.36 7.28 6.64 6.57 6.69 6.89 6.76 6.63 6.64 6.77 6.37 6.92 
Energy (Kcal) 1581 1619 1828 1520 1739 1587 1571 1599 1646 1617 1586 1588 1617 1522 1653 
Alcohol (g)1 13.3 10.1 -2 11.5 16.1 9.7 10.6 15.0 13.6 12.8 10.2 13.4 12.6 10.2 15.0 
Carbohydrate (g) 191.6 198.4 222.0** 184.2 220.4 186.2 192.4 190.1 211.4 200.9 195.8 192.7 197.2 185.8 203.1 
% Energy 46.8 46.9 47.6 46.5 47.2 47.8 46.9 46.1 48.1 47.1 47.5 46.6 46.7 47.3 46.2 
NMES (g) 42.3 41.5 63.6** 38.8 49.5 40.2 41.5 42.6 45.9 44.5 45.7 41.4 46.6 41.5 43.9 
% Energy 10.0 10.2 12.9* 9.8 10.6 9.5 10.0 10.3 9.9 10.1 10.3 9.8 10.1 10.1 10.1 
NSP (g) 10.4 9.4** 7.1*** 9.9 11.0 10.1 9.9 10.1 11.7** 10.8** 10.4* 9.9 9.1 10.0** 11.3*** 
Total Fat (g) 65.5 64.7 74.4 63.9 68.1 60.8 65.5 66.6 65.0 66.0 63.9 67.1 66.8 62.3 69.7 
% Energy 36.8 37.3 37.7 36.9 36.4 37.3 36.9 37.6 35.6 35.7 36.6 37.2 37.3 36.7 36.7 
SFA (g) 24.0 24.9 25.6 23.5 25.3 22.3 23.5 25.5 24.4 24.4 24.9 24.1 25.3 23.3 25.4 
% Energy 13.6 13.7 12.9 13.6 13.2 13.5 13.5 14.4 13.1 13.4 13.4 13.7 14.1 13.5 13.4 
MUFA (g) 15.8 14.9 14.5 15.3 16.3 15.4 15.5 15.7 16.1 15.2 16.5 16.0 14.7 14.8 16.7* 
% Energy 9.0 8.2 7.8** 9.0 8.6 9.3 8.8 9.0 8.4 8.6 9.1 8.9 8.3 8.7 9.2* 
PUFA (g) 6.5 5.9 4.1* 6.5 6.4 6.4 6.6 6.3 5.9 6.4 6.5 6.3 5.2 6.2* 6.9*** 
% Energy 3.6 3.3 2.3** 3.7 3.3 3.8 3.6 3.4 3.0 3.4 3.7 3.4 2.8 3.5* 3.8** 
Protein (g) 61.2 61.1 61.9 58.3 67.5 55.0* 59.4 62.0 65.7 63.5 59.5 61.1 59.6 58.0 66.2* 
% Energy 15.7 15.3 14.0 15.7 15.9 14.3 15.7 15.5 15.7 15.7 15.8 15.5 15.3 15.4 16.1* 
NSP, non-starch polysaccharides; NS-SEC, National Statistics Socioeconomic Classification. Class 1: Higher managerial, administrative and professional occupations; Class 2: Intermediate occupations; 
Class 3: Routine or manual occupations. NMES, non-milk extrinsic sugars; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. All models were adjusted 
for sex except NSP which was adjusted for sex and energy intake. Standard housing, living alone, ≤9 years of full time education, class 3 of past occupation and low physical activity were the reference 
categories. 
* p<0.05 ** p<0.01*** p<0.001. 
1 Only alcohol drinkers. 
2 Not reported due to low participant number.3 Excludes people in institutional care.
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Figure 3.1. Contribution (%) of 15 food groups to average energy and macronutrient intake 
in the Newcastle 85+ Study. 
 
Contribution to a. energy b carbohydrate c NMES d NSP e fat f SFA g PUFA and h protein intake. 
NMES, non-milk extrinsic sugars; NSP, non-starch polysaccharides; SFA, saturated fatty acids; PUFA, 
polyunsaturated fatty acids.
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Figure 3.2. Distribution and adequacy of energy and macronutrient intake in the Newcastle 
85+ Study. 
 
Distribution and adequacy of food energy intake (MJ) in a, Men and b, Women; of NMES intake (%) in c, Men 
and d, Women; of NSP intake (g) in e, Men and f, Women and; of SFA intake (%) in g, Men and h, Women. 
Vertical dashed lines represent the DRVs in the UK for adults(69) and for adults aged 75 and over for energy(34). 
EAR, Estimated Average Intake; DRV; Dietary Reference Value; NMES, non-milk extrinsic sugars; NSP, non-
starch polysaccharides; SFA, saturated fatty acids. 
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3.5. Supplemental material  
Supplemental Table 3.1. United Kingdom dietary reference values and group compliance 
(%) in the Newcastle 85+ Study by sex. 
Macronutrients 
All Men Women 
Group 
Compliance 
(%) 
DRV 
Group 
Compliance 
(%) 
DRV 
Group 
Compliance 
(%) 
Energy 19.8 9.6 MJ1 19.9 7.7 MJ1 19.8 
Alcohol2 83.3 32 g3 77.5 24 g2 90.8 
Carbohydrate 33.0 50 % en 34.4 50 % en 32.2 
NMES  56.5 11 % en 52.6 11 % en 58.9 
NSP 9.0 18 g 14.2 18 g 5.7 
Total Fat 41.1 35 % en 44.0 35 % en 39.3 
SFA 27.9 11 % en 32.5 11 % en 25.1 
Protein 71.5 0.75 g/Kg 78.1 0.75 g/Kg 67.4 
DRV, Dietary Reference Value; NMES, non-milk extrinsic sugars; NSP, non-starch 
polysaccharides; SFA, saturated fatty acids; % en, percentage of energy. 
DRVs were taken from the Committee on Medical Aspects of Food Policy report (69) unless 
stated otherwise. Group compliance is the percentage above or below the DRVs as 
appropriate. 
1 Scientific Advisory Committee on Nutrition (34). 
2 Only alcohol drinkers. 
3 Sensible-Drinking limits(185).
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Supplemental Table 3.2. Daily energy, EI:BMRest, macronutrient and NSP intakes of 539 non-misreporters and difference between 731 total 
reporters by sex in the Newcastle 85+ Study1. 
Macronutrients 
All  Men  Women 
Median IQR Dif  Median IQR Dif  Median IQR Dif 
Energy (MJ) 7.00 6.13-8.34 -0.36  8.47 7.39-9.40 -0.75  6.39 5.66-7.25 -0.24 
Energy (Kcal) 1674 1466-1993 -86  2024 1766-2248 -178  1527 1353-1734 -57 
EI:BMRest 1.41 1.24-1.62 -0.08  1.43 1.27-1.61 -0.1  1.40 1.23-1.63 -0.07 
Carbohydrate (g) (% en) 207.6 (46.5) 172.3-242.4 -14.1  242.2 (46.6) 213.9-280.8 -14.2  185.9 (46.3) 162.5-219.5 -8.9 
NMES (g) (% en) 47.7 (10.4) 30.2-66.2 -5.1  58.2 (10.8) 39.3-83.4 -8.1  41.9 (10.2) 26.7-59.6 -3.9 
NSP (g) 10.8 8.3-14.4 -0.6  12.5 9.8-16.1 -1.2  10.2 7.6-13.2 -0.7 
Total Fat (g) (% en) 70.6 (37.1) 57.2-87.2 -5.1  81.1 (36.4) 66.1-99.9 -6.6  63.9 (37.4) 53.5-77.3 -3.6 
SFA (g) (% en) 26.3 (13.7) 19.9-34.2 -2.2  29.5 (13.0) 22.4-37.5 -2.6  24.2 (14.0) 18.6-31.4 -1.5 
MUFA (g) (% en) 16.8 (8.9) 12.5-22.3 -1.1  19.7 (8.7) 14.8-25.0 -1.5  15.6 (9.0) 11.7-20.1 -1.3 
PUFA (g) (% en) 6.9 (3.6) 4.5-10.5 -0.4  8.2 (3.6) 5.5-11.8 -0.8  6.3 (3.5) 3.9-9.5 -0.4 
P:S ratio 0.26 0.15-0.41 0.00  0.29 0.17-0.41 0.00  0.24 0.14-0.41 0.01 
Protein (g) (% en) 65.3 (15.6) 52.5-79.0 -3.8  77.7 (15.8) 65.6-93.3 -4.4  57.9 (15.4) 49.3-68.9 -3.5 
EI:BMRest, energy intake by estimated basal metabolic rate(182); NSP, non-starch polysaccharides; IQR, interquartile range; IQR, interquartile range; 
Dif, Difference between without and with cut-offs (accurate reporters); % en, percentage of energy; NMES, non-milk extrinsic sugars; SFA, saturated 
fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; P:S ratio, PUFA/SFA ratio.  
Cut-offs were defined as an EI:BMRest at 1.05-2.0. Sixty-two participants did not have weight and/or height; therefore, cut-offs could not be applied 
to the entire cohort and only to 731 participants.  
1 26.3% were misreporters (21.6% underreporters and 4.7% overreporters).
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Supplemental Figure 3.1. Comparison between the Newcastle 85+ Study and old Eatwell Plate (Balance of Good Health). 
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3.6. Summary of Chapter 3 
Food and nutrient intake data are scarce in very old adults (85 years and older) – one 
of the fastest growing age segments of western societies, including the UK. The primary 
objective of this chapter was to assess energy and macronutrients intake and, respective 
food sources in 793 eighty-five-year-olds (302 men and 491 women) living in North-East 
England and participating in the Newcastle 85+ cohort Study. Dietary information was 
collected using a repeated multiple pass recall (2x24hr recalls). Energy, macronutrient and 
non-starch polysaccharide (NSP) intakes were estimated and the contribution (%) of food 
groups to nutrient intake was calculated. Median energy intake was 6.65 (IQR: 5.49-8.16) 
MJ/ day, 46.8% was from carbohydrate, 36.8% from fat and 15.7% from protein. NSP intake 
was 10.2 g/ day (IQR: 7.3-13.7). NSP intake was higher in non-institutionalised, more 
educated, from higher social class and more physically active 85 year olds. Cereals and cereal 
products were the top contributors to intakes of energy and most macronutrients 
(carbohydrate, non-milk extrinsic sugars, NSP and fat), followed by meat and meat products. 
Median intakes of energy and NSP were much lower than the estimated average 
requirement (EAR) for energy (9.6 MJ for men and 7.7 MJ for women per day) and the 
dietary reference value (DRV) for NSP (≥ 18g/ day). Median saturated fatty acids intake was 
higher than the DRV (≤ 11% of dietary energy). This chapter provides much needed 
information on dietary intake and DRVs for this age group.  
A number of socioeconomic, biological and lifestyle characteristics change with 
advancing age and place very old adults at increased risk of micronutrient deficiencies. 
Chapter 4 will continue to investigate the dietary intake of the very old, focusing on 
micronutrients, such as iron, folate and vitamin B12, the food sources and associated 
factors, as well as determining micronutrient intake “inadequacy” against UK DRVs. 
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CHAPTER FOUR 
 
 
4. Micronutrient intake and food sources in the 
very old 
 
[Mendonça N et al. (2016) Micronutrient intake and food sources in the very old: Analysis of 
the Newcastle 85+ Study. Br J Nutr. 116(4):751-61.] 
 
Key words: dietary intake, vitamins, minerals, ‘aged, 80 and over’, Newcastle 85+
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4.1. Abstract 
A number of socio-economic, biological and lifestyle characteristics change with 
advancing age and place very old adults at increased risk of micronutrient deficiencies. The 
aim of this study was to assess vitamin and mineral intakes and respective food sources in 
793 85-year-olds (302 men and 491 women) in the North-East of England, participating in 
the Newcastle 85+ Study. Micronutrient intakes were estimated using a multiple-pass recall 
tool (2 × 24 h recalls). Determinants of micronutrient intake were assessed with multinomial 
logistic regression. Median vitamin D, Ca and Mg intakes were 2.0 (interquartile range (IQR) 
1.2–6.5) μg/d, 731 (IQR 554–916) mg/d and 215 (IQR 166–266) mg/d, respectively. Fe intake 
was 8.7 (IQR 6.7–11.6) mg/d, and Se intake was 39.0 (IQR 27.3–55.5) μg/d. Cereals and 
cereal products were the top contributors to intakes of folate (31.5 %), Fe (49.2%) and Se 
(46.7%) and the second highest contributors to intakes of vitamin D (23.8 %), Ca (27.5%) and 
K (15.8 %). More than 95% (n=756) of the participants had vitamin D intakes below the UK’s 
Reference Nutrient Intake (10 μg/d). In all, >20% of the participants were below the Lower 
Reference Nutrient Intake for Mg (n=175), K (n=238) and Se (n=418) (comparisons with 
dietary reference values (DRV) do not include supplements). As most DRV are not age 
specific and have been extrapolated from younger populations, results should be interpreted 
with caution. Participants with higher education, from higher social class and who were 
more physically active had more nutrient-dense diets. More studies are needed to inform 
the development of age-specific DRV for micronutrients for the very old. 
4.2. Introduction  
The scarcity of dietary data on very old adults, and lack of evidence for relationships 
with risk factors and health outcomes, have resulted in DRVs based on extrapolations from 
younger populations (187). For example, In the UK, apart from the Reference Nutrient Intake 
(RNI) for vitamin D which sets a Dietary Reference Intake (DRV) for people aged 65 and over, 
all other DRVs for vitamins or minerals apply equally to everyone aged ≥50 (69). 
The 1994-95 National Diet and Nutrition Survey (NDNS) of people aged 65 and over 
identified a significant number of older adults with inadequate micronutrient intakes, 
namely vitamin D, magnesium and potassium (72). A review of micronutrient intakes across 
Europe revealed that inadequacy (assessed against the Nordic Nutrition Recommendations, 
estimated average intake) was present in more than 20% of older adults (≥65 years) for 
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vitamin D, folate, calcium and selenium (71). Similarly, a review of non-institutionalised older 
adults living in western countries concluded that at least 30% were below the Estimated 
Average Requirement (EAR) for vitamin D, vitamin B12, calcium, magnesium and selenium 
(70).  
The aim of this chapter was to assess daily energy, vitamin and mineral intakes of 85 
year olds participating in the Newcastle 85+ Study; determine its food sources; compare 
intakes with the current UK DRVs; and explore socioeconomic and lifestyle determinants of 
micronutrient intake. 
4.3. Methods 
Participants 
This chapter uses data from the Newcastle 85+ Study and details were reported in 
Chapter 2, General Methods -  2.1 The Newcastle 85+ Study.  
Micronutrient estimation, food group contribution and supplement use  
Dietary intake assessment and food allocation to tertiary food groups was described 
on Chapter 2, General Methods - 2.2 Dietary assessment and food group allocation. Energy, 
vitamin and mineral intakes were estimated using the McCance and Widdowson's sixth 
edition food composition tables (used as published) (178) together with a purpose-designed in 
house Microsoft Office Access database on the nutrient composition of commonly 
consumed foods (16). Intakes of energy, vitamin A, β-carotene, vitamin B2, vitamin B6, folate, 
vitamin B12, vitamin E, vitamin C, vitamin D, calcium, iron, magnesium, potassium, sodium, 
selenium and zinc are reported here (excluding supplements). Vitamin and mineral density 
per 1 MJ of energy was also calculated. The average contribution of food groups to vitamin 
and mineral intakes was reported so that ≥90% of intakes were explained.  
Supplement use details were described in Chapter 2, General Methods - 2.4 Other 
socioeconomic, health and lifestyle variables. Supplement users were characterised by 
supplement type: those taking fish and omega-3 oil preparations, single mineral/vitamin 
preparations, multivitamin and/or multimineral preparations and, other supplements. 
Micronutrient intakes from all sources (including supplements) and the difference (%) 
between micronutrient intakes from dietary sources only (excluding supplements) were 
determined but supplements were not included in the main analysis.   
CHAPTER 4 
54 
 
Statistical analysis 
Baseline characteristics, micronutrient intake and percentage of participants below 
the Lower Reference Nutrient Intake (LRNI), EAR, RNI and UL were calculated using 
descriptive statistics. If available, LRNI was the preferred DRV to be reported. The LRNI is 
only supposed to meet the needs of 2.5% of a given population and intakes below this are 
likely to be “inadequate”. Most micronutrient intake data were continuous and non-
normally distributed therefore, sex differences were determined by the Mann-Whitney U 
test. Vitamin and mineral intakes were stratified by housing, living arrangements (with 
whom participants lived), years of full time education, social class [coded to the National 
Statistics Socio-economic Classification (NS-SEC) 3 class system (172)] and physical activity 
groups, and compared by multinomial logistic regression. Apart from energy, which was 
adjusted for sex only, all vitamins and minerals were adjusted for sex and energy. General 
statistical methods are presented in Chapter 2, General Methods - 2.5 General statistical 
analysis. 
4.4. Results 
 Vitamin intakes 
Men had higher vitamin intakes than women except for vitamin C (Table 4.2). 
However, the overall higher vitamin intake by men disappeared when the results were 
expressed per 1 MJ. Specifically, women’s vitamin A intake was 12 µg-RE/MJ or 13% higher 
(p=0.008) and vitamin C intake was 20 mg/MJ or 28% higher (p=0.001) than men’s intake. 
Despite 43% of participants (n=335) consuming one or more supplements on a regular basis 
(Table 4.1), on a population level, vitamin intakes changed only marginally when 
supplements were included except for vitamin A and D which increased by 19.2% (from 620 
to 752 µg-RE) and by 22.5% (from 2.0 to 2.5 µg), respectively (Supplemental Table 4.1). Due 
to the modest differences to micronutrient intake when including supplements, and 
limitations in supplement frequency data, micronutrient consumption from supplements 
was not included in the main analysis.  
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Vitamin food sources 
Figure 4.1 shows the percent contribution of food groups to vitamin intake for all 
participants. Meat and meat products contributed to 40% of vitamin A intake - the majority 
coming from liver and liver products and dishes (94.4%). Vegetables were the second biggest 
contributor (22.4%) to vitamin A intake, of which most came from carrots (71.1%). Cereals 
and cereal products (CCP) were the biggest contributors (31.5%) to folate intake, 86.9% of 
which came from bread and breakfast cereals. Vegetables were the second biggest 
contributor (15.8%) to folate intake with 42.4% coming from cruciferous vegetables. Half 
(49.6%) of the vitamin B12 intake from meat and meat products (52.3%) came from liver and 
liver products and dishes. One third (33.8%) of vitamin D intake came from fish and fish 
dishes (98.9% of which was from oily fish), and 23.8% from CCP (45.2% of which was from 
breakfast cereals and 43.3% from buns, cakes, pastries and fruit pies).  
Mineral intakes 
Similar to vitamin intake, men had an overall higher mineral intake than women (24% 
higher on average) (Table 4.2). When expressed per 1 MJ of energy, men still had higher 
intakes of iron (p=0.005), selenium (p=0.028) and zinc (p<0.001) compared to women but 
lower calcium intakes (p=0.008). On a population level, supplement contribution to mineral 
intakes was almost negligible (Supplemental Table 4.1). The highest difference between 
dietary intake with and without supplements was only 2.7% for zinc (from 7.1 to 7.3 mg). 
Mineral food sources 
Figure 4.1 shows the percent contribution of food groups to vitamin intakes for all 
participants. Milk and milk products were the biggest contributors (31.3%) to calcium intake 
while CCP was second with 27.5% (36.6% of which came from bread). Non-alcoholic 
beverages contributed 18.9% to calcium intake mainly because tea and coffee (with added 
milk) were included in this group (95.4% came from tea, coffee and water). Non-alcoholic 
beverages accounted for 19% of potassium intake (81.5% of which was from tea, coffee and 
water). CCP (15.8%) and potatoes (14.6%) were the second and third, respectively, biggest 
contributors to potassium intake. CCP explained 46.7% of selenium intake, and 93.2% of this 
came from bread. Meat and meat products made a higher contribution to intakes of iron 
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(19.3% vs. 14.2%), vitamin D (20.3% vs. 13.4%) and vitamin B12 (59.2% vs. 47.8%) for men 
than for women.  
Micronutrient adequacy 
The failure of both men and women in the Newcastle 85+ Study to meet several 
micronutrients’ DRVs was widespread (Figure 4.2 and Supplemental Table 4.2). Twenty 
percent of the participants had intakes below the LRNI for magnesium, potassium and 
selenium. The proportion of participants below the LRNI for vitamin A, vitamin B12 and zinc 
was around 10%. However, 4.6% (n=36) of the participants had vitamin A intakes above the 
UL. The widest disparity between intake and recommendations was seen for vitamin D 
intake, with more than 95% (n=756) of participants having intakes below the RNI for vitamin 
D of 10 µg per day (EAR or LRNI for vitamin D have not been defined for the UK) (69) and 
52.7% (n=418) of participants were below the LRNI for selenium. In contrast, 82.2% (n=652) 
of participants were above the RNI for sodium of 1600 mg per day (69). The 95th percentile of 
sodium intake was 4663 mg per day and within those that were above the RNI, median 
intake was 2594 mg. Fewer men had intakes below the DRV for vitamin B12, iron, potassium 
and folate than women. The widest difference between men and women not meeting the 
LRNI was for vitamin B12 (5.0% vs. 12.4%, p<0.001) and iron (2.3% vs. 7.8%, p<0.001). Meat 
and meat products were top contributors for both micronutrients. 
Micronutrient intake by housing, socioeconomic status and physical activity 
Table 4.3 reports the energy, vitamin and mineral intakes in the Newcastle 85+ Study 
stratified by housing, living arrangements, years of full time education, social class (past 
occupation according to NS-SEC) and physical activity. All micronutrient models were 
adjusted for sex and food energy intake. Energy and vitamin D intake were higher in 
participants who lived in institutional care (nursing or residential) than in standard housing. 
Conversely, vitamin E, magnesium and potassium intakes were lower in institutional than in 
standard housing. Participants who lived with their spouses had higher potassium and 
selenium intake than those who lived alone. Those with 12 or more years of full time 
education had higher intakes of vitamin C, vitamin D, calcium, magnesium and potassium 
than those with ≤ nine years of full time education. Social class also associated with the 
intake of several vitamins and minerals. Participants with previous higher managerial, 
administrative and professional occupations (class 1) had higher intakes of vitamin B2, 
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folate, calcium, iron, magnesium, potassium and zinc than those who had routine and 
manual occupations (class 3). Those with high physical activity had a more nutrient-dense 
diet in vitamin B6, folate, vitamin E, vitamin C, iron, magnesium, potassium and zinc than 
those with lower physical activity. 
Table 4.1. Energy intake and supplement use by sex.  
 All Men Women p-value1 
Sex 793 38 (302) 62 (491) - 
Energy (MJ) 6.65 (5.49-8.16) 7.73 (6.36-9.20) 6.15 (5.09-7.25) <0.0012 
  Carbohydrate (% en) 46.8 (42.6-51.5) 46.8 (42.7-52.0) 46.8 (42.5-51.4) 0.7603 
  Fat (% en) 36.8 (32.0-41.8) 36.4 (31.6-41.1) 37.2 (32.2-42.2) 0.0933 
  Protein (% en) 15.7 (13.5-18.3) 15.9 (13.8-18.9) 15.5 (13.6-17.9) 0.0063 
Dietary Supplement Use    0.252 
None 58 (456) 62 (185) 55 (271)  
1 29 (227) 27 (81) 30 (146)  
2+ 14 (108) 12 (35) 15 (73)  
Dietary Supplement Type    0.590 
Fish and Omega-3 Oil 48 (162) 48 (56) 48 (106)  
Mineral/ Vitamin Preparations 10 (32) 8 (9) 11 (23)  
Multivitamin and/or Multimineral 12 (39) 10 (12) 12 (27)  
Other 31 (102) 34 (39) 29 (63)  
Values are percentages (numbers). Energy and % en from macronutrients are presented as medians 
(interquartile range). % en, percentage of energy; NS-SEC, National Statistics Socioeconomic Classification. 
1 Chi-squared test (χ2) for no sex difference unless otherwise stated. 
2 Mann-Whitney U test for no sex difference. 
3 Independent t-test for no sex difference. 
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Table 4.2. Daily energy, vitamin and mineral intakes of the Newcastle 85+ Study participants by sex and per 1 MJ of energy1. 
Micronutrients 
All Men Women 
Median IQR Median IQR Median/ 1 MJ Median IQR Median/ 1 MJ p-value3 
Energy (MJ)2 6.65 5.49-8.16 7.73 6.36-9.20 - 6.15 5.09-7.25 - <0.001 
Vitamins          
Vitamin A (μg RE)  620 398-910 674 414-988 86.5 593 390-851 98.5 0.008 
β-Carotene (μg) 1516 517-2883 1769 606 -3167 212.5 1335 488-2666 215.0 0.577 
Vitamin B2 (mg) 1.5 1.2-1.9 1.7 1.3-2.1 0.22 1.4 1.1-1.8 0.23 0.138 
Vitamin B6 (mg) 1.7 1.2-2.1 2.0 1.5-2.5 0.25 1.5 1.1-1.9 0.25 0.217 
Folate (μg) 208 157-264 245 183-295 30.9 189 146-243 31.7 0.564 
Vitamin B12 (μg) 2.9 1.9-4.4 3.4 2.2-5.2 0.46 2.6 1.6-3.9 0.42 0.047 
Vitamin E (mg) 4.7 3.2-7.5 5.0 2.4-8.3 0.65 4.5 2.9-6.9 0.69 0.128 
Vitamin C (mg) 56.5 30.5-99.1 55.5 32.4-98.4 7.10 57.2 30.0-99.4 9.27 0.001 
Vitamin D (μg) 2.0 1.2-6.5 2.3 1.4-3.7 0.33 1.8 1.0-2.9 0.30 0.200 
Minerals          
Calcium (mg) 731 554-916 829 634-1007 103.7 683 537-862 111.2 0.008 
Iron (mg) 8.7 6.7-11.6 10.5 8.4-13.5 1.35 7.8 6.1-9.9 1.28 0.005 
Magnesium (mg) 215 166-266 251 196-309 32.6 196 156-239 32.4 0.316 
Potassium (mg) 2477 1890-3023 2798 2230-3448 356.6 2262 1804-2797 373.4 0.100 
Sodium (mg)4 2388 1829-3188 2987 2216-3743 372.1 2162 1691-2707 361.6 0.101 
Selenium (μg) 39.0 27.3-55.5 48.3 33.9-65.1 6.19 35.2 25.3-48.4 5.83 0.028 
Zinc (mg) 7.1 5.5-9.6 8.6 6.8-11.1 1.12 6.3 5.1-8.2 1.05 <0.001 
IQR, Interquartile Range; RE, Retinol Equivalents. 
1 Does not include supplements. 2 Does not include energy from alcohol.  
3 Mann-Whitney U test for no sex difference (Median/ 1 MJ of energy). 4 Does not include table salt and salt used for cooking.
CHAPTER 4 
59 
 
Table 4.3. Daily energy, vitamin and mineral intakes according to demographic, socioeconomic and lifestyle characteristics1. 
Micronutrients 
Housing Live With Education (years) Past-Occupation (NS-SEC) Physical Activity 
Stand 
(n=620) 
Sheltered 
(n=137) 
Institut 
(n=34) 
Alone 
(n=437) 
Spouse 
(n=204) 
Others 
(n=79) 
≤9 
(n=501) 
10-11 
(n=183) 
≥12 
(n=97) 
Class 1 
(n=385) 
Class 2 
(n=109) 
Class 3 
(n=259) 
Low 
(n=176) 
Medium 
(n=343) 
High 
(n=270) 
Energy (MJ) 2 6.62 6.78 7.65* 6.36 7.28 6.64 6.57 6.69 6.89 6.76 6.63 6.64 6.77 6.37 6.92 
Vitamins                
Vitamin A (μg RE) 606 623 709 600 642 582 602 625 667 639 636* 600 627 599 648 
β-Carotene (μg) 1589 1093 1546 1381 1792 1365 1492 1493 1470 1575 1576 1339 1382 1339 1730 
Vitamin B2 (mg) 1.5 1.5 1.8 1.4 1.6 1.4 1.5 1.6 1.7 1.6** 1.5* 1.5 1.6 1.4 1.6 
Vitamin B6 (mg) 1.7 1.6 1.7 1.6 1.9 1.6 1.6 1.7 1.8 1.7 1.7 1.6 1.5 1.6* 1.9*** 
Folate (μg) 208 195 231 195 231 191 201 209 234 214* 208 203 185 201 232** 
Vitamin B12 (μg) 2.9 2.7 3.8 2.7 3.1 2.2 2.8 3.1 3.0 3.0 2.8* 2.8 3.0 2.5 3.2 
Vitamin E (mg) 4.7 4.7 3.9* 4.7 4.8 4.6 4.7 4.7 5.1 4.7 5.2 4.5 4.5 4.4 5.2* 
Vitamin C (mg) 59.0 49.6 62.1 55.2 56.7 62.3 54.8 55.5 80.0** 61.7 64.5 52.1 46.6 56.4 66.6* 
Vitamin D (μg) 1.9 1.9 3.5** 1.8 2.1 1.9 1.9 2.1* 2.1* 2.0 1.9 1.9 2.6 1.8* 2.1 
Minerals                
Calcium (mg) 730 731 736 713 799 638* 710 738 778* 753* 730 722 735 702 771 
Iron (mg) 8.9 8.0*** 9.0 8.3 9.8 7.9 8.3 9.6 9.9 9.3** 8.7 8.6 8.6 8.4* 9.5** 
Magnesium (mg) 220 205** 195*** 209 236 196 211 216. 235** 226*** 223*** 209 197 208*** 235*** 
Potassium (mg) 2504 2445* 2363** 2348 2738* 2276 2397 2495 2904** 2656*** 2440 2402 2278 2381** 2725*** 
Sodium (mg)3 2357 2482* 2678 2363 2532 2077* 2351 2464 2390 2381 2363 2392 2401 2285* 2573 
Selenium (μg) 39.1 36.2 41.5 37.9 40.8* 34.0 38.1 40.0 39.0 38.1 39.7* 39.3 37.8 38.1 41.1 
Zinc (mg) 7.2 7.0 7.4 6.9 7.9 6.2 7.0 7.3 7.6 7.4** 7.2* 7.0 7.0 6.7 8.0* 
NS-SEC, National Statistics Socioeconomic Classification; Stand, Standard; Institut, Institutional Housing; Class 1: Higher managerial, administrative and professional occupations; Class 2: Intermediate 
occupations; Class 3: Routine or manual occupations. 
All models were adjusted for sex and energy intake except for energy intake which was only adjusted for sex. Standard housing, living alone, ≤9 years of full time education, class 3 of past occupation 
and low physical activity were the reference categories. 
* p<0.05 ** p<0.01*** p<0.001. 
1 Does not include supplements. 
2 Does not include energy from alcohol. 
3 Does not include table salt and salt used for cooking.
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Figure 4.1. Contribution (%) of 15 food groups to average micronutrient intake in the 
Newcastle 85+ Study. 
 
Contribution to a, Vitamin A; b, Folate; c, Vitamin B12; d, Vitamin D; e, Potassium; f, Calcium; 
g, Iron; and h, Selenium intake. 
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Figure 4.2. Intake distribution and inadequacy of selected micronutrients by sex. 
 
Intake of folate (µg) in a, Men and b, Women; of vitamin D (µg) in c, Men and d, Women; of potassium (µg) in 
e, Men and f, Women; of selenium (µg) in g, Men and h, Women. Horizontal dashed lines represent the LRNI, 
EAR and RNI for people aged 50 and over, except for vitamin D which is set for ≥65 years(6). Nutrient intakes do 
not include supplements. RNI, Reference Nutrient Intake; EAR, Estimated Average Intake; LRNI, Lower 
Reference Nutrient Intake.
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4.5. Supplemental material 
Supplemental Table 4.1. Vitamin and mineral intakes from all sources (including supplements) and, the difference (%) between including and not 
including supplement estimation by sex. 
Micronutrients 
All Men Women 
Median IQR Dif (%) Median IQR Median/ 1MJ Dif (%) Median IQR Median/ 1 MJ Dif (%) 
Vitamins            
Vitamin A (μg RE) 752 462-1255 19.2 801 479-1281 104 17.2 711 450-1243 116 18.1 
Vitamin B2 (mg) 1.6 1.2-2.0 6.5 1.7 1.3-2.2 0.2 0.0 1.4 1.1-1.9 0.2 0.0 
Vitamin B6 (mg) 1.7 1.3-2.2 0.0 2.0 1.5-2.5 0.3 0.0 1.6 1.2-2.0 0.3 6.5 
Folate (μg) 212 158-276 1.9 247 186-300 32 0.8 193 147-253 31 2.1 
Vitamin B12 (μg) 3.0 1.9-4.6 3.4 3.5 2.2-5.4 0.5 2.9 2.6 1.6-4.1 0.4 0.0 
Vitamin E (mg) 5.0 3.3-8.2 6.2 5.3 3.5-8.6 5.8 5.8 4.9 3.1-7.9 0.8 8.5 
Vitamin C (mg) 60.5 31.7-110.3 6.8 57.7 35.1-108.8 0.7 3.9 62.4 31.2-112.2 10.2 8.7 
Vitamin D (μg) 2.5 1.3-6.2 22.2 2.7 1.6-6.3 0.4 16.0 2.3 1.2-6.2 0.4 24.4 
Minerals            
Calcium (mg) 735 555-922 0.5 833 640-1008 104 0.5 691 538-868 112 1.0 
Iron (mg) 8.9 6.8-11.8 2.3 10.6 8.3-13.7 1.4 1.0 7.9 6.2-10.2 1.3 1.3 
Magnesium (mg) 218 169-269 1.1 254 200-312 33 1.3 198 157-247 33 0.6 
Selenium (μg) 39.4 27.6-57.5 1.0 49.2 34.4-67.9 6.4 1.9 35.7 25.4-50.1 5.9 1.4 
Zinc (mg) 7.3 5.7-9.9 2.7 8.7 7.0-11.7 1.1 1.2 6.6 5.3-8.7 1.1 4.7 
IQR, Interquartile Range; RE, Retinol Equivalents; Dif, difference between median vitamin and mineral intakes from all sources (including supplements) and dietary sources only. 
There is no β-carotene and sodium supplementation use. 
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Supplemental Table 4.2. Percentage (%) of the Newcastle 85+ Study participants below the 
RNI, EAR and LRNI for the UK by sex1. 
Micronutrients 
All Men Women p-
value2 <LRNI <EAR <RNI <LRNI <EAR <RNI <LRNI <EAR <RNI 
Vitamins           
Vitamin A (μg 
RE)  
10.5 28.1 51.7 13.1 31.9 52.3 8.8 25.8 51.3 
0.786 
Vitamin B2 (mg) 6.8 10.9 26.0 3.6 11.4 23.5 8.8 9.9 27.5 0.214 
Vitamin B6 (mg) - - 27.1 - - 20.9 - - 31.0 0.002 
Folate (μg) 3.4 22.1 46.4 1.3 13.5 30.3 4.7 27.4 56.4 <0.001 
Vitamin B12 
(μg) 
9.6 13.6 17.5 5.0 8.0 9.9 12.4 17.1 22.2 
<0.001 
Vitamin C (mg) 4.2 19.0 34.1 2.6 17.4 30.5 5.1 20.0 36.3 0.095 
Vitamin D (μg) - - 95.3 - - 94.4 - - 95.9 0.313 
Minerals           
Calcium (mg) 5.7 19.4 44.6 3.3 14.8 31.9 5.7 22.3 52.6 <0.001 
Iron (mg) 5.7 25.0 49.6 2.3 4.4 29.6 7.8 33.3 62.0 <0.001 
Magnesium 
(mg) 
22.1 51.3 81.3 22.2 50.0 71.2 22.0 52.1 87.6 
<0.001 
Potassium (mg) 30.0 - 87.5 18.9 - 77.2 36.9 - 93.9 <0.001 
Sodium (mg)3 0.0 - 17.8 0.0 - 10.9 0.0 - 22.0 <0.001 
Selenium (μg) 52.7 - 85.9 37.5 - 83.6 62.2 - 87.3 0.145 
Zinc (mg) 10.2 32.0 60.3 11.2 31.6 60.9 9.6 32.3 59.2 0.625 
RNI, Reference Nutrient Intake; EAR, Estimated Average Intake; LRNI, Lower Reference Nutrient Intake; RE, 
Retinol Equivalents. 
RNI, EAR and LRNI were taken from the UK dietary reference values for people aged 50 and over, except for 
vitamin D which is set for older adults (6). 
1 Does not include supplements. 
2 Chi-squared test (χ2) for no sex difference in percentage below RNI. 
3 Does not include table salt and salt used for cooking. 
CHAPTER 4 
64 
 
4.6. Summary 
A number of socioeconomic, biological and lifestyle characteristics change with 
advancing age and place very old adults at increased risk of micronutrient deficiencies. The 
aim of this chapter was to assess vitamin and mineral intake and respective food sources in 
793 eighty-five-year-olds (302 men and 491 women) in the North-East of England, 
participating in the Newcastle 85+ Study. Micronutrient intakes were estimated using a 
multiple pass recall tool (2x24hr recalls). Determinants of micronutrient intake were 
assessed with multinomial logistic regression. Median vitamin D, calcium and magnesium 
intakes were 2.0 (IQR: 1.2-6.5) µg/day, 731 (IQR: 554-916) mg/day and 215 (IQR: 166-266) 
mg/day, respectively. Iron intake was 8.7 (IQR: 6.7-11.6) mg/day and selenium intake was 
39.0 (IQR: 27.3-55.5) µg/day. Cereals and cereal products were the top contributors to 
intakes of folate (31.5%), iron (49.2%) and selenium (46.7%) and the second biggest 
contributors to intakes of vitamin D (23.8%), calcium (27.5%) and potassium (15.8%). More 
than 95% (n=756) of the participants had vitamin D intakes below the UK’s Reference 
Nutrient Intake (10 µg/d). Twenty percent or more of the participants were below the Lower 
Reference Nutrient Intake for magnesium (n=175), potassium (n=238) and selenium (n=418) 
(comparisons to dietary reference values (DRVs) do not include supplements). Since most 
DRVs are not age-specific and have been extrapolated from younger populations, results 
should be interpreted with caution. Participants with higher education, from higher social 
class and more physically active had more nutrient-dense diets. More studies are needed to 
inform the development of age-specific DRVs for micronutrients for the very old. 
Very old adults are at increased risk of folate and vitamin B12 deficiencies due to 
reduced food intake and gastrointestinal absorption. Chapter 5 will explore folate and 
vitamin B12 status, the associations between the top contributing dietary sources of folate 
and vitamin B12 and status, and whether high dietary intakes of both vitamins are 
associated with reduced risk of “inadequate” status.  
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CHAPTER FIVE 
 
 
5. Intakes of folate and vitamin B12 and 
biomarkers of status in the very old 
 
[Mendonça N et al. (2016) Intakes of folate and vitamin B12 and biomarkers of status in the 
very old: The Newcastle 85+ Study. Nutrients. 8(10), 604.] 
 
Key words: ‘aged 80 and over’; Newcastle 85+ Study; red blood cell folate; vitamin B12; 
FUT2; MTHFR; food groups.
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5.1. Abstract 
Very old adults are at increased risk of folate and vitamin B12 deficiencies due to 
reduced food intake and gastrointestinal absorption. The main aim was to determine the 
association between folate and vitamin B12 intake from total diets and food groups, and 
status. Folate or vitamin B12 intakes (2 x 24 h multiple pass recalls) and red blood cell (RBC) 
folate or plasma vitamin B12 (chemiluminescence immunoassays) concentrations were 
available at baseline for 731 participants aged 85 from the Newcastle 85+ Study (North-East 
England). Generalized additive and binary logistic models estimated the associations 
between folate and vitamin B12 intakes from total diets and food groups, and RBC folate and 
plasma B12. Folate intake from total diets and cereal and cereal products (grains) was 
strongly associated with RBC folate (p < 0.001). Total vitamin B12 intake was weakly 
associated with plasma vitamin B12 (p = 0.054) but those with higher intakes from total diets 
or meat and meat products were less likely to have deficient status. Women homozygous for 
the FUT2 G allele had higher concentrations of plasma vitamin B12. Cereals and cereal 
products are a very important source of folate in the very old. Higher intakes of folate and 
vitamin B12 lower the risk of “inadequate” status. 
5.2. Introduction 
 There is conflicting evidence about relationships between folate and vitamin B12 intake 
and, folate and vitamin B12 status, respectively, in older adults. Some studies report a 
significant association between folate and vitamin B12 intake and status in older adults 
(83,126-130) while others do not (131-133). In light of concerns about dietary inadequacy, it is 
imperative to assess folate and vitamin B12 status in older people, particularly the very old 
(85 years and older). The aims were to determine i) the prevalence of “inadequate” folate 
and vitamin B12 intake and status in the Newcastle 85+ Study, ii) the associations between 
the top contributing dietary sources of folate and vitamin B12, and status, and iii) whether 
high dietary intakes of both vitamins are associated with reduced risk of “inadequate” 
status. 
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5.3. Methods 
Participants 
This chapter uses data from the Newcastle 85+ Study and details were reported in 
Chapter 2, General Methods -  2.1 The Newcastle 85+ Study.  
Dietary assessment and food groups 
Dietary intake assessment and food allocation to tertiary food groups was described on 
Chapter 2, General Methods - 2.2 Dietary assessment and food group allocation. The top 
three food group contributors to folate or vitamin B12 intakes (accounted for > 50% of total 
intake) were included in the analysis. These food groups were also widely consumed by this 
population and, therefore a possible target for public health policies/ fortification. 
Information on supplement use was limited to type and brand and, therefore, this was only 
used as a dichotomous covariate (yes/no) (188).  
Nutritional biomarkers and single nucleotide polymorphisms 
Blood samples collection, RBC folate and plasma vitamin B12 analyses, and genotyping 
were described in Chapter 2, General Methods - 2.3 Blood collection, one-carbon metabolism 
biomarkers and genotyping. Complete dietary intake data, and RBC folate and plasma 
vitamin B12 concentrations were available for 731 and 732 participants, respectively. The 
single nucleotide polymorphisms (SNP) in the MTHFR (rs1801133, chromosome 1, position 
11796321), FUT2 (rs492602, chromosome 19, position 48703160), MTR (rs1805087, 
chromosome 1, position 236885200) and TCN1 (rs526934, chromosome 11, position 
59866020) genes were chosen as candidate modifiers of RBC folate and plasma vitamin B12 
concentrations. All SNPs were assessed for deviation from the Hardy-Weinberg equilibrium. 
Statistical analysis 
Linearity and homoscedasticity assumptions were tested with residuals versus predicted 
values plots. Differences between RBC folate and plasma vitamin B12 concentrations 
according to MTHFR (rs1801133), MTR (rs1805087), TCN1 (rs526934) and FUT2 (rs492602) 
genotype were assessed using Kruskal Wallis tests followed by Dunn-Bonferoni tests if the 
null hypothesis was rejected.  
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The semi-parametric generalized additive models (gam) were investigated in R 
version 3.0.1 (R foundation for statistical computing) using the package “gam” and used to 
plot the relationship between vitamin intakes (thin plate regression splines for smoothing) 
and corresponding biomarkers. The generated reference value of zero in the y-axis 
corresponds to the RBC folate/ plasma vitamin B12 concentrations for the mean intake of 
folate and vitamin B12, respectively. Odds ratio (OR) (and 95% confidence interval (CI)) of 
RBC folate concentrations <600 nmol/L and plasma B12 <148 pmol/L according to quartiles 
of folate and vitamin B12 intake from total diets and top contributing food groups were 
computed using binary logistic regression. The commonly used cut-off to define folate 
deficiency of RBC folate <340 nmol/L (89) could not be used for these models due to the low 
percentage of deficiency among study participants. Gam and binary logistic regression 
models were adjusted for sex, energy intake, folic acid or vitamin B12 containing supplement 
use, folate/ vitamin B12 intake from other food groups, MTHFR or FUT2 genotype. The 
vitamin B12 models were additionally adjusted for H2 receptor antagonists, biguanides and 
proton pump inhibitor (PPI) use. General statistical methods are presented in Chapter 2, 
General Methods - 2.5 General statistical analysis. 
5.4. Results 
 Folate and vitamin B12 intake and status “inadequacies” 
Although 43% of participants (n=335) consumed one or more supplements on a regular 
basis (188), only 4.8% were users of folic acid and vitamin B12 as part of multivitamin 
supplements (Table 5.1). A low percentage of participants (3.1%) had folate intakes below 
the UK LRNI (100 µg/d) (69) or had RBC folate concentrations below the classic cut-off for 
deficiency of 340 nmol/L (3.6%) (89). Folate intake and status were “inadequate” in only five 
participants. Cereals and cereal products, vegetables and fruit and fruit juice were the top 
food group contributors to folate intake, explaining almost 60% of total folate intake. 
Vitamin B12 intakes were below the UK LRNI (1 µg/d) (69) in 9.2% (n=67) of the population 
while 17.1% (n=125) were below 148 pmol/L of plasma vitamin B12 (112) (110 of these 125 
had also total homocysteine concentrations > 15 µmol/L). In addition, 17 participants had 
“inadequate” intakes as well as deficient plasma concentrations of vitamin B12. There were 
twice as many women with vitamin B12 intakes below the UK LRNI than men (5.0% vs. 
12.4%, p<0.001) but not with plasma vitamin B12 concentrations <148 pmol/L (17.4% vs. 
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16.9%, p=0.238). Eighty-six percent (n=628) of the participants had plasma vitamin B12 
concentration <400 pmol/L, a concentration that has been associated with high total 
homocysteine and methylmalonic acid concentrations (189,190). Intake of the top three food 
groups (meat, fish and dairy) explained more than 80% of total vitamin B12 intake. 
Folate, vitamin B12 status and genotype 
RBC folate and plasma vitamin B12 concentrations according to FUT2, MTHFR, MTR and 
TCN1 and genotypes are shown in Table 5.2. Individuals with the MTHFR (rs1801133) AG or 
GA genotype [minor allele frequency (MAF) = 0.33 in the Newcastle 85+ Study vs. 0.32 for 
the A allele from the 1000 Genomes Project British population phase 3 (191)] had higher RBC 
folate concentrations than those homozygous for G (p=0.024). Participants with the FUT2 
(rs492602) GG genotype had higher concentrations of plasma vitamin B12 than other FUT2 
genotypes (p<0.001) [MAF=0.45 in the Newcastle 85+ Study vs. 0.48 for the G allele in 
residents of England and Scotland (191)]. The association between FUT2 genotype and plasma 
vitamin B12 concentrations was significant in women (p<0.001) but not in men (p=0.140). 
Association between folate intake and status 
The associations between folate intake from all food sources, from cereals and cereal 
products, from fruit and fruit juice and from vegetables, and RBC folate concentrations are 
shown in Figure 5.1 (gam model adjusted for sex, energy intake, MTHFR genotype, folate 
intake from the two other food groups and folic acid supplement use). Total folate intakes 
were associated with RBC folate (p<0.001). The steepest part of the dose-response curve 
appeared to be for folate intakes of 50-200 µg per day but RBC folate concentrations 
continued to increase with increasing folate intake up to ≈500 µg per day. Folate intake from 
cereals and cereal products, and from fruit and fruit juice were also associated with RBC 
folate concentrations (p<0.001 and p=0.014, respectively) (Figure 5.1) 
Risk of low folate status by folate intake 
Table 5.3 shows the odds ratios (and 95% CI) of low RBC folate (<600 nmol/L) according 
to total, cereals and cereal products, vegetables and, fruit and fruit juice folate intake 
quartiles. Individuals in the highest quartile of total folate intake (>264 µg/d) were less likely 
to have RBC folate concentrations <600 nmol/L than those in the lowest quartile (<157 µg/d) 
in the unadjusted model (OR: 0.58, 95% CI: 0.36, 0.94) and adjusted model (OR: 0.43, 95% CI: 
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0.23, 0.82). Individuals in higher quartiles of folate intake from cereals and cereal products 
and from vegetables were also less likely to have low RBC folate concentrations (<600 
nmol/L) than those in quartile 1. The same was not true for folate intake from fruit and fruit 
juice in any model. 
Association between vitamin B12 intake and status 
Total vitamin B12 intake was weakly associated with plasma vitamin B12 concentrations 
while adjusting for sex, energy intake, vitamin B12 intake from the other two food groups, 
FUT2 genotype, vitamin B12 supplement use and H2 antagonists, biguanides or PPI use 
(p=0.054) (Figure 5.2). Plasma vitamin B12 concentration appeared to decrease when 
vitamin B12 intake exceeded 10 µg/d but the CI were very wide thereafter. Vitamin B12 
intake from meat and meat products, milk and milk products and fish and fish dishes were 
not associated with plasma vitamin B12 concentration. 
Risk of deficient vitamin B12 status by vitamin B12 intake 
Participants with total vitamin B12 intake above the median (2.88 µg/d) were half as 
likely to be deficient for plasma B12 as those with the lowest intake (<1.87 µg/d) in the 
adjusted model (Table 5.4). Individuals in quartile 4 of vitamin B12 intake from meat and 
meat products (>2.10 µg/d) were also half as likely to be deficient for plasma vitamin B12 as 
those in quartile 1 in the unadjusted (OR: 0.55, 95% CI: 0.31-0.98) and adjusted models (OR: 
0.41, 95% CI: 0.20-0.81). The same trend was present for milk and milk products but this did 
not reach statistical significance (p=0.054).  
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Table 5.1. Population characteristics, folate and vitamin B12 intakes and biomarkers of one 
carbon metabolism in the Newcastle 85+ Study. 
 All Men Women p-value1 
Sex (%) (n) 732 39 (287) 61 (445) - 
BMI (kg/m2) (mean±SD) 24.4±4.3 24.7±3.9 24.3±4.6 0.2442 
Smokers (%) (n) 5.6 (41) 4.2 (12) 6.5 (29) 0.183 
Alcohol Drinkers (%) (n) 72 (364) 84 (192) 62 (172) <0.001 
Total Energy Intakes (MJ/d) 6.78 (5.62-8.31) 8.01 (6.65-9.59) 6.26 (5.17-7.38) <0.001 
Folate and vitamin B12 supplement use (%) 
(n) 
4.8 (35) 3.8 (11) 5.4 (24) 0.334 
H2 antagonists, PPI and biguanides use (%) (n) 26.8 (196) 27.2 (78) 26.5 (118) 0.844 
Total Homocysteine (µmol/L) 16.7 (13.5-21.4) 18.0 (14.5-21.9) 16.1 (13.1-21.0) 0.001 
>15 µmol/L (%) (n) 63.1 (471) 70.3 (206) 58.5 (265) 0.001 
Folate 
Intake (µg/d) 209 (157-265) 246 (185-296) 189 (144-242) <0.001 
< 100 µg/d (%) (n) 3.1 (23) 0.7 (2) 4.7 (21) 0.002 
Top food group contributors 
Cereals (32%), 
Vegetables (16%), 
Fruit (9%) 
Cereals (32%), 
Vegetables (15%), 
Fruit (8%) 
Cereals (31%), 
Vegetables (17%), 
Fruit (10%) 
- 
Red Blood Cell Folate (nmol/L) 863 (451-1287) 868 (596-1282) 854 (614-1287) 0.728 
<340 nmol/L (%) (n) 3.6 (26) 2.1 (6) 4.5 (20) 0.103 
Vitamin B12 
Intake (µg/d) 2.9 (1.9-4.4) 3.5 (2.2-5.2) 2.5 (1.6-3.9) <0.001 
< 1.0 µg/d (%) (n) 9.2 (67) 4.5 (13) 12.1 (54) <0.001 
Top food group contributors 
Meat (53%), Fish 
(17%), Milk (13%) 
Meat (59%), Fish 
(16%), Milk (10%) 
Meat (48%), Fish 
(19%), Milk (15%) 
- 
Plasma Vitamin B12 (pmol/L) 232 (170-324) 228 (166-309) 238 (174-337) 0.238 
<148 pmol/L (%) (n) 17.1 (125) 17.4 (50) 16.9 (75) 0.841 
BMI, body mass index; Cereals, Cereals and cereal products; Fruit, Fruit and fruit juice; 
Meat, Meat and meat products; Fish, Fish and fish dishes; Milk, Milk and milk products; 
PPI, proton pump inhibitors. Values are medians and IQR unless otherwise stated. 
1 No sex difference by Chi-squared test (χ2) for categorical or Mann-Whitney test for 
non-parametric continuous variables. 
2 Independent t-test. 
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Table 5.2. Plasma vitamin B12 and red blood cell folate concentrations by FUT2, MTHFR, 
MTR, and TCN1 genotypes in the Newcastle 85+ Study. 
 
RBC folate  
(nmol/L) 
p-value1 
Plasma vitamin B12 
(pmol/L) 
p-value1 
FUT2 (rs492602) 0.531  <0.001 
AA (n=128) 894 (629-1349  216 (146-281) Ref. 
A/G (n=308) 917 (603-1322)  221 (163-309) 0.413 
GG (n=187) 835 (595-1206)  277 (209-381) <0.001 
MTHFR (rs1801133) 0.028  0.244 
GG (n=276) 871 (614-1275) Ref. 234 (168-331)  
A/G (n=279) 845 (584-1263) 1.000 230 (164-312)  
AA (n=67) 1010 (693-1626) 0.060 249 (193-339)  
MTR (rs1805087) 0.547  0.277 
AA (n=419) 881 (613-1278)  240 (173-337)  
A/G (n=178) 845 (596-1332)  226 (162-297)  
GG (n=26) 1053 (580-1593)  247 (162-310)  
TCN1 (rs526934) 0.065  0.298 
AA (n=331) 877 (606-1317)  237 (178-336)  
A/G (n=247) 845 (595-1223)  231 (160-325)  
GG (n=45) 1074 (630-1439)  222 (182-273)  
RBC folate, Red blood cell folate; FUT2, Fucosyltrasnferase 2; MTHFR, 
Methylenetetrahydrofolate reductase; MTR, Methionine synthase; TCN1, 
Transcobalamin 1. Ref., Reference used for post hoc comparisons. 
1 Kruskal Wallis test followed by Dunn-Bonferroni post-hoc test if the null hypothesis 
was rejected.
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Table 5.3. Odds ratio (95% CI) of low RBC folate concentration according to quartiles of 
total folate intake and intakes from cereals and cereal products, from vegetables and from 
fruit and fruit juice in the Newcastle 85+ Study. 
Folate intake Model 1 (unadjusted) Model 2 (adjusted) 
Total (µg/d) <600 nmol/L (n=170) p <600 nmol/L (n=170) p 
<157 1.00 (ref) - 1.00 (ref) - 
157-208 0.64 (0.40, 1.04) 0.071 0.65 (0.38, 1.09) 0.103 
209-264 0.72 (0.45, 1.15) 0.173 0.58 (0.34, 1.02) 0.057 
>264 0.58 (0.36, 0.94) 0.028 0.43 (0.23, 0.82) 0.010 
Cereals and Cereal  
products (µg/d) 
<600 nmol/L (n=170) p <600 nmol/L (n=170) p 
<36 1.00 (ref) - 1.00 (ref) - 
36-59 0.96 (0.61, 1.49) 0.840 0.84 (0.51, 1.38) 0.493 
59-92 0.40 (0.24, 0.66) <0.001 0.32 (0.18, 0.57) <0.001 
>92 0.41 (0.25, 0.68) 0.001 0.33 (0.18, 0.61) <0.001 
Vegetables (µg/d) <600 nmol/L (n=154) p <600 nmol/L (n=154) p 
<15 1.00 (ref) - 1.00 (ref) - 
15-30 0.72 (0.43, 1.21) 0.212 0.49 (0.25, 0.95) 0.035 
30-51 0.86 (0.52, 1.41) 0.550 0.59 (0.32, 1.08) 0.089 
>51 0.79 (0.48, 1.30) 0.357 0.52 (0.28, 0.99) 0.045 
Fruit and Fruit Juice 
(µg/d) 
<600 nmol/L (n=127) p <600 nmol/L (n=127) p 
<7.3 1.00 (ref) - 1.00 (ref) - 
7.3-16 0.90 (0.53, 1.52) 0.682 1.01 (0.56, 1.83) 0.979 
16-34 0.61 (0.35, 1.07) 0.086 0.67 (0.36, 1.25) 0.213 
>34 0.76 (0.44, 1.31) 0.329 0.79 (0.43, 1.44) 0.437 
RBC folate, Red blood cell folate; p, p-value. Low folate status was defined as RBC folate 
concentration <600 nmol/L. Binary logistic regression model. Model 1 is unadjusted and 
Model 2 is adjusted for sex, energy intake, folate intake from the other two food sources 
(except for total folate), MTHFR genotype and folic acid-containing supplement use.
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Table 5.4. Odds ratio (95% CI) of plasma vitamin B12 deficiency according to quartiles of 
intake of total vitamin B12 and intakes from meat and meat products, from fish and fish 
products, and from milk and milk products in the Newcastle 85+ Study. 
Vitamin B12 intake  Model 1 (unadjusted) Model 2 (adjusted) 
Total (µg/d) <148 pmol/L (n=125) p <148 pmol/L (n=125) p 
<1.87 1.00 (ref) - 1.00 (ref) - 
1.87-2.88 0.70 (0.42, 1.18) 0.180 0.57 (0.32, 1.01) 0.056 
2.88-4.40 0.60 (0.35, 1.02) 0.057 0.50 (0.28, 0.92) 0.026 
>4.40 0.53 (0.31, 0.92) 0.024 0.40 (0.21, 0.76) 0.005 
Meat and Meat 
products (µg/d) 
<148 pmol/L (n=118) p <148 pmol/L (n=118) p 
<0.35 1.00 (ref) - 1.00 (ref) - 
0.35-1.03 0.72 (0.42, 1.24) 0.236 0.69 (0.38, 1.25) 0.220 
1.03-2.10 0.84 (0.50, 1.44) 0.533 0.78 (0.43, 1.42) 0.422 
>2.10 0.55 (0.31, 0.98) 0.043 0.41 (0.20, 0.81) 0.010 
 Fish and Fish 
products (µg/d) 
<148 pmol/L (n=43) p <148 pmol/L (n=43) p 
<0.46 1.00 (ref) - 1.00 (ref) - 
0.46-1.06 0.61 (0.23, 1.65) 0.331 0.66 (0.23, 1.91) 0.444 
1.06-2.45 0.86 (0.34, 2.15) 0.743 0.66 (0.23, 1.86) 0.427 
>2.45 1.00 (0.41, 2.42) 0.992 0.70 (0.25, 1.97) 0.503 
Milk and Milk 
products (µg/d) 
<148 pmol/L (n=102) p <148 pmol/L (n=102) p 
<0.27 1.00 (ref) - 1.00 (ref) - 
0.27-0.53 0.84 (0.47, 1.52) 0.562 0.88 (0.46, 1.71) 0.711 
0.53-0.88 1.12 (0.64, 1.96) 0.698 1.28 (0.70, 2.37) 0.425 
>0.88 0.58 (0.31, 1.08) 0.086 0.49 (0.24, 1.01) 0.054 
P, P-value. Binary logistic regression model. Deficient plasma vitamin B12 concentration was defined as 
<148 pmol/L. Model 1 is unadjusted and Model 2 is adjusted for sex, energy intake, FUT2 genotype, 
vitamin B12 intake from the other two food sources (except total vitamin B12 intake) (e.g. the meat and 
meat products model is adjusted for fish and fish dishes, and milk and milk products), vitamin B12 
containing supplement use, H2 antagonists, biguanides and proton pump inhibitors use. 
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Figure 5.1. Estimated difference from the mean (and 95% CI) of RBC folate concentration according to folate intake from all dietary sources, from 
cereals and cereal products, from fruit and fruit juice and from vegetables. 
 
Generalized additive model (gam) adjusted for sex, energy intake, MTHFR genotype, folic acid supplement use and folate intake from the two other food sources (e.g. the cereals 
and cereal products model is adjusted for fruit and fruit juice, and vegetables). The highest 2.5th percentiles of RBC folate concentrations are not included. Three participants with 
a folate intake above 150 µg only from vegetables were not included. One participant with a folate intake of 327 µg only from fruit and fruit juice was excluded. P values are from 
the corresponding gam model.
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Figure 5.2. Estimated difference from the mean (and 95% CI) of plasma B12 concentrations according to vitamin B12 intake from all dietary 
sources, from meat and meat products, from milk and milk products and from fish and fish products. 
 
Generalized additive model (gam) adjusted for sex, energy intake, FUT2 genotype, H2 antagonists, proton pump inhibitors or biguanides use, vitamin B12 supplement 
use and vitamin B12 intakes from the other two food sources (e.g. the meat and meat products model is adjusted for fish and fish dishes, and milk and milk products). 
The lowest and highest 2.5th percentiles of vitamin B12 intakes and plasma vitamin B12 concentrations are not included except for meat and meat products where the 
highest 5th percentile was excluded. P values are from the corresponding gam model.  
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5.5. Summary 
Very old adults are at increased risk of folate and vitamin B12 deficiencies due to 
reduced food intake and gastrointestinal absorption. The main aim was to determine the 
association between folate and vitamin B12 intake from total diets and food groups, and 
status. Folate or vitamin B12 intakes (2x24h multiple pass recalls) and red blood cell (RBC) 
folate or plasma vitamin B12 (chemiluminescence immunoassays) concentrations were 
available at baseline for 731 participants aged 85 from the Newcastle 85+ Study (North-East 
England). Generalized additive and binary logistic models estimated the associations 
between folate and vitamin B12 intakes from total diets and food groups, and RBC folate and 
plasma B12. Folate intake from total diets and cereal and cereal products was strongly 
associated with RBC folate (p<0.001). Total vitamin B12 intake was weakly associated with 
plasma vitamin B12 (p=0.054) but those with higher intakes from total diets or meat and 
meat products were less likely to have deficient status. Women homozygous for the FUT2 G 
allele had higher concentrations of plasma vitamin B12. Cereals and cereal products are a 
very important source of folate in the very old. Higher intakes of folate and vitamin B12 
lower the risk of “inadequate” status. 
Chapter 6 will determine the associations between RBC folate, plasma vitamin B12 
and tHcy concentrations at baseline, and cognitive impairment and the rate of cognitive 
decline in global and attention-specific cognition over 5 years in the very old. 
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CHAPTER SIX 
 
 
6. One-carbon metabolism biomarkers and 
cognitive decline in the very old 
 
[Mendonça N et al. (2017) One-carbon metabolism biomarkers and cognitive decline in the 
very old: the Newcastle 85+ Study. J Am Med Dir Assoc. 18(9): 806.] 
 
Key words: ‘aged, 80 and over’, Newcastle 85+, cognition, folate, B12, homocysteine
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6.1. Abstract 
Although the biological rationale for the association between folate, vitamin B12, and 
homocysteine with cognitive function seems plausible, conflicting results have been 
reported. This study aimed to determine the associations between 1-carbon (1-C) 
metabolism biomarkers (folate, vitamin B12, and homocysteine), and cognitive impairment 
at baseline and the rate of cognitive decline over 5 years in the very old. The Newcastle 85+ 
Study was a prospective longitudinal study of people 85 years old and followed over 5 years 
in North-east England. The analytical sample included 765 community-dwelling and 
institutionalized very old participants with 1-C metabolism biomarkers and cognitive 
measures. Global cognition was measured by the Standardized Mini-Mental State 
Examination (SMMSE) at baseline, and at 3 and 5 years of follow-up and, attention-specific 
cognition with the Cognitive Drug Research (CDR) System at baseline, and at 1.5 and 3.0 
years of follow-up. Baseline red blood cell folate (RBC folate), plasma vitamin B12, and total 
homocysteine (tHcy) concentrations were determined by immunoassay. Linear mixed 
models were used to estimate the associations between quartiles of 1-C metabolism 
biomarkers and cognition over 3 (CDR) and 5 years (SMMSE). Compared with participants in 
the lowest quartile of RBC folate concentrations (<612 nmol/L), those in the highest quartile 
of RBC folate concentrations (>1280 nmol/L) had 1 more point on the SMMSE (β=+1.02, 
SE=0.43, P=0.02). Those in quartile 4 of tHcy (>21.4 mmol/L) had 1 point less in the SMMSE 
at baseline than those in the lowest quartile (<13.5 mmol/L) (β=-1.05, SE=0.46, P=0.02). 
Plasma vitamin B12 was not predictive of global or attention-specific cognition at baseline 
and at follow-up. None of the 1-C metabolism biomarkers except tHcy was associated with 
the rate of decline in attention scores over 3 years. RBC folate and tHcy, but not plasma 
vitamin B12, were associated with better global cognition in the very old at baseline but 
were not predictive of rate of decline over 5 years. 
6.2. Introduction 
 Although the biological rationale for associations between folate, vitamin B12 and 
homocysteine with cognitive function seem plausible, conflicting results have been reported. 
Folate, vitamin B12 and homocysteine have been associated with cognitive decline in some 
longitudinal studies (82,123,143) but not all (144-146), in some randomized controlled trials (RCTs) 
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(83,147), for one vitamin but not the other or only for certain cognitive domains. Insufficient 
follow-up time, small sample size, participants’ age at recruitment and different cognitive 
tests used are frequently reported reasons for the conflicting results. Furthermore, studies 
targeting the very old are lacking. We hypothesized that higher red blood cell (RBC) folate 
and plasma vitamin B12 concentrations would be associated with better cognitive 
performance and slower rate of cognitive decline, primarily through homocysteine-lowering 
effects. This study aimed to determine the associations between RBC folate, plasma vitamin 
B12 and total homocysteine (tHcy) concentrations at baseline, and cognitive impairment and 
the rate of cognitive decline in global and attention-specific cognition over 5 years in a large 
population of the very old who participated in the Newcastle 85+ Study.  
6.3. Methods 
 Participants 
This chapter uses data from the Newcastle 85+ Study and details were reported in 
Chapter 2, General Methods -  2.1 The Newcastle 85+ Study.  
Biomarkers of 1-C metabolism 
Blood samples collection, RBC folate, plasma vitamin B12 and tHcy analyses, and 
genotyping were described in Chapter 2, General Methods - 2.3 Blood collection, one-carbon 
metabolism biomarkers and genotyping.  
Cognitive assessment 
The Standardized Mini-mental State Examination (SMMSE) was used to assess global 
cognitive status at baseline, 3- (36 months) and 5-year (60 months) follow-up. The SMMSE is 
a short-standardised screening test for cognitive impairment in older adults that ranks global 
cognitive function from 0 to 30. Individuals with SMMSE scores ≥26 were considered as 
normal and <26 as cognitively impaired (192). Three automated tests of attention from the 
Cognitive Drug Research (CDR) System were used to assess cognition at baseline and again 
after 1.5- (18 months) and 3-years (36 months). The tests were simple reaction time (SRT), 
which assesses focussed attention and concentration; choice reaction time (CRT) which 
assessed similar abilities in addition to information processing and decision making; and the 
digit vigilance task (DVT) that assesses the ability to sustain attention (193). Using the 
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measures of speed and accuracy from the tasks, three validated composite measures were 
derived: power of attention (PoA), the sum of three speed scores which reflects the ability to 
focus attention and the intensity of concentration; reaction time variability (RTV) which is a 
sum of the coefficients of variance of the reaction time scores and reflects variations in 
attention during the tasks; and continuity of attention (CoA) which combines the accuracy 
scores from CRT and DVT and reflects the ability to sustain attention (30,194). All three of these 
composite scores have been validated previously (195,196). Higher scores in the SMMSE and 
the CoA, and lower scores for the PoA and RTV measures reflect superior performance 
(Appendix F).  
Other confounders 
Details on genotyping were described in Chapter 2, General Methods - 2.3 Blood 
collection, one-carbon metabolism biomarkers and genotyping. The gene encoding 
apolipoprotein E (APOE) was genotyped for common polymorphisms at rs429358 and rs7412 
(to provide information on zygosity at ε2, ε3 and ε4 alleles). Details on the variables 
recorded by the multidimensional health questionnaires and the GP medical records review 
were also described in Chapter 2, General Methods - 2.4 Other socioeconomic, health and 
lifestyle variables.  
Statistical analysis 
General statistical methods are presented in the Chapter 2, General Methods - 2.5 
General statistical analysis. Linearity assumptions were tested with residuals versus 
predicted values plots. Multicollinearity of confounders was assessed with variance inflation 
factor, tolerance and eigenvalues. To account for within-person variability and missing 
values, the longitudinal effects of RBC folate, plasma vitamin B12 and tHcy on cognitive 
function were assessed by linear mixed models. Random effects terms included both 
intercept and slopes of SMMSE and attention scores with the time in the study coded as 0 
(baseline), 1 (1.5 or 3 years) or 2 (3 or 5 years), respectively. Parameters (β coefficients) were 
estimated by the maximum likelihood method and the model followed an autoregressive 
heterogeneous covariance structure. RTV was logarithmically (ln) transformed to correct a 
positive skew and aid convergence. Other attention scores (PoA and CoA) were not 
transformed because the distribution of the residuals of each respective linear mixed model 
was roughly normal and did not interfere with convergence. An interaction between the 
biomarker and time was added to assess the rate of cognitive decline.  
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Binary logistic regression models were fitted to predict cognitive impairment 
(SMMSE≤25) at baseline and incident cognitive impairment after 3 and 5 years. All models 
were adjusted for sex, APOE e4 genotype (rs429358 and rs7412), hypertension, diabetes 
type 1 and 2, history of cardiovascular diseases, depression, alcohol intake, smoking status, 
physical activity, years of full time education, BMI, homocysteine in the folate and vitamin 
B12 models and renal impairment in the homocysteine models.  
In sensitivity analyses, all models were re-run after excluding participants diagnosed 
with Alzheimer’s disease/dementia or living in institutions at baseline, use of folic acid/ 
vitamin B12 containing supplements, with RBC folate concentrations > 4000 nmol/L, plasma 
vitamin B12 concentrations >1000 pmol/L or tHcy concentrations >40 µmol/L. 
6.4. Results 
Population characteristics by 1-C metabolism biomarkers 
1-C metabolism biomarkers and SMMSE data were available for 752-765 participants 
at baseline, 414-450 at 3 years and 311-318 at 5 years. Attention-specific scores (CDR) were 
available for 705-718 participants at baseline, 528-538 at 1.5 years and 391-400 at 3 years 
depending on the 1-C metabolism assay used. The median concentration for tHcy, RBC folate 
and plasma vitamin B12 was 16.7 µmol/L (IQR:13.5-21.4), 863 (IQR:451-1287) nmol/L and 
232 pmol/L (IQR:170-324), respectively in the Newcastle 85+ Study (169). A concentration >15 
µmol/L of tHcy is commonly used to define hyperhomocysteinemia and, concentrations 
<340 nmol/L and <148 pmol/L to define inadequacy of RBC folate and plasma vitamin B12, 
respectively. Sixty-three percent of the cohort (n=482) had tHcy concentrations >15 µmol/L, 
4% (n=26) had RBC folate concentrations <340 nmol/L and 17% (n=125) had plasma vitamin 
B12 concentrations < 148 pmol/L (169).  Table 6.1-Table 6.3 show the population 
characteristics at baseline and cognitive scores at follow-up by quartile of RBC folate (Q1: 
<612, Q2: 612-870, Q3: 870-1280, Q4: >1280 nmol/L), plasma vitamin B12 (Q1: >170, Q2: 
170-232, Q3: 232-325, Q4: >325 pmol/L) and tHcy (Q1: >13.5, Q2: 13.5-16.7, Q3: 16.7-21.4, 
Q4: >21.4 µmol/L), respectively. There were fewer APOE ε4 carriers in quartile 2 (17%) than 
in other quartiles (28-32%) of RBC folate (p=0.002), and fewer individuals in quartile 1 with 
history of cardiovascular diseases (45%) than in other quartiles (57%-63%) (p<0.001). As RBC 
folate increased, so did plasma vitamin B12 and vice-versa. There was an inverse association 
between tHcy and the other 1-C metabolism biomarkers. There were more men in tHcy 
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quartile 3 (50%) than in other quartiles (p<0.001). Furthermore, participants in quartile 4 of 
tHcy concentrations (>21.3 µmol/L) were less physically active and more likely to be renally 
impaired compared with those in other quartiles (Table 6.3). 
Longitudinal associations with cognitive performance 
Participants lost to follow-up (died or unable to complete any cognitive test) after 5 
years (n=501) had slightly higher median tHcy (p=0.01) and plasma vitamin B12 
concentrations (p=0.05), were more likely to be APOE ε4 carriers (p=0.01), less likely to drink 
alcohol (p<0.001), less physically active (p<0.001), more likely to have a history of CVD 
(p=0.003), diabetes type 1 and 2 (p=0.01) and Alzheimer’s disease/dementia (p<0.001), and 
more likely to live in institutions (p<0.001) at baseline compared with those who had SMMSE 
data 5 years later. Furthermore, more participants lost to follow-up during every phase were 
cognitively impaired than those who continued on the study. 
Table 6.4 shows the associations between RBC folate, plasma vitamin B12 and tHcy 
quartiles and attention specific and global cognitive decline over 3 and 5 years, respectively 
using linear mixed models.  
Participants in the highest quartile of RBC folate concentrations had 1 more point on 
the SMMSE at baseline than those in quartile 1 (β=+1.02, SE=0.43, p=0.02) after adjustment 
for sex, alcohol intake, smoking status, APOE genotype, education, BMI, depression, diabetes 
type 1 and 2, hypertension, history of cardiovascular disease, physical activity and tHcy 
(Table 6.4). Plasma vitamin B12 concentration measured at baseline was not predictive of 
global cognition (SMMSE) in the non-adjusted or fully adjusted models. Conversely, 
participants in the highest quartile of tHcy had 1 point less on the SMMSE score than those 
in the lowest quartile at baseline (β=-1.05, SE=0.46, p=0.02). Folate, vitamin B12 and tHcy 
were not predictive of any attention-specific measures (PoA, CoA and RTV) over 3 years 
(Table 6.4).  
Prevalent and incident cognitive impairment  
Binary logistic regression models, adjusted for the same covariates, showed that 
participants in quartile 4 of tHcy had an increased risk (OR: 2.15, CI: 1.12-4.11, p=0.02) of 
prevalent cognitively impairment (defined as SMMSE≤25 points in SMMSE) than those in 
quartile 4, but not for incident impairment after 3 or 5 years (Supplemental Table 6.1).  
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Rate of cognitive decline by 1-C metabolism biomarkers 
All domains of cognitive performance declined significantly (lower scores of SMMSE 
and CoA and higher scores in PoA and RTV) with time. SMMSE and CoA decreased on 
average by 1.68 (SE: 0.18, p<0.001) and by 1.27 ms (SE: 0.3, p<0.001) respectively, PoA and 
RTV (ln) increased by 105 ms (SE:15, p<0.001) and by 0.021 (SE:0.008), p=0.01) respectively, 
for every phase. There were no significant changes in the rate of global cognitive decline 
(SMMSE) by quartiles of RBC folate, plasma vitamin B12 and tHcy (Table 6.4). There were 
also no significant differences in the rate of decline in attention-specific scores (CDR) except 
for a slower decline in focused attention (PoA) (e.g. Q4 vs. Q1: β=-100 SE=44, p=0.02) and a 
trend for slower decline of sustained attention (CoA) (e.g. Q4 vs Q1: β=+1.58 SE=0.87, 
p=0.07) in the higher quartiles of tHcy concentration (Table 6.4 and Supplemental Figure 
6.1-Supplemental Figure 6.3).  
Sensitivity analysis 
Sensitivity analyses excluding those with diagnosed Alzheimer’s disease/dementia 
(n=52-56), living in institutions at baseline (n=61-62), use of folic acid or vitamin B12 
containing supplements (n=35-37), with RBC folate concentrations >4000 nmol/L (n=6), 
plasma vitamin B12 concentrations >1000 pmol/L (n=16) or tHcy concentrations >40 µmol/L 
(n=16) did not generally change the results. However, higher homocysteine quartiles were 
significantly associated with higher scores in PoA (poorer performance) over 5 years when 
participants diagnosed with dementia or Alzheimer’s disease at baseline were excluded. The 
interaction between quartiles of tHcy concentration and time for focused attention (PoA) 
was no longer present when these same participants were excluded from the analysis.  
CHAPTER 6 
85 
 
Table 6.1. Population characteristics and cognitive test scores at baseline and at follow-up in the Newcastle 85+ Study by quartile of red 
blood cell folate concentration. 
 Q1 (<612 nmol/L) Q2 (612-870 nmol/L) Q3 (870-1280 nmol/L) Q4 (>1280 nmol/L) p1 
Men (%, n) 41 (77) 38 (72) 40 (75) 38 (72) 0.86 
BMI (kg/m2) (mean, SD) 24.2 (4.3) 24.7 (4.5) 24.3 (4.1) 24.4 (4.3) 0.782 
APOE ε4 carriers (%, n) 32 (49) 17 (25) 30 (47) 28 (42) 0.02 
Plasma Vitamin B12 (pmol/L) 201 (135-280) 216 (159-275) 259 (193-371) 278 (205-391) <0.001 
Total Homocysteine (µmol/L) 19.9 (16.3-24.6) 18.3 (14.9-22.9) 15.6 (13.0-19.6) 13.8 (11.1-17.4) <0.001 
Alcohol Drinkers (%, n) 70 (92) 73 (94) 80 (96) 66 (89) 0.10 
Smokers (%, n) 9 (16) 4 (8) 4 (8) 5 (10) 0.35 
Physical Activity (High) (%, n) 38 (71) 33 (62) 34 (63) 37 (68) 0.75 
Education (≥12 y) (%, n) 11 (20) 11 (20) 14 (25) 14 (26) 0.18 
History of Cardiovascular disease (%, n) 45 (84) 57 (108) 66 (123) 63 (119) <0.001 
Diabetes type 1 or 2 (%, n) 9 (16) 16 (31) 13 (25) 17 (32) 0.08 
Hypertension (%, n) 54 (100) 59 (112) 54 (101) 65 (122) 0.12 
Renal Impairment (%, n) 20 (38) 26 (49) 22 (41) 28 (52) 0.36 
Depression (Severe) (%, n) 4 (7) 10 (19) 11 (19) 9 (16) 0.25 
Global cognition (SMMSE) 
Baseline 27 (24-29) 28 (25-29) 28 (25-29) 28 (25-29) 0.17 
Impaired (≤25) (%, n) 31 (58) 25 (48) 26 (49) 25 (48) 0.52 
3 years 27 (23-29) 28 (24-29) 26 (23-29) 27 (25-29) 0.19 
Impaired (≤25) (%, n) 37 (41) 35 (35) 40 (48) 25 (27) 0.10 
5 years 28 (23-29) 27 (23-29) 27 (23-28) 28 (25-29) 0.17 
Impaired (≤25) (%, n) 32 (26) 37 (27) 43 (33) 26 (21) 0.16 
Focused attention (PoA, ms) 
Baseline 1499 (1341-1691) 1494 (1371-1752) 1484 (1360-1719) 1473 (1341-1667) 0.54 
1.5 years 1546 (1398-1745) 1538 (1377-1740) 1533 (1399-1731) 1515 (1366-1718) 0.84 
3 years 1594 (1409-1777) 1567 (1378-1775) 1550 (1420-1782) 1490 (1367-1688) 0.16 
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 Q1 (<612 nmol/L) Q2 (612-870 nmol/L) Q3 (870-1280 nmol/L) Q4 (>1280 nmol/L) p1 
Sustained attention (CoA, ms) 
Baseline 87.8 (80.7-91.4) 87.5 (80.8-91.0) 85.7 (77.0-91.0) 87.7 (82.3-91.3) 0.20 
1.5 years 86.6 (79.4-90.4) 88.0 (81.9-91.6) 87.0 (78.4-90.5) 86.5 (80.8-90.9) 0.24 
3 years 86.7 (81.1-91.0) 86.8 (79.4-90.7) 86.4 (78.6-90.7) 87.0 (82.2-91.5) 0.73 
Reaction time variability (RTV) 
Baseline 59.1 (50.6-71.4) 61.2 (54.6-71.7) 61.5 (53.2-73.1) 57.6 (50.3-68.6) 0.06 
1.5 years 60.0 (53.8-71.0) 60.0 (52.1-68.2) 60.2 (52.2-72.0) 57.6 (52.1-67.0) 0.68 
3 years 59.9 (50.8-70.0) 59.8 (49.4-69.6) 61.4 (51.8-72.3) 59.3 (50.3-66.7) 0.60 
Lower scores in PoA and RTV and, higher scores in CoA reflect better performance. Continuous variables are presented as medians and IQR 
unless otherwise stated. History of cardiovascular disease includes cardiac, cerebrovascular and peripheral vascular diseases. 1 No quartile 
difference by Chi-squared test (χ2) for categorical or by Kruskal-Wallis test for non-parametric continuous variables. 2 No BMI difference by 
one-way ANOVA. CoA, continuity of attention; IQR, interquartile range; ms, milliseconds; PoA, power of attention; Q, quartile; RTV, reaction 
time variability; SD, standard deviation; SMMSE, Standardized Mini-mental State Examination.
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Table 6.2. Population characteristics and cognitive test scores at baseline and at follow-up in the Newcastle 85+ Study by quartile of plasma 
vitamin B12 concentration. 
 Q1 (<170 pmol/L) Q2 (170-232 pmol/L) Q3 (232-325 pmol/L) Q4 (>325 pmol/L) p1 
Men (%, n) 42 (79) 41 (77) 39 (74) 35 (66) 0.56 
BMI (kg/m2) (mean, SD) 25.1 (4.5) 23.8 (4.1) 25.0 (4.3) 23.7 (4.3) 0.0012 
APOE ε4 carriers (%, n) 26 (40) 24 (38) 23 (35) 32 (50) 0.30 
Red blood cell folate (nmol/L) 683 (479-992) 838 (605-1159) 913 (690-1393) 1058 (745-1608) <0.001 
Total Homocysteine (µmol/L) 19.7 (15.9-25.1) 17.3 (14.5-21.8) 15.9 (13.3-19.8) 13.9 (11.1-18.2) <0.001 
Alcohol Drinkers (%, n) 73 (103) 72 (91) 80 (91) 65 (86) 0.07 
Smokers (%, n) 6 (11) 5 (10) 6 (12) 5 (9) 0.77 
Physical Activity (High) (%, n) 38 (72) 37 (68) 34 (63) 33 (62) 0.55 
Education (≥12 y) (%, n) 10 (19) 13 (23) 14 (27) 12 (22) 0.15 
History of Cardiovascular disease (%, n) 51 (96) 60 (113) 62 (117) 57 (108) 0.10 
Diabetes type 1 or 2 (%, n) 12 (23) 18 (33) 12 (22) 13 (25) 0.32 
Hypertension (%, n) 58 (111) 54 (100) 61 (114) 59 (110) 0.55 
Renal Impairment (%, n) 23 (44) 27 (51) 23 (44) 22 (41) 0.65 
Depression (Severe) (%, n) 8 (14) 8 (14) 10 (18) 9 (15) 0.90 
Dementia/ Alzheimer (%, n) 6 (12) 8 (14) 8 (15) 6 (11) 0.83 
Global cognition (SMMSE) 
Baseline 28 (25-29) 27 (25-29) 28 (25-29) 28 (25-29) 0.73 
Impaired (≤25) (%, n) 28 (53) 26 (49) 27 (50) 27 (51) 0.99 
3 years 27 (23-29) 27 (25-29) 27 (24-29) 27 (24-29) 0.94 
Impaired (≤25) (%, n) 40 (48) 32 (35) 31 (33) 35 (35) 0.47 
5 years 27 (22-29) 27 (24-29) 27 (23-28) 28 (24-29) 0.95 
Impaired (≤25) (%, n) 38 (33) 35 (28) 32 (24) 33 (23) 0.83 
Focused attention (PoA, ms) 
Baseline 1502 (1351-1723) 1497 (1370-1710) 1482 (1356-1676) 1467 (1342-1705) 0.75 
1.5 years 1537 (1370-1848) 1519 (1390-1799) 1548 (1402-1694) 1506 (1373-1725) 0.95 
3 years 1503 (1361-1744) 1560 (1389-1778) 1555 (1425-1732) 1547 (1405-1757) 0.69 
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 Q1 (<170 pmol/L) Q2 (170-232 pmol/L) Q3 (232-325 pmol/L) Q4 (>325 pmol/L) p1 
Sustained attention (CoA, ms) 
Baseline 87.8 (80.7-91.6) 86.8 (81.5-90.9) 87.5 (18.7-91.7) 86.6 (78.5-90.8) 0.54 
1.5 years 86.8 (81.2-90.9) 87.3 (82.0-90.8) 87.9 (79.6-91.0) 85.8 (78.9-90.7) 0.63 
3 years 86.9 (81.7-91.3) 87.5 (81.0-90.4) 88.3 (81.1-91.8) 85.3 (79.6-90.0) 0.09 
Reaction time variability (RTV) 
Baseline 60.9 (52.0-70.4) 60.2 (51.0-70.3) 59.6 (52.2-69.6) 58.9 (51.2-72.2) 1.00 
1.5 years 60.0 (51.2-67.7) 60.1 (53.7-70.8) 60.4 (52.1-68.3) 57.3 (51.1-68.8) 0.45 
3 years 59.9 (49.5-67.4) 59.8 (51.5-71.6) 59.2 (51.3-67.8) 60.9 (50.6-71.5) 0.74 
Lower scores in PoA and RTV and, higher scores in CoA reflect better performance. Continuous variables are presented as medians and IQR 
unless otherwise stated. History of cardiovascular disease includes cardiac, cerebrovascular and peripheral vascular diseases. 1 No quartile 
difference by Chi-squared test (χ2) for categorical or by Kruskal-Wallis test for non-parametric continuous variables. 2 No BMI difference by 
one-way ANOVA. CoA, continuity of attention; IQR, interquartile range; ms, milliseconds; PoA, power of attention; Q, quartile; RTV, reaction 
time variability; SD, standard deviation; SMMSE, Standardized Mini-mental State Examination.
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Table 6.3. Population characteristics and cognitive test scores at baseline and at follow-up in the Newcastle 85+ Study by quartile of total 
homocysteine concentration. 
 Q1 (<13.5 µmol/L) Q2 (13.5-16.7 µmol/l) Q3 (16.7-21.4 µmol/l) Q4 (>21.4 µmol/L) p* 
Men (%, n) 32 (61) 32 (62) 50 (96) 43 (83) <0.001 
BMI (kg/m2) (mean, SD) 24.3 (4.4) 24.3 (4.3) 24.9 (4.5) 24.5 (4.3) 0.44† 
APOE ε4 carriers (%, n) 23 (35) 28 (46) 29 (44) 26 (40) 0.70 
Red blood cell folate (nmol/L) 1272 (896-1748) 940 (675-1279) 779 (573-1084) 680 (477-898) <0.001 
Plasma vitamin B12 (pmol/L) 297 (225-430) 230 (185-303) 225 (161-293) 186 (134-262) <0.001 
Alcohol Drinkers (%, n) 69 (86) 73 (101) 80 (102) 68 (90) 0.14 
Smokers (%, n) 5 (9) 3 (5) 7 (14) 8 (15) 0.01 
Physical Activity (High) (%, n) 38 (72) 34 (65) 38 (72) 31 (58) 0.02 
Education (≥12 y) (%, n) 15 (28) 13 (25) 12 (22) 9 (17) 0.57 
History of Cardiovascular disease (%, n) 56 (106) 58 (112) 59 (113) 59 (113) 0.88 
Diabetes type 1 or 2 (%, n) 14 (27) 13 (25) 13 (25) 16 (31) 0.80 
Hypertension (%, n) 56 (107) 52 (99) 59 (113) 63 (121) 0.14 
Renal Impairment (%, n) 8 (15) 15 (29) 22 (41) 51 (98) <0.001 
Depression (Severe) (%, n) 9 (16) 11 (19) 5 (9) 10 (18) 0.52 
Dementia/ Alzheimer (%, n) 9 (17) 8 (15) 6 (12) 7 (13) 0.77 
Global cognition (SMMSE) 
Baseline 28 (26-29) 28 (26-29) 28 (25-29) 27 (24-29) 0.01 
Impaired (≤25) (%, n) 24 (46) 23 (45) 29 (55) 32 (61) 0.19 
3 years 27 (24-29) 27 (24-29) 27 (25-29) 27 (22-29) 0.46 
Impaired (≤25) (%, n) 31 (35) 30 (34) 35.0 (43) 43 (42) 0.17 
5 years 28 (25-28) 27 (23-29) 28 (25-29) 27 (23-29) 0.80 
Impaired (≤25) (%, n) 32 (28) 38 (31) 28 (24) 41 (26) 0.32 
Focused attention (PoA, ms) 
Baseline 1450 (1326-1662) 1486 (1354-1723) 1476 (1351-1659) 1517 (1409-1753) 0.03 
1.5 years 1532 (1371-1731) 1519 (1371-1711) 1513 (1379-1724) 1601 (1444-1782) 0.13 
3 years 1492 (1369-1689) 1546 (1383-1749) 1564 (1442-1786) 1559 (1406-1800) 0.25 
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 Q1 (<13.5 µmol/L) Q2 (13.5-16.7 µmol/l) Q3 (16.7-21.4 µmol/l) Q4 (>21.4 µmol/L) p* 
Sustained attention (CoA, ms) 
Baseline 87.8 (80.7-91.7) 87.6 (81.4-91.3) 87.3 (79.2-90.8) 86.3 (78.3-91.3) 0.44 
1.5 years 86.0 (81.7-90.8) 88.2 (82.7-91.5) 88.0 (81.5-90.8) 85.1 (76.8-90.2) 0.02 
3 years 86.8 (80.2-91.8) 87.5 (81.0-91.7) 87.0 (81.3-90.7) 86.3 (76.5-90.0) 0.35 
Reaction time variability (RTV) 
Baseline 57.1 (50.8-67.3) 61.8 (52.0-72.1) 60.3 (51.5-72.8) 61.2 (53.0-71.8) 0.08 
1.5 years 60.5 (53.1-71.1) 57.0 (50.8-67.0) 59.4 (52.9-67.8) 62.9 (54.0-71.4) 0.04 
3 years 55.8 (49.6-67.8) 60.8 (52.0-68.6) 60.7 (51.2-72.5) 61.8 (51.6-69.7) 0.34 
Lower scores in PoA and RTV and, higher scores in CoA reflect better performance. Continuous variables are presented as medians and IQR 
unless otherwise stated. History of cardiovascular disease includes cardiac, cerebrovascular and peripheral vascular diseases. * No quartile 
difference by Chi-squared test (χ2) for categorical or by Kruskal-Wallis test for non-parametric continuous variables. † No BMI difference by 
one-way ANOVA. CoA, continuity of attention; IQR, interquartile range; ms, milliseconds; PoA, power of attention; Q, quartile; RTV, reaction 
time variability; SD, standard deviation; SMMSE, Standardized Mini-mental State Examination.
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Table 6.4. Association between folate, vitamin B12 and homocysteine and attention 
specific and global cognitive decline in the Newcastle 85+ Study. 
1-C Biomarker 
Change over Time, β 
(SE); p value 
Intercept, β (SE); p 
value 
Biomarker x Time, β 
(SE); p value 
Global cognitive function (SMMSE) 
Red blood cell folate (nmol/L) 
Q2 (612-870) 
-1.69 (0.18); <0.001 
+0.57 (0.42); 0.17 -0.38 (0.51); 0.46 
Q3 (870-1280) +0.61 (0.42); 0.15 -0.88 (0.49); 0.08 
Q4 (>1280) +1.02 (0.43); 0.02 +0.13 (0.51); 0.80 
Plasma vitamin B12 (pmol/L) 
Q2 (170-232) 
-1.68 (0.18); <0.001 
+0.62 (0.42); 0.14 +0.50 (0.49); 0.30 
Q3 (232-325) -0.15 (0.43); 0.73 -0.55 (0.50); 0.27 
Q4 (>325) +0.54 (0.43); 0.21 +0.15 (0.51); 0.77 
Total homocysteine (µmol/L) 
Q2 (13.5-16.7) 
-1.68 (0.18); <0.001 
-0.53 (0.41); 0.20 +0.61 (0.52); 0.24 
Q3 (16.7-21.4) -0.74 (0.43); 0.08 -0.09 (0.51); 0.86 
Q4 (>21.4) -1.05 (0.46); 0.02 -0.35 (0.53); 0.28 
Focused attention (PoA, ms) 
Red blood cell folate (nmol/L) 
Q2 (612-870) 
+104 (15); <0.001 
+19 (62); 0.76 -10 (43); 0.82 
Q3 (870-1280) +20 (63); 0.75 +98 (42); 0.02 
Q4 (>1280) -45 (63); 0.48 +27 (43); 0.52 
Plasma vitamin B12 (pmol/L) 
Q2 (170-232) 
+105 (15); <0.001 
-95 (62); 0.13 +40 (42); 0.34 
Q3 (232-325) -41 (62); 0.52 +26 (43); 0.55 
Q4 (>325) -114 (64); 0.07 +35 (43); 0.42 
Total homocysteine (µmol/L) 
Q2 (13.5-16.7) 
+105 (15); <0.001 
+108 (61); 0.08 -110 (42); 0.01 
Q3 (16.7-21.4) +53 (63); 0.40 -93 (42); 0.03 
Q4 (>21.4) +81 (68); 0.23 -100 (44); 0.02 
Sustained Attention (CoA, ms) 
Red blood cell folate (nmol/L) 
Q2 (612-870) 
-1.26 (0.30); <0.001 
0.91 (1.20); 0.45 -0.34 (0.84); 0.69 
Q3 (870-1280) -1.27 (1.22); 0.30 -0.45 (0.83); 0.58 
Q4 (>1280) +1.00 (1.23); 0.41 -1.07 (0.84); 0.21 
Plasma vitamin B12 (pmol/L) 
Q2 (170-232) 
-1.27 (0.30); <0.001 
+0.76 (1.21); 0.53 -0.45 (0.81); 0.58 
Q3 (232-325) -1.00 (1.22); 0.41 -0.62 (0.83); 0.45 
Q4 (>325) -0.32 (1.24); 0.80 -0.75 (0.84); 0.37 
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1-C Biomarker 
Change over Time, β 
(SE); p value 
Intercept, β (SE); p 
value 
Biomarker x Time, β 
(SE); p value 
Total homocysteine (µmol/L) 
Q2 (13.5-16.7) 
-1.27 (0.30); <0.001 
+0.38 (1.18); 0.75 +1.65 (0.82); 0.04 
Q3 (16.7-21.4) +1.58 (1.22); 0.20 +2.19 (0.83); 0.01 
Q4 (>21.4) +0.04 (1.32); 0.98 +1.58 (0.87); 0.07 
Reaction time variability (RTV) 
Red blood cell folate (nmol/L) 
Q2 (612-870) 
+0.021 (0.008); 0.01 
+0.017 (0.026); 0.52 -0.037 (0.022); 0.09 
Q3 (870-1280) +0.043 (0.027); 0.10 +0.001 (0.021); 0.97 
Q4 (>1280) -0.019 (0.027); 0.49 +0.028 (0.022); 0.20 
Plasma vitamin B12 (pmol/L) 
Q2 (170-232) 
+0.021 (0.008); 0.01 
+0.015 (0.026); 0.58 +0.001 (0.021); 0.95 
Q3 (232-325) +0.034 (0.027); 0.20 -0.017 (0.021); 0.44 
Q4 (>325) +0.010 (0.027); 0.72 -0.015 (0.022); 0.49 
Total homocysteine (µmol/L) 
Q2 (13.5-16.7) 
+0.021 (0.008); 0.01 
+0.016 (0.026); 0.53 +0.035 (0.028); 0.22 
Q3 (16.7-21.4) +0.018 (0.027); 0.49 +0.030 (0.030); 0.31 
Q4 (>21.4) +0.034 (0.029); 0.24 +0.042 (0.031); 0.18 
For all models, quartile 1 (<612 nmol/L red blood cell folate, <170 pmol/L plasma vitamin 
B12 and <13.5 total homocysteine, respectively) was used as the reference (0.00). Models 
are adjusted for alcohol intake, smoking status, APOE genotype (rs429358 and rs7412), sex, 
education, BMI, depression, hypertension, diabetes type 1 and 2, history of cardiovascular 
diseases and physical activity. Red blood cell folate and plasma vitamin B12 models were 
additionally adjusted for total homocysteine and the homocysteine model for renal 
impairment. Higher scores in the SMMSE and CoA and, lower scores in PoA and RTV tests 
represent better performance. CoA, continuity of attention; ms, milliseconds; PoA, power of 
attention; Q, quartile; RTV, reaction time variability; SE, standard error; SMMSE, 
Standardized Mini-mental State Examination. 
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6.5. Supplemental material 
Supplemental Table 6.1. Association between folate, vitamin B12 and homocysteine and prevalent cognitive impairment at baseline and incident 
cognitive impairment after 5 years (SMMSE<26). 
 
Prevalent Cognitive Impairment Incident Cognitive Impairment 
Model 1 Model 2 Model 1 Model 2 
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Red blood cell folate (nmol/l) 
Q2 (612-870) 0.77 (0.44-1.33) 0.35 0.73 (0.40-1.31) 0.29 1.68 (0.68-4.14) 0.26 1.68 (0.61-4.65) 0.31 
Q3 (870-1280) 0.74 (0.43-1.28) 0.29 0.71 (0.38-1.30) 0.26 2.40 (1.02-5.65) 0.05 2.59 (0.96-7.02) 0.06 
Q4 (>1280) 0.84 (0.49-1.45) 0.53 0.73 (0.40-1.34) 0.31 1.10 (0.42-2.87) 0.84 0.84 (0.27-2.67) 0.88 
Plasma vitamin B12 (pmol/l) 
Q2 (170-232) 0.80 (0.46-1.40) 0.44 0.64 (0.35-1.18) 0.16 1.15 (0.52-2.53) 0.73 1.41 (0.56-3.53) 0.46 
Q3 (232-325) 1.06 (0.62-1.81) 0.84 1.03 (0.57-1.87) 0.93 0.64 (0.26-1.54) 0.32 0.61 (0.23-1.66) 0.34 
Q4 (>325) 0.89 (0.51-1.54) 0.66 0.67 (0.36-1.23) 0.19 0.85 (0.36-2.03) 0.72 1.12 (0.40-4.11) 0.84 
Total homocysteine (µmol/l) 
Q2 (13.5-16.7) 0.99 (0.56-1.75) 0.96 1.05 (0.57-1.96) 0.87 1.12 (0.50-2.54) 0.79 1.71 (0.68-4.30) 0.26 
Q3 (16.7-21.4) 1.18 (0.67-2.09) 0.57 1.40 (0.75-2.60) 0.29 0.79 (0.34-1.88) 0.60 0.97 (0.37-2.56) 0.96 
Q4 (>21.4) 1.55 (0.89-2.69) 0.13 2.15 (1.12-4.11) 0.02 1.10 (0.46-2.64) 0.83 1.81 (0.63-5.25) 0.27 
Quartile 1 (<612 nmol/L red blood cell folate, <170 pmol/L plasma vitamin B12 and <13.5 total homocysteine, respectively) was used as the reference category 
(1.00) for all models. Model 1 is unadjusted, Model 2 is adjusted for alcohol intake, smoking status, APOE genotype (rs429358 and rs7412), sex, education, BMI, 
depression, hypertension, diabetes type 1 and 2, history of cardiovascular diseases and physical activity. Red blood cell folate and plasma vitamin B12 models were 
additionally adjusted for total homocysteine and the homocysteine model for renal impairment. CI; confidence interval; OR, odds ratio; SMMSE, Standardized 
Mini-mental State Examination.
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Supplemental Figure 6.1. Linear decline in cognition by quartiles of red blood cell folate 
concentration. 
 
A. global cognition (SMMSE), B. focused attention (PoA), C. sustained attention (CoA) and D. 
reaction time variability. β estimates were derived from linear mixed models adjusted for 
alcohol intake, smoking status, APOE genotype (rs429358 and rs7412), sex, education, BMI, 
depression, hypertension, diabetes type 1 and 2, history of cardiovascular diseases, physical 
activity and total homocysteine. Quartile 1 was used as the reference (0.00). Higher scores in 
the SMMSE and CoA and, lower scores in PoA and RTV tests represent better performance. 
CoA, continuity of attention; Ln, natural logarithm; ms, milliseconds; PoA, power of 
attention; RTV, reaction time variability; SMMSE, Standardized Mini-mental State 
Examination. 
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Supplemental Figure 6.2. Linear decline in cognition by quartiles of plasma vitamin B12 
concentration. 
 
A. global cognition (SMMSE), B. focused attention (PoA), C. sustained attention (CoA) and D. 
reaction time variability. β estimates were derived from linear mixed models adjusted for 
alcohol intake, smoking status, APOE genotype (rs429358 and rs7412), sex, education, BMI, 
depression, hypertension, diabetes type 1 and 2, history of cardiovascular diseases, physical 
activity and total homocysteine. Quartile 1 was used as the reference (0.00). Higher scores in 
the SMMSE and CoA and, lower scores in PoA and RTV tests represent better performance. 
CoA, continuity of attention; Ln, natural logarithm; ms, milliseconds; PoA, power of 
attention; RTV, reaction time variability; SMMSE, Standardized Mini-mental State 
Examination. 
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Supplemental Figure 6.3. Linear decline in cognition by quartiles of total homocysteine 
concentration. 
 
A. global cognition (SMMSE), B. focused attention (PoA), C. sustained attention (CoA) and D. 
reaction time variability. β estimates were derived from linear mixed models adjusted for 
alcohol intake, smoking status, APOE genotype (rs429358 and rs7412), sex, education, BMI, 
depression, hypertension, diabetes type 1 and 2, history of cardiovascular diseases, physical 
activity and renal impairment. Quartile 1 was used as the reference (0.00). Higher scores in 
the SMMSE and CoA and, lower scores in PoA and RTV tests represent better performance. 
CoA, continuity of attention; Ln, natural logarithm; ms, milliseconds; PoA, power of 
attention; RTV, reaction time variability; SMMSE, Standardized Mini-mental State 
Examination. 
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6.6. Summary 
Although the biological rationale for the association between folate, vitamin B12 and 
homocysteine with cognitive function seems plausible, conflicting results have been 
reported. This chapter aimed to determine the associations between 1-C metabolism 
biomarkers (folate, vitamin B12 and homocysteine), and cognitive impairment at baseline 
and the rate of cognitive decline over 5 years in 765 very old adults. Global cognition was 
measured by the SMMSE at baseline, and at 3 and 5 years of follow-up and, attention-
specific cognition with the CDR system at baseline, and at 1.5 and 3 years of follow-up. 
Baseline RBC folate, plasma vitamin B12 and tHcy concentrations were determined by 
immunoassay. Linear mixed models were used to estimate the associations between 
quartiles of 1-C metabolism biomarkers and cognition over 3 (CDR) and 5 years (SMMSE). 
Compared to participants in the lowest quartile of RBC folate concentrations (<612 nmol/L), 
those in the highest quartile of RBC folate concentrations (>1280 nmol/L) had 1 more point 
on the SMMSE over 5 years (β=+1.02, SE=0.43, p=0.02). Those in quartile 4 of tHcy (>21.4 
µmol/L) had 1 point less in the SMMSE over 5 years than those in the lowest quartile (<13.5 
µmol/L) (β=-1.05, SE=0.46, p=0.02). Plasma vitamin B12 was not predictive of global or 
attention-specific cognition at baseline and at follow-up. None of the 1-C metabolism 
biomarkers except tHcy was associated with the rate of decline in attention scores over 3 
years. RBC folate and tHcy but not plasma vitamin B12 were associated with better global 
cognition in the very old at baseline and over 5 years. 
Chapter 7 is the last experimental chapter in this thesis and will examine associations 
between RBC folate, plasma vitamin B12 and tHcy concentrations at baseline, and all-cause 
and cardiovascular mortality over 9 years mortality follow-up in very old adults.
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CHAPTER SEVEN 
 
 
7. One-carbon metabolism biomarkers and all-
cause and cardiovascular mortality in the very 
old 
 
[Mendonça N et al. (2017) Elevated total homocysteine and plasma vitamin B12 
concentrations are associated with all-cause and cardiovascular mortality in the very old: 
The Newcastle 85+ Study. J Gerontol A Biol Sci Med Sci. In review] 
 
Key words: ‘aged, 80 and over’, Newcastle 85+, homocysteine, folate, vitamin B12, mortality.
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7.1. Abstract 
Folate and vitamin B12 are key to the correct functioning of one-carbon (1-C) 
metabolism. The current evidence on associations between 1-C metabolism biomarkers and 
mortality is inconclusive and generally based on younger populations. This study aimed to 
determine the associations between biomarkers of 1-C metabolism and all-cause and 
cardiovascular (CVD) mortality in the very old. The Newcastle 85+ Study is a prospective 
longitudinal study of participants aged 85 years at recruitment living in Northeast England. 
Baseline red blood cell folate (RBC folate), plasma vitamin B12 and total homocysteine 
(tHcy) concentrations were available for 752-766 participants. Associations between 
biomarkers of 1-C metabolism and all-cause and CVD mortality for up to 9 years were 
assessed by Cox proportional hazard models and confirmed by restricted cubic splines. 
Participants with higher tHcy concentrations had twice the risk of death from any cause 
than those with lower concentrations (e.g. Q4 vs. Q1, HR: 2.05, 95% CI: 1.51-2.77, p<0.001) 
after adjustment for sociodemographic, lifestyle and health variables. Women with elevated 
plasma vitamin B12 concentrations (>500 pmol/L) had increased risk of all-cause mortality 
(HR: 1.70, 95% CI: 1.13-2.56, p=0.011) compared with those with concentrations 148-500 
pmol/L. Higher concentrations of tHcy and plasma vitamin B12 were associated with 
increased risk of all-cause and CVD mortality in the very old. This confirms findings for tHcy 
in younger populations but the adverse relationships between elevated plasma vitamin B12 
concentrations and mortality in this population are novel and require further investigation. 
7.2. Introduction 
 Given the close involvement in 1-C metabolism, it is no surprise that folate and 
vitamin B12 have been associated with cardiovascular disease (CVD), cancer and all-cause 
mortality. However, the current evidence for links between 1-C metabolism biomarkers and 
mortality is inconclusive and most is based on studies in younger populations. A recent 
meta-analysis pooling data from 30 randomized controlled trials (RCTs) reported that folic 
acid supplementation reduced CVD risk by 4% and the risk of stroke by 10% (149). Part of this 
effect might be due to reduction of homocysteine concentrations as supplementation with 
folic acid typically lowers homocysteine concentrations by 13-25% with a further reduction 
of 7% with the addition of vitamin B12 (124). However several studies did not find a 
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significant association between folate status and all-cause and cardiovascular-specific 
mortality (151,197-201). With regards to vitamin B12, it is hypothesized that a very high vitamin 
B12 concentration may be primarily due to disruption and release into the circulation of 
vitamin B12 stores, especially from the liver, but no clear mechanism has been determined 
(114,160). Some have found that high concentrations of vitamin B12 are associated with all-
cause mortality (152,153) while others did not (156-159). 
This chapter aimed to examine associations between red blood cell folate (RBC 
folate), plasma vitamin B12 and total homocysteine (tHcy) concentrations at baseline, and 
all-cause and cardiovascular mortality over 9 years in a large sample of very old adults.  
7.3. Methods 
 Participants 
This chapter uses data from the Newcastle 85+ Study and details were reported in 
Chapter 2, General Methods -  2.1 The Newcastle 85+ Study.  
Biomarkers of 1-C metabolism  
Blood samples collection, tHcy, RBC folate and plasma vitamin B12 analyses, and 
genotyping were described in Chapter 2, General Methods - 2.3 Blood collection, one-carbon 
metabolism biomarkers and genotyping. tHcy, RBC folate and plasma vitamin B12 
concentrations were categorised into the following quartiles: RBC folate - Quartile 1 (Q1) 
<612, Q2:612-870, Q3:870-1280, Q4>1280 nmol/L); tHcy - Q1 <13.5, Q2:13.5-16.7, Q3:16.7-
21.4, Q4>21.4 µmol/L; plasma vitamin B12 - Q1 <170, Q2:170-232, Q3: 232-325, Q4>325 
pmol/L. Sex-specific quartiles were used for sex-specific models. For plasma vitamin B12 
concentrations we also used pre-defined thresholds of <148, 148-500 and >500 pmol/L. 
Plasma vitamin B12 concentration <148 pmol/L is commonly used to diagnose deficiency 
(112) while a concentration >600 pmol/L is used to identify high plasma vitamin B12 
concentrations (154,155). Further, an upper limit of 569 pmol/L is used by the department of 
clinical biochemistry at Newcastle Royal Victoria Infirmary where samples were analysed 
(202). However, because there were not enough participants with plasma vitamin B12 
concentrations >600 pmol/L, >500 pmol/L was used.  
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All-cause and cardiovascular mortality 
Information on dates and cause of death (International classification of diseases and 
related disorders, 10th revision (203)) were obtained from the Health and Social Care 
Information Service (now NHS Digital), UK. Deaths coded as I00-I99 (Chapter IX) were used 
to determine CVD mortality (203). The time to event of interest (all-cause mortality or 
cardiovascular-specific mortality) was calculated as the time between blood draw (2006-
2007) and time of death (or censored at 28 April 2015). Mortality follow-up was conducted 
over 9 years. 
Health assessment and disease count 
Details on the variables recorded by the multidimensional health questionnaires, the 
GP medical records review and the disease count were also described in Chapter 2, General 
Methods - 2.4 Other socioeconomic, health and lifestyle variables. The Standardized Mini-
Mental State Examination (SMMSE) 30-point scale was used to assess global cognitive 
function.  
Statistical analysis 
Longitudinal associations between quartiles of 1-C metabolism biomarkers and 
mortality (all-cause and CVD) were assessed with Kaplan-Meier curves (unadjusted) and Cox 
proportional hazards models. Model 1 was adjusted for sex, years of full time education and 
housing (community-dwelling/ institutionalized), and model 2 was further adjusted for BMI, 
physical activity (low/ medium/ high), smoking status (never/ former/ current), current 
alcohol drinkers (yes/no), disease count, SMMSE and the other 1-C metabolism biomarkers. 
tHcy models were also adjusted for renal impairment (yes/no). The fully adjusted CVD 
mortality model was also adjusted for history of CVD, hypertension and diagnosis of 
diabetes type 1 and 2 instead of disease count.  
A fully-adjusted Cox proportional hazards model using pre-defined thresholds of 
plasma vitamin B12 concentrations was also fitted in sensitivity analysis.  
To confirm findings and to assess the linearity of relationships, restricted cubic 
splines were fitted to the fully adjusted Cox proportional hazards models with 5 knots at 
default locations based on quantiles. For example, the quantiles for the tHcy model for all 
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participants were 10, 14, 17, 21 and 32 µmol/L; for the RBC folate model they were 370, 
639, 868, 1205 and 2244 nmol/L; and 102, 178, 232, 307 and 584 pmol/L for plasma vitamin 
B12. Multicollinearity was checked with tolerance, variation inflation factor and eigenvalues. 
The proportional hazards assumption for 1-C metabolism biomarkers quartiles was tested 
by visual inspection of log(-log(survival) vs log(time) plots and Schoenfeld residuals. Analyses 
were repeated after further adjustment for alanine aminotransferase (ALT), alkaline 
phosphatase and bilirubin concentrations, or further adjustment for high sensitivity C-
reactive protein (hs-CRP), or excluding participants who died during the first year of follow-
up, or who were taking folic acid or vitamin B12 supplements at baseline. 
All analyses were carried out in IBM SPSS statistics v22.0 except for checking the 
Schoenfeld residuals and plotting the restricted cubic splines which used R v3.2.2 (packages 
“survival” and “rms”). General statistical methods are presented in Chapter 2, General 
Methods - 2.5 General statistical analysis. 
7.4. Results 
Over the 4082 person-years of follow-up, 73% (n=564) (13.8 deaths per 100 person-
years) of those that had 1-C metabolism biomarkers measured at baseline died. Of these, 
53% (n=299) (7.3 deaths per 100 person-years) died from CVD. The median survival time 
was 5.5 (IQR: 2.7-8.0) years.  
Data on biomarkers of 1-C metabolism were more likely to be missing from women 
(p=0.004), those who lived in institutions (p<0.001), who were less physically active 
(p<0.001) and who had a lower score in the SMMSE (p=0.030).   
Total homocysteine 
There were more men, more active smokers (p=0.01), more renally impaired 
participants (p<0.001) and with lower concentrations of ALT (p<0.001) in higher quartiles of 
tHcy (p<0.001). tHcy quartiles were inversely associated with RBC folate and plasma vitamin 
B12 concentrations in a dose-dependent manner (p<0.001) (Figure 7.1).  
Survival was longest in Q1 of tHcy concentrations (median: 7.1, 95% CI: 5.9-8.2 years) 
and lowest in Q4 (median: 4.0, 95% CI: 3.3-4.7) (p<0.001) in unadjusted models (Figure 7.1 
and Supplemental Table 7.1). These differences emerged after the first year of follow-up 
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and were present in women (p=0.001) but not in men (Figure 7.1). Participants in Q4 of tHcy 
concentration had twice the risk of death from any cause than those in the lowest quartile 
of tHcy (Q1) in models with all participants (e.g. HR: 2.05, 95% CI: 1.51-2.77, p<0.001) (Table 
7.4), and in both men (Table 7.5) and women (Table 7.6) after adjustment for sex, 
education, housing, BMI, physical activity, smoking, alcohol intake, disease count, SMMSE, 
renal impairment, RBC folate and plasma vitamin B12. Visual inspection of restricted cubic 
splines for tHcy in the fully adjusted Cox proportional hazards model confirmed these 
findings (Figure 7.4.-Figure 7.6) Results were similar for cardiovascular mortality (Figure 7.1 
and Supplemental Figure 7.1-Supplemental Figure 7.3 and Table 7.4-Table 7.6). All 
relationships between tHcy and mortality were linear except for all-cause mortality in men 
(p=0.038)  
Red blood cell folate 
Those in higher quartiles of RBC folate had a slightly higher chronic disease count 
(p=0.01), more history of CVD (<0.001) and higher ALT concentration (p<0.001) than those 
in lower quartiles (Table 7.2).  
Hazard ratios for all-cause and cardiovascular mortality with RBC folate 
concentration quartiles were not significantly different in unadjusted (Figure 7.2) or fully-
adjusted Cox proportional hazards models (Table 7.4-Table 7.6). All relationships between 
RBC folate and mortality were linear (Figure 7.4.-Figure 7.6 and Supplemental Figure 7.1-
Supplemental Figure 7.3).  
Plasma vitamin B12 
There were no significant differences in the prevalence of chronic diseases or risk 
factors between quartiles of plasma vitamin B12 except for BMI (p=0.001) and ALT 
concentration (p=0.034) (Table 7.3). 
Like RBC folate, individuals in different quartiles of plasma vitamin B12 concentration 
had similar survival rates in unadjusted Kaplan-Meier estimates (Figure 7.3) and fully-
adjusted Cox models (Table 7.4-Table 7.6). However, women in Q4 (>336 pmol/L) had a 
higher risk of cardiovascular death compared with those in Q1 (<174 pmol/L) (HR: 1.69, 95% 
CI: 1.01-2.85, p=0.046) (Table 7.6) although this association was no longer significant 
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(p=0.078) when those who died in the first year of follow-up were excluded. Visual 
inspection of restricted cubic spline curves showed a linear relationship with mortality. 
Seventeen percent (n=128) of participants had plasma vitamin B12 concentrations 
<148 pmol/L, 76% (n=569) with concentrations 148-500 pmol/L and 7.4% (n=56) with 
concentrations >500 pmol/L. Cox proportional hazards models using these cut-offs showed 
that women with >500 pmol/L of plasma vitamin B12 had increased risk of all-cause 
mortality than those with <148 pmol/L (HR:2.06, 95% CI:1.23-3.47, p=0.006) and 148-500 
pmol/L (HR:1.70, 95% CI:1.13-2.56, p=0.011) and increased risk of CVD mortality 
(Supplemental Table 7.2). Figure 7.4.-Figure 7.6 confirmed these findings. The relationship 
was weaker when those who died during the first year of follow-up were excluded. All 
relationships between plasma vitamin B12 and mortality were linear except for 
cardiovascular mortality in women (p=0.016) (Figure 7.4.-Figure 7.6 and Supplemental 
Figure 7.1-Supplemental Figure 7.3).
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Table 7.1. Population characteristics in the Newcastle 85+ Study by quartiles of total homocysteine. 
 Q1 (<13.5 µmol/L) Q2 (13.5-16.7 µmol/l) Q3 (16.7-21.4 µmol/l) Q4 (>21.4 µmol/L) p1 
Men (%, n) 32 (61) 32 (62) 50 (96) 43 (83) <0.001 
Education (≥12 y) (%, n) 15 (28) 13 (25) 12 (22) 9 (17) 0.57 
Housing (Institutional) (%, n) 8 (15) 9 (17) 7 (13) 9 (17) 0.86 
BMI (mean, SD) 24.3 (4.4) 24.3 (4.3) 24.9 (4.5) 24.5 (4.3) 0.442 
Red blood cell folate (nmol/L) 1272 (896-1748) 940 (675-1279) 779 (573-1084) 680 (477-898) <0.001 
Plasma vitamin B12 (pmol/L) 297 (225-430) 230 (185-303) 225 (161-293) 186 (134-262) <0.001 
Alcohol drinkers (%, n) 69 (86) 73 (101) 80 (102) 68 (90) 0.14 
Smokers (%, n) 5 (9) 3 (5) 7 (14) 8 (15) 0.01 
Physical activity (High) (%, n) 38 (72) 34 (65) 38 (72) 31 (58) 0.02 
Self-rated health (fair or poor) (%, n) 23 (43) 20 (37) 19 (36) 26 (48) 0.45 
Disease count (mean, SD) 2.1 (1.2) 2.2 (1.2) 2.3 (1.2) 2.5 (1.3) 0.082 
History of Cardiovascular disease (%, n) 56 (106) 58 (112) 59 (113) 59 (113) 0.88 
Diabetes type 1 or 2 (%, n) 14 (27) 13 (25) 13 (25) 16 (31) 0.80 
Hypertension (%, n) 56 (107) 52 (99) 59 (113) 63 (121) 0.14 
SMMSE (0-30) 28 (26-29) 28 (26-29) 28 (25-29) 27 (24-29) 0.01 
Renal impairment (%, n) 8 (15) 15 (29) 22 (41) 51 (98) <0.001 
ALT (U/L) 18 (15-23) 17 (14-21) 16 (13-20) 15 (12-19) <0.001 
hs-CRP (mg/L) 2.2 (1.0-5.3) 2.4 (1.3-5.8) 2.6 (1.3-6.1) 3.3 (1.4-6.2) 0.075 
Continuous variables are presented as medians and interquartile range unless otherwise stated. History of cardiovascular disease includes 
cardiac, cerebrovascular and peripheral vascular diseases. 1 No quartile difference by Chi-squared test (χ2) for categorical or by Kruskal-Wallis 
test for non-parametric continuous variables. 2 No BMI or disease count difference by one-way ANOVA. ALT, alanine aminotransferase; BMI, 
body mass index; hs-CRP, high sensitivity C-reactive protein; ms, milliseconds; Q, quartile; SD, standard deviation; SMMSE, standardized mini-
mental state examination. 
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Table 7.2. Population characteristics in the Newcastle 85+ Study by quartiles of red blood cell folate. 
 Q1 (<612 nmol/L) Q2 (612-870 nmol/L) Q3 (870-1280 nmol/L) Q4 (>1280 nmol/L) p1 
Men (%, n) 41 (77) 38 (72) 40 (75) 38 (72) 0.86 
Education (≥12 y) (%, n) 11 (20) 11 (20) 14 (25) 14 (26) 0.18 
Housing (Institutional) (%, n) 12 (22) 7 (14) 7 (12) 7 (14) 0.23 
BMI (mean, SD) 24.2 (4.3) 24.7 (4.5) 24.3 (4.1) 24.4 (4.3) 0.782 
Plasma Vitamin B12 (pmol/L) 201 (135-280) 216 (159-275) 259 (193-371) 278 (205-391) <0.001 
Total Homocysteine (µmol/L) 19.9 (16.3-24.6) 18.3 (14.9-22.9) 15.6 (13.0-19.6) 13.8 (11.1-17.4) <0.001 
Alcohol drinkers (%, n) 70 (92) 73 (94) 80 (96) 66 (89) 0.10 
Smokers (%, n) 9 (16) 4 (8) 4 (8) 5 (10) 0.35 
Physical activity (High) (%, n) 38 (71) 33 (62) 34 (63) 37 (68) 0.75 
Self-rated health (fair or poor) (%, n) 20 (37) 22 (42) 20 (37) 23 (43) 0.88 
Disease count (mean, SD) 2.0 (1.2) 2.3 (1.3) 2.4 (1.2) 2.4 (1.2) 0.01 
History of Cardiovascular disease (%, n) 45 (84) 57 (108)  66 (123) 63 (119) <0.001 
Diabetes type 1 or 2 (%, n) 9 (16) 16 (31) 13 (25) 17 (32) 0.08 
Hypertension (%, n) 54 (100) 59 (112) 54 (101) 65 (122) 0.12 
SMMSE (0-30) 27 (24-29) 28 (25-29) 28 (25-29) 28 (25-29) 0.17 
Renal impairment (%, n) 20 (38) 26 (49) 22 (41) 28 (52) 0.36 
ALT (U/L) 15 (12-20) 16 (13-21) 17 (14-21) 18 (15-22) <0.001 
hs-CRP (mg/L) 2.9 (1.3-6.9) 2.8 (1.2-6.2) 2.5 (1.3-5.8) 2.5 (1.0-5.5) 0.441 
Continuous variables are presented as medians and interquartile range unless otherwise stated. History of cardiovascular disease includes 
cardiac, cerebrovascular and peripheral vascular diseases. 1 No quartile difference by Chi-squared test (χ2) for categorical or by Kruskal-Wallis 
test for non-parametric continuous variables. 2 No BMI or disease count difference by one-way ANOVA. ALT, alanine aminotransferase; BMI, 
body mass index; hs-CRP, high sensitivity C-reactive protein; ms, milliseconds; Q, quartile; SD, standard deviation; SMMSE, standardized mini-
mental state examination. 
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Table 7.3. Population characteristics in the Newcastle 85+ Study by quartiles of plasma vitamin B12. 
 Q1 (<170 pmol/L) Q2 (170-232 pmol/L) Q3 (232-325 pmol/L) Q4 (>325 pmol/L) p1 
Men (%, n) 42 (79) 41 (77) 39 (74) 35 (66) 0.56 
Education (≥12 y) (%, n) 10 (19) 13 (23) 14 (27) 12 (22) 0.15 
Housing (Institutional) (%, n) 6 (12) 7 (13) 8 (15) 12 (22) 0.23 
BMI (mean, SD) 25.1 (4.5) 23.8 (4.1) 25.0 (4.3) 23.7 (4.3) 0.0012 
Red blood cell folate (nmol/L) 683 (479-992) 838 (605-1159) 913 (690-1393) 1058 (745-1608) <0.001 
Total Homocysteine (µmol/L) 19.7 (15.9-25.1) 17.3 (14.5-21.8) 15.9 (13.3-19.8) 13.9 (11.1-18.2) <0.001 
Alcohol Drinkers (%, n) 73 (103) 72 (91) 80 (91) 65 (86) 0.07 
Smokers (%, n) 6 (11) 5 (10) 6 (12) 5 (9) 0.77 
Physical Activity (High) (%, n) 38 (72) 37 (68) 34 (63) 33 (62) 0.55 
Self-rated health (fair or poor) (%, n) 21 (40) 22 (40) 18 (34) 25 (45) 0.52 
Disease count (mean, SD) 2.2 (1.3) 2.4 (1.2) 2.2 (1.2) 2.3 (1.2) 0.51 
History of Cardiovascular disease (%, n) 51 (96) 60 (113) 62 (117) 57 (108) 0.10 
Diabetes type 1 or 2 (%, n) 12 (23) 18 (33) 12 (22) 13 (25) 0.32 
Hypertension (%, n) 58 (111) 54 (100) 61 (114) 59 (110) 0.55 
SMMSE (0-30) 28 (25-29) 27 (25-29) 28 (25-29) 28 (25-29) 0.73 
Renal Impairment (%, n) 23 (44) 27 (51) 23 (44) 22 (41) 0.65 
ALT (U/L) 16 (13-20) 16 (13-21) 17 (14-21) 17 (14-22) 0.03 
hs-CRP (mg/L) 2.7 (1.2-6.3) 3.0 (1.4-5.6) 2.5 (1.2-5.6) 2.3 (1.0-7.0) 0.668 
Continuous variables are presented as medians and interquartile range unless otherwise stated. History of cardiovascular disease includes 
cardiac, cerebrovascular and peripheral vascular diseases. 1 No quartile difference by Chi-squared test (χ2) for categorical or by Kruskal-Wallis 
test for non-parametric continuous variables. 2 No BMI or disease count difference by one-way ANOVA. ALT, alanine aminotransferase; BMI, 
body mass index; hs-CRP, high sensitivity C-reactive protein; ms, milliseconds; Q, quartile; SD, standard deviation; SMMSE, standardized mini-
mental state examination.
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Figure 7.1. Kaplan-Meier plot of the probability of survival for all-cause and cardiovascular mortality by quartiles of total homocysteine. 
 
Total homocysteine quartiles for all-cause mortality in A. all, B. men and C. women and for cardiovascular mortality in D. all, E. men and F. 
women. Q, quartile. Crosses indicate censoring.
CHAPTER 7 
109 
 
Figure 7.2. Kaplan-Meier plot of the probability of survival for all-cause and cardiovascular mortality by quartiles of red blood cell folate. 
 
Red blood cell folate quartiles for all-cause mortality in A. all, B. men and C. women and for cardiovascular mortality in D. all, E. men and F. 
women. Q, quartile. Crosses indicate censoring.
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Figure 7.3. Kaplan-Meier plot of the probability of survival for all-cause and cardiovascular mortality by quartiles of plasma vitamin B12. 
 
Plasma vitamin B12 quartiles for all-cause mortality in A. all, B. men and C. women and for cardiovascular mortality in D. all, E. men and F. 
women. Q, quartile. Crosses indicate censoring.
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Table 7.4. Hazard ratios for all-cause and cardiovascular mortality by total homocysteine, red blood cell folate and plasma vitamin B12 
quartiles in all participants. 
 All-cause mortality Cardiovascular mortality 
 Model 1 Model 2 Model 1 Model 2 
Quartiles HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p 
 Total Homocysteine (µmol/L) 
<13.5 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
13.5-16.7 1.36 1.05-1.76 0.018 1.78 1.36-2.33 <0.001 1.39 0.98-1.96 0.067 1.79 1.24-2.58 0.002 
16.7-21.4 1.23 0.94-1.61 0.106 1.43 1.08-1.88 0.011 1.33 0.95-1.88 0.101 1.65 1.14-2.40 0.008 
>21.4 1.67 1.30-2.15 <0.001 2.05 1.51-2.77 <0.001 1.68 1.20-2.37 0.003 2.29 1.51-3.48 <0.001 
 Red Blood Cell Folate (nmol/L) 
<612 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
612-868 1.12 0.87-1.44 0.375 1.03 0.80-1.34 0.796 1.11 0.79-1.57 0.553 0.89 0.62-1.27 0.515 
868-1280 1.24 0.97-1.58 0.093 1.18 0.92-1.53 0.199 1.35 0.96-1.88 0.084 1.08 0.76-1.54 0.661 
>1280 1.24 0.97-1.59 0.086 1.16 0.89-1.50 0.277 1.37 0.98-1.91 0.067 1.12 0.79-1.60 0.521 
 Plasma Vitamin B12 (pmol/L) 
<170 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
170-232 1.03 0.80-1.32 0.819 0.99 0.77-1.28 0.923 1.36 0.96-1.92 0.083 1.26 0.87-1.81 0.217 
232-325 1.06 0.83-1.36 0.621 1.01 0.78-1.31 0.961 1.41 1.00-2.00 0.048 1.25 0.86-1.81 0.237 
>325 1.14 0.89-1.46 0.292 1.09 0.83-1.42 0.537 1.48 1.05-2.08 0.026 1.43 0.98-2.08 0.067 
Model 1 is adjusted for sex, education and housing; Model 2 is additionally adjusted for body mass index, physical activity, smoking, alcohol 
intake, disease count, mini-mental state examination score and the other 1-C metabolism biomarkers. The cardiovascular mortality model 2 
was also adjusted for history of cardiovascular diseases, hypertension and diagnosis of diabetes type 1 and 2 instead of disease count. The 
total homocysteine model is additionally adjusted for renal impairment. CI, confidence interval; HR, hazard ratio.
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Table 7.5. Hazard ratios for all-cause and cardiovascular mortality by total homocysteine, red blood cell folate and plasma vitamin B12 
quartiles in men. 
 All-cause mortality Cardiovascular mortality 
 Model 1 Model 2 Model 1 Model 2 
Quartiles HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p 
 Total Homocysteine (µmol/L) 
<14.2 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
14.2-18.0 1.43 0.98-2.08 0.062 1.56 1.04-2.33 0.031 1.37 0.84-2.25 0.211 1.62 0.94-2.79 0.081 
18.0-21.9 1.10 0.75-1.62 0.626 1.11 0.73-1.71 0.621 1.26 0.78-2.05 0.348 1.62 0.93-2.82 0.091 
>21.9 1.63 1.12-2.38 0.011 1.80 1.13-2.89 0.014 1.45 0.87-2.40 0.152 2.09 1.09-4.01 0.026 
 Red Blood Cell Folate (nmol/L) 
<585 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
585-865 0.91 0.62-1.36 0.656 0.94 0.63-1.41 0.762 0.89 0.53-1.51 0.671 0.73 0.42-1.27 0.261 
865-1271 1.33 0.91-1.94 0.137 1.34 0.90-2.00 0.149 1.39 0.84-2.30 0.201 1.09 0.63-1.87 0.763 
>1271 1.14 0.78-1.67 0.497 1.16 0.77-1.74 0.479 1.36 0.83-2.23 0.227 1.24 0.73-2.10 0.427 
 Plasma Vitamin B12 (pmol/L) 
<166 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
166-228 0.99 0.68-1.43 0.943 1.08 0.72-1.60 0.720 1.18 0.70-1.99 0.546 1.08 0.62-1.89 0.776 
228-309 1.19 0.83-1.71 0.351 1.25 0.84-1.86 0.278 1.80 1.10-2.95 0.020 1.60 0.92-2.75 0.094 
>309 1.04 0.72-1.51 0.831 0.99 0.64-1.53 0.976 1.46 0.88-2.41 0.146 1.17 0.65-2.10 0.609 
Model 1 is adjusted for education and housing; Model 2 is additionally adjusted for body mass index, physical activity, smoking, alcohol intake, 
disease count, mini-mental state examination score and the other 1-C metabolism biomarkers. The cardiovascular mortality model 2 was also 
adjusted for history of cardiovascular diseases, hypertension and diagnosis of diabetes type 1 and 2 instead of disease count. The 
homocysteine model is additionally adjusted for renal impairment. CI, confidence interval; HR, hazard ratio.
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Table 7.6. Hazard ratios for all-cause and cardiovascular mortality by total homocysteine, red blood cell folate and plasma vitamin B12 
quartiles in women. 
 All-cause mortality Cardiovascular mortality 
 Model 1 Model 2 Model 1 Model 2 
Quartiles HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p 
 Total Homocysteine (µmol/L) 
<13.2 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
13.2-16.1 1.15 0.82-1.62 0.419 1.75 1.20-2.54 0.003 1.03 0.64-1.65 0.915 1.50 0.90-2.52 0.123 
16.1-21.0 1.29 0.92-1.81 0.147 1.55 1.07-2.24 0.020 1.20 0.75-1.91 0.443 1.35 0.82-2.24 0.239 
>21.0 1.81 1.30-2.50 <0.001 2.60 1.69-3.98 <0.001 1.72 1.11-2.67 0.016 2.38 1.33-4.24 0.003 
 Red Blood Cell Folate (nmol/L) 
<615 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
615-870 1.12 0.80-1.57 0.497 0.92 0.65-1.29 0.620 1.03 0.65-1.65 0.889 0.78 0.48-1.26 0.306 
870-1290 1.07 0.77-1.49 0.675 0.93 0.66-1.32 0.694 1.13 0.72-1.76 0.604 0.82 0.51-1.31 0.406 
>1290 1.23 0.89-1.71 0.213 1.01 0.71-1.43 0.980 1.18 0.75-1.85 0.483 0.83 0.51-1.36 0.457 
 Plasma Vitamin B12 (pmol/L) 
<174 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
174-239 0.93 0.67-1.31 0.689 0.88 0.62-1.24 0.454 1.31 0.82-2.09 0.256 1.28 0.78-2.11 0.324 
239-336 0.95 0.68-1.33 0.774 0.91 0.63-1.30 0.603 1.06 0.65-1.74 0.807 0.92 0.54-1.57 0.772 
>336 1.20 0.87-1.66 0.261 1.19 0.83-1.71 0.336 1.49 0.94-2.37 0.092 1.69 1.01-2.85 0.046 
Model 1 is adjusted for education and housing; Model 2 is additionally adjusted for body mass index, physical activity, smoking, alcohol intake, 
disease count, mini-mental state examination score and the other 1-C metabolism biomarkers. The cardiovascular mortality model 2 was also 
adjusted for history of cardiovascular diseases, hypertension and diagnosis of diabetes type 1 and 2 instead of disease count. The 
homocysteine model is additionally adjusted for renal impairment. CI, confidence interval; HR, hazard ratio
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Figure 7.4. Restricted cubic spline curves of dose-response relationship between one-
carbon metabolism biomarkers and all-cause mortality in all participants. 
 
(A.) total homocysteine, (B.) red blood cell folate and (C.) plasma vitamin B12. Hazard ratios 
are from the fully-adjusted cox regression models. 
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Figure 7.5. Restricted cubic spline curves of dose-response relationship between one-
carbon metabolism biomarkers and all-cause mortality in men. 
 
(A.) total homocysteine, (B.) red blood cell folate and (C.) plasma vitamin B12. Hazard ratios 
are from the fully-adjusted cox regression models. 
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Figure 7.6. Restricted cubic spline curves of dose-response relationship between one-
carbon metabolism biomarkers and all-cause mortality in women. 
 
(A.) total homocysteine, (B.) red blood cell folate and (C.) plasma vitamin B12. Hazard ratios 
are from the fully-adjusted cox regression models.  
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7.5. Supplemental material 
Supplemental Table 7.1. Survival time and deaths by quartiles of biomarkers of one-
carbon metabolism in the Newcastle 85+ Study. 
Total homocysteine (µmol/l) Q1 (<13.5) Q2 (13.5-16.7) Q3 (16.7-21.4) Q4 (>21.4) 
Survival time (years) 7.1 (3.3-8.3) 5.8 (2.5-8.0) 5.4 (3.2-7.9) 4.1 (2.4-7.5) 
Deaths (%, n) 64 (122) 72 (138) 74 (142) 80 (154) 
Cardiovascular deaths (%, n) 33 (62) 38 (73) 42 (81) 43 (82) 
Red blood cell folate (nmol/L) Q1 (<612) Q2 (612-870) Q3 (870-1280) Q4 (>1280) 
Survival time (years) 5.6 (2.9-8.1) 5.5 (2.5-8.1) 5.3 (2.9-7.9) 5.7 (2.6-7.9) 
Deaths (%, n) 70 (130) 70 (133) 75 (140) 75 (141) 
Cardiovascular deaths (%, n) 34 (64) 36 (68) 43 (79) 42 (80) 
Plasma vitamin B12 (pmol/L) Q1 (<170) Q2 (170-232) Q3 (232-325) Q4 (>325) 
Survival time (years) 5.6 (3.3-8.2) 6.1 (2.2-8.0) 5.3 (2.6-7.9) 5.2 (2.5-7.9) 
Deaths (%, n) 71 (134) 70 (130) 75 (140) 76 (142) 
Cardiovascular deaths (%, n) 31 (59) 40 (74) 43 (81) 42 (78) 
Values are medians and interquartile range unless otherwise mentioned. Q, quartile.
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Supplemental Figure 7.1. Restricted cubic spline curves of dose-response relationship 
between one-carbon metabolism biomarkers and cardiovascular mortality in all 
participants. 
 
(A.) total homocysteine, (B.) red blood cell folate and (C.) plasma vitamin B12. Hazard ratios 
are from the fully-adjusted cox regression models.  
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Supplemental Figure 7.2. Restricted cubic spline curves of dose-response relationship 
between one-carbon metabolism biomarkers and cardiovascular mortality in men. 
 
(A.) total homocysteine, (B.) red blood cell folate and (C.) plasma vitamin B12. Hazard ratios 
are from the fully-adjusted cox regression models.  
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Supplemental Figure 7.3. Restricted cubic spline curves of dose-response relationship 
between one-carbon metabolism biomarkers and cardiovascular mortality in women. 
 
(A.) total homocysteine, (B.) red blood cell folate and (C.) plasma vitamin B12. Hazard ratios 
are from the fully-adjusted cox regression models.  
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Supplemental Table 7.2. Hazard ratios for all-cause and cardiovascular mortality by plasma vitamin B12 categories and sex. 
Vit. B12 
(pmol/L) 
 All-cause mortality Cardiovascular mortality 
 Model 1 Model 2 Model 1 Model 2 
n HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p 
All Participants 
<148 124 0.90 0.71-1.14 0.369 0.83 0.64-1.08 0.166 0.62 0.43-0.89 0.009 0.59 0.40-0.88 0.010 
148-500 549 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
>500 53 1.23 0.89-1.69 0.209 1.42 1.03-1.96 0.034 1.06 0.68-1.66 0.791 1.34 0.84-2.11 0.218 
Men 
<148 50 0.89 0.63-1.27 0.526 0.76 0.51-1.14 0.186 0.62 0.37-1.04 0.067 0.62 0.35-1.12 0.112 
148-500 219 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
>500 20 0.90 0.53-1.54 0.695 1.27 0.72-2.26 0.411 0.63 0.27-1.43 0.268 0.70 0.29-1.70 0.431 
Women 
<148 74 0.90 0.65-1.24 0.512 0.82 0.58-1.17 0.279 0.61 0.37-1.02 0.058 0.51 0.29-0.90 0.021 
148-500 330 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
>500 33 1.67 1.12-2.49 0.012 1.70 1.13-2.56 0.011 1.66 0.97-2.84 0.065 2.04 1.17-3.55 0.013 
Model 1 is adjusted for education and housing; Model 2 is additionally adjusted for body mass index, physical activity, smoking, alcohol intake, 
disease count, mini-mental state examination score and the other 1-C metabolism biomarkers. The cardiovascular mortality model 2 was also 
adjusted for history of cardiovascular diseases, hypertension, and diagnosis of diabetes type 1 and 2 instead of disease count. The 
homocysteine model is additionally adjusted for renal impairment. CI, confidence interval; HR, hazard ratio.
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7.6. Summary 
Folate and vitamin B12 are key to the correct functioning of one-carbon (1-C) 
metabolism. The current evidence on associations between 1-C metabolism biomarkers and 
mortality is inconclusive and generally based on younger populations. This chapter aimed to 
determine the associations between biomarkers of 1-C metabolism (tHcy, RBC folate and 
plasma vitamin B12) measured at baseline and all-cause and cardiovascular (CVD) mortality 
in 752-766 very old adults. Associations between biomarkers of 1-C metabolism and all-
cause and CVD mortality for up to 9 years were assessed by Cox proportional hazard models 
and confirmed by restricted cubic splines. Participants with higher tHcy concentrations had 
twice the risk of death from any cause than those with lower concentrations (e.g. Q4 vs. Q1, 
HR: 2.05, 95% CI: 1.51-2.77, p<0.001) after adjustment for sociodemographic, lifestyle and 
health variables. Women with elevated plasma vitamin B12 concentrations (>500 pmol/L) 
had increased risk of all-cause mortality (HR: 1.70, 95% CI: 1.13-2.56, p=0.011) compared 
with those with concentrations 148-500 pmol/L. Higher concentrations of tHcy and plasma 
vitamin B12 were associated with increased risk of all-cause and CVD mortality in the very 
old. This confirms findings for tHcy in younger populations but the adverse relationships 
between elevated plasma vitamin B12 concentrations and mortality in this population are 
novel and require further investigation.  
Chapter 8 is the final chapter of this thesis and will summarise the main findings from 
the 5 experimental chapters (Chapter 3: Macronutrient intake and food sources; Chapter 4: 
Micronutrient intake and food sources; Chapter 5: Intakes of folate and vitamin B12 and 
biomarkers of status; Chapter 6: One-carbon metabolism biomarkers and cognitive decline; 
and Chapter 7: One-carbon metabolism biomarkers and all-cause and cardiovascular 
mortality in the very old). It will also discuss the chapters separately, compare them with 
current relevant literature, state each chapter’s strengths and limitations, explore the 
potential public health implications of the findings and provide recommendations for future 
research. 
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CHAPTER EIGHT 
8. Discussion and Conclusion 
8.1. General findings 
There is a dearth of data on dietary intake, nutritional status and associations with 
health trajectories in the very old in the UK and elsewhere. This thesis successfully used a 
unique cohort of more than 800 very old adults to reach the objectives laid out in Chapter 1, 
Introduction - 1.14 Objectives. The overall objective of providing an accurate snapshot of the 
dietary habits of the very old and examine health trajectories with respect to 1-C 
metabolism biomarkers in the Newcastle 85+ Study was broadly achieved. These are the 
general findings while specific results will be discussed for chapter 3 to 7 in sections 8.2 to 
8.6.  
 Participants in the Newcastle 85+ Study had a median energy intake of 6.7 MJ per 
day where 47%, 37% and 16% were from carbohydrate, fat and protein 
respectively; 
 Median folate intake was 208 µg/day and vitamin B12 was 2.9 µg/day;  
 Intake of several macro and micronutrients did not meet the dietary reference 
values (DRV) currently used in the UK but its health significance in the very old is 
largely unknown;  
 Participants who had higher levels of education, higher social class or were more 
physically active, had more nutrient-dense diets; 
 Cereals and cereal products (CCP) were the top contributors for energy, most 
macronutrients and several micronutrients, including folate and vitamin B12, 
followed by meat and meat products; 
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 Median folate and vitamin B12 status was 863 nmol/L and 232 pmol/L, 
respectively; 
 Folate from CCP may be more bioavailable than from other food sources and the 
relationship between vitamin B12 intake and status was weak; 
 Participants with a higher folate status at baseline had better global cognition 
over 5 years but there was no difference in the rate of cognitive decline; 
 Those with lower concentrations of tHcy performed better in global cognition 
tests but only in cross-sectional analyses; 
 Vitamin B12 status was not predictive of cognitive function and rate of cognitive 
decline; 
 Higher concentrations of tHcy were predictive of all-cause mortality and CVD 
mortality in the very old; 
 Women with elevated vitamin B12 concentrations were at higher risk of death 
from all-causes.  
8.2. Macronutrient intake and food sources 
Main findings 
Participants in the Newcastle 85+ Study had a median energy intake of 6.65 MJ 
where 46.8%, 36.8% and 15.7% were from carbohydrate, fat and protein respectively. 
Cereals and cereal products (CCP) were the top contributors to most macronutrients, 
followed by meat and meat products. Only 20% of the cohort had higher energy intakes than 
the estimated average requirement (EAR). This recommendation was established for those 
aged ≥ 75 years and its relevance for those aged 85 years is unclear. Most participants did 
not meet the DRV for non-starch polysaccharide (NSP) and saturated fatty acid (SFA) intake 
(91% and 72%, respectively). NSP intake was higher in non-institutionalised, more educated, 
from higher social class and more physically active 85 year olds. 
Comparison with other studies 
The Newcastle 85+ Study is the first to investigate the dietary intakes of such a large 
and sociodemographically representative sample of 85 year olds in the UK. There have been 
two earlier studies with considerable numbers of 85 year olds: the 1994-95 NDNS of people 
aged 65 years old and over (172 men and 287 women aged 85 and over) (10) and the 
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European Prospective Investigation into Cancer and Nutrition (EPIC)-Oxford study (411 men 
and 872 women aged 80 and over at the third follow-up in 2010-2014) (14).  
Non-institutionalised (standard and sheltered housing) very old adults (aged 85 and 
over) in the 1994-95 NDNS had lower median energy (6.99 MJ and 5.60 MJ in men and 
women, respectively), carbohydrate, fat and protein intakes but higher non-milk extrinsic 
sugar (NMES), SFA, monounsaturated (MUFA) and polyunsaturated fatty acid (PUFA) intake 
than the Newcastle 85+ participants (49). The food groups used in the Newcastle 85+ Study 
are comparable with those used in the NDNS and our analysis showed that food sources of 
macronutrients for non-institutionalised very old adults were similar in both studies. 
However, very old respondents in the NDNS derived more energy (15% vs. 9%) and SFA (29% 
vs. 19%) from milk and milk products, more carbohydrate (13% vs. 9%) and NMES (44% vs. 
32%) from sugar, preserves and confectionery and, more NSP from CCP (50% vs. 42%) than 
in the Newcastle 85+ Study cohort (49). While the Newcastle 85+ Study included 85 year olds 
only, the 1994-95 NDNS included those aged 85 and over. Further, dietary data collection 
diverged by more than a decade which might reflect not only different dietary habits but 
also different prevalence of age-related diseases and disabilities (135).  
At the third follow-up, EPIC-Oxford participants had higher mean energy intake (9.84 
MJ and 9.02 MJ in men and women, respectively), percentage of energy from carbohydrate, 
NSP intake and P: S ratio than the Newcastle 85+ Study participants but fat and SFA did not 
contribute to energy intake as much (personal communication from Professor Tim Key and 
Dr. Paul Appleby). Some notable differences between the two studies include different ages 
(80 and over vs. 85 year olds), dietary assessment methods (food frequency questionnaire 
vs. 24hr-MPR), dietary habits (14% of the participants aged 80 and over in the EPIC-Oxford 
were vegetarians or vegans) and use of different descriptive statistics to report the results 
(mean vs. median).  
It will take several years until the current NDNS rolling programme has similar 
numbers of very old adults to compare with the Newcastle 85+ Study. Until then, the 
contemporary dietary data from the Newcastle 85+ Study are likely to be the most reliable 
for this age group. However, younger counterparts in the NDNS (191 men and 237 women 
aged 65 and over - weighted) had similar macronutrient intakes to those of the Newcastle 
85+ Study cohort except for the percentage of energy from protein and NSP intake, which 
were higher in the NDNS (74,177). The top food group contributors did not greatly differ but 
sugar, preserves and confectionery contributed less to NMES intake and CCP and oils and fat 
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spreads contributed less to total fat intake in the NDNS current rolling programme’ older 
adults than in the Newcastle 85+ Study (74,177). Differences between studies might reflect 
age-specific dietary habits. 
Significance and explanations 
A European Society for Clinical Nutrition and Metabolism (ESPEN) consensus 
statement defines unintentional weight-loss as >5% over 3 months or >10% of habitual 
weight (irrespective of time) as one of the criteria for diagnosing malnutrition (204). The 
majority of the Newcastle 85+ Study participants did not meet the current energy EAR at 
baseline which might lead to unintended weight-loss and account for the increased 
malnutrition risk in this age group. Follow-up analysis of weight change may help to confirm 
this finding. 
Failure to meet the NSP intake DRV of 18g per day might be a cause for concern in 
very old adults since it can contribute to the high prevalence of constipation (205). Non-
compliance with the NSP’s DRV was significantly higher in women than in men, partly 
because the recommendations do not differ between sexes (69). The Scientific Advisory 
Committee on Nutrition (SACN) recommended that the DRV of dietary fibre be increased to 
30g per day as measured by international methods (an increase from 18g/day to 23g/day of 
NSP by the Englyst method) (206). In comparison with the proposed new reference values, 
only 16 participants (eleven men and five women) or 2% would meet the DRV for dietary 
fibre. CCP (half from bread) and vegetables (half from cruciferous vegetables and peas) 
together account for 64.3% of the NSP intake. Efforts to reduce the burden of constipation 
and increase NSP intake should focus on these food sources. The use of laxatives (bulk 
forming, stimulant or osmotic) was collected by the Newcastle 85+ Study and will be 
explored in a future publication. 
Median NMES intake in the Newcastle 85+ Study exceeded the DRV for NMES of less 
than 11% of dietary energy (69) and would exceed the SACN DRV for free sugars (or NMES) of 
5% of total energy intake (206). This is a consequence of 89% of men and 86% of women who 
would exceed the new DRV. These findings may be a concern because high NMES intake is 
strongly associated with dental caries in older people (23).  
A plethora of socioeconomic, biological and lifestyle characteristics change with 
advancing age which may place very old adults at increased risk of poor nutrition. However, 
the lack of robustly-based dietary recommendations for very old people limits our ability to 
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interpret the dietary intakes of the Newcastle 85+ Study participants by reference to age-
appropriate DRVs. Given the projected increase in the numbers of very old people in the UK 
(7), filling this evidence gap should have high priority (207).   
Malnutrition is prevalent among institutionalised older adults in the UK (208). In our 
study, participants living in institutional housing had higher intakes of energy and percentage 
of energy from NMES while NSP intake and percentage of energy from MUFA and PUFA was 
lower than for those living in standard housing. Despite the numerous challenges of dietary 
assessment in an institutional setting, a higher prevalence of disabilities in institutionalised 
than in non-institutionalised very old adults may explain these differences.  
SES is frequently associated with diet quality and this was also seen in  the Newcastle 
85+ Study (209). Participants who were more educated or from higher social class (NS-SEC) 
had higher NSP intakes than those less educated and from a lower social class. Healthy 
behavioural habits tend to cluster together (healthier diet, higher physical activity, non-
smoking, moderate or low alcohol intake) (210). In the Newcastle 85+ Study, physically active 
85 year olds had a higher intake of NSP, MUFA, PUFA and protein than those with low 
physical activity.  
Strengths and weaknesses 
The challenges of dietary assessment in this age group were discussed in Chapter 2, 
General Methods - 2.2 Dietary intake assessment and food group allocation. General 
strengths and weakness of the Newcastle 85+ Study were discussed in Chapter 2, General 
Methods - 2.1 The Newcastle 85+ Study. Thirty-five percent of the 24hr-recalls were 
performed during summer (June-August) while the rest were evenly distributed throughout 
the other three seasons. Seasonality is known to influence nutrient intake but the slight bias 
towards summer is unlikely to have changed the results. For practical reasons, 24hr-MPRs 
were not conducted during the weekend, therefore food and drink eaten on Fridays and 
Saturdays was not recalled. Misreporting was estimated to be 26% (211). Twenty-seven 
percent (n=214) of the participants were classified as cognitively impaired at baseline 
(SMMSE ≤25) which was associated with misreporting (OR 1·61; 95% CI 1·11, 2·33, P =0·012). 
Since most of the estimated misreporting is underreporting (22%)(211), dietary intakes may 
have been underestimated.  
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8.3. Micronutrient intake and food sources 
Main findings 
Median vitamin D, magnesium, potassium and selenium intake were 2.0 (IQR:1.2-6.5) 
µg/day, 215 (IQR:166-266) mg/day, 2477 (IQR: 1890-3023) mg/day and 39.0 (IQR:27.3-55.5) 
µg/day, respectively. Median folate intake was 208 (157-264) µg/day and vitamin B12 was 
2.9 (1.9-4.4) µg/day. Participants who spent more full-time years in education, were from 
higher social class and were more physically active had more nutrient-dense diets in several 
vitamins and minerals. The most notable finding is that 20% or more of the participants in 
the Newcastle 85+ Study had intakes below the LRNI for magnesium, potassium and 
selenium and that more than 95% of participants were below the RNI of 10 µg/day of 
vitamin D.  
Comparison with other studies 
Since the 1994-95 NDNS of people aged 65 and over, which included 172 men and 
287 women aged 85 and over (all non-institutionalised), no study has described 
micronutrient intakes and food sources in a large sample of very old adults in the UK. Most 
vitamin and mineral intakes were similar between the 1994-95 NDNS and the Newcastle 85+ 
Study except for β-carotene (1141 vs. 1516 µg/day), vitamin C (41.4 vs. 56.5 mg/day) and 
calcium (644 vs. 731 mg/day) which were higher in the latter (intakes from food sources 
only)(49). In the 1994-95 NDNS, less vitamin A (34% vs. 40%) and vitamin B12 (43% vs. 53%) 
were derived from meat and meat products and less potassium from non-alcoholic drinks 
(10% vs. 19%). However, more vitamin B12 (29% vs. 13%), calcium (54% vs. 31%) and 
potassium (20% vs. 9%) came from milk and milk products in the 1994-95 NDNS than in the 
Newcastle 85+ Study. The food sources of vitamin D were considerably different between 
the studies with fish and fish dishes making a lower contribution to intake (17% vs. 34%) 
while fat spreads made a higher contribution (23% vs. 8%) in the 1994-95 NDNS than in our 
study (49). The observed differences are unlikely to be due to fortification policies. The 
Newcastle 85+ Study included 85 year olds only while the 1994-95 NDNS included those 
aged 85 and over. Other possible reasons include different dietary assessments (4-d 
weighted diet record vs. 2x24hr-MPR) that diverged by more than a decade. 
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The European Prospective Investigation into Cancer and Nutrition (EPIC)-Oxford third 
follow-up questionnaire in 2010-2014 included 411 men and 872 women aged 80 and over 
(14). Intakes of all vitamins and minerals were at least 20% higher in the EPIC-Oxford than in 
the Newcastle 85+ Study participants (personal communication with Professor Tim Key and 
Dr. Paul Appleby). Different descriptive statistics and dietary assessment methods used, 
different ages (≥80 vs. 85 year olds) and characteristics of the participants (14% of EPIC-
Oxford participants were vegetarians) are potential explanations for the wide differences 
observed in micronutrient intake.  
The current NDNS rolling programme (from 2008/2009 to 2011/2012 or years 1 to 4) 
does not yet have enough very old adults for comparison with our results. Nonetheless, it 
included 428 adults (191 men and 237 women) aged ≥65 (74). Although energy intakes were 
similar between both studies, vitamin and mineral intakes (without supplements) were 
slightly higher in the NDNS than in the Newcastle 85+ Study (except for sodium where 
intakes were 1947 and 2383 mg/day, respectively). More than 10% of the participants had 
intakes for magnesium, potassium and selenium below the LRNI (74). Similarly, >20% of the 
Newcastle 85+ Study participants were also below the LRNI for these minerals. 
Significance and explanations 
In this chapter, men had higher energy intakes than women therefore, it was 
expected that intakes of most micronutrients by men were also higher. However, when 
vitamin and mineral intakes were expressed per 1 MJ, vitamin A, C and calcium were higher 
in women than in men. Conversely, men’s diets were more nutrient-dense in vitamin B12, 
iron and selenium than women’s. Higher meat and meat products consumption by men was 
the main driver for these differences.  
Several micronutrient intakes were lower than the current DRVs. Twenty percent or 
more of the participants were below the LRNI for magnesium, potassium and selenium while 
95.3% were below the RNI for vitamin D [the Scientific Advisory committee set the same RNI 
as the Committee on Medical Aspects of Food and Nutrition Policy (212)]. This is of concern 
because magnesium is associated with physical performance (213), systemic inflammation, 
endothelial function (214) and bone mineral density in older adults (215); inadequate selenium 
has been linked with anaemia (216), cancer and all-cause mortality (217); and low vitamin D 
intake has consistently been associated with musculoskeletal (67) and extra-skeletal 
outcomes including cognitive impairment and mortality (29,30). However, the major 
CHAPTER 8 
130 
 
“inadequacy” in vitamin D intake may not reflect vitamin D status since circulating 
concentrations of 25-hydroxyvitamin D depend largely on sun exposure (67). Higher 
potassium intakes are a known protective factor for hypertension (218) whereas excessive 
sodium intake is a risk factor for hypertension in older adults (219). In this chapter, only a fifth 
of the participants were below the RNI of 1600 mg per day of sodium but half met the 
recommendation of less than 2400 mg per day. Sodium intake reduction and increased 
potassium intake might help reduce the prevalence of stroke and fatal coronary heart 
disease in this population (220).  
More than 10% of participants had vitamin A intakes below the LRNI but, 
interestingly, 5% had intakes above the upper level (UL) of 3000 µg-RE per day set by the 
European Food Safety Authority (EFSA) (221). This classic paradox may not be the result of 
habitual intake, but the result of consuming high vitamin A content foods (e.g. liver and liver 
dishes) on one or more of the non-consecutive 24h recalls of the 24hr-MPR (222). In fact, 35 
out of the 36 participants who had vitamin A intakes above the UL of 3000 µg-RE ate liver 
and liver products on at least one of the 24hr-MPR. 
Assessing micronutrient intake inadequacies in this age group has several 
methodological limitations. Further, due to a scarcity of nutrition data in this age group, 
most DRVs were extrapolated from younger populations. This leads to uncertainty regarding 
the health significance of inadequacies in the very old.  
In line with previous studies (209) and a recent review on socioeconomic determinants 
of micronutrient intakes in older adults (223), participants with more education and from a 
higher social class had overall higher micronutrient intakes. Similarly, perhaps because 
healthy habits cluster together, those who were more physically active had more nutrient 
dense diets. It has been argued that nutrient-dense foods are more expensive than less 
healthy foods in the UK and United States of America (USA) (224,225) and this price differential 
might explain the difference in nutrient density between lower and higher socio-economic 
(SES) groups. However, others have challenged the view that healthier foods or dietary 
patterns are more expensive than unhealthy ones and e.g. price differentials are dependent 
on the unit of comparison (e.g. per calorie, per mass) (226,227). Physical proximity to (and/or 
means to access) fresh-produce stores has been proposed as an explanation for higher 
micronutrient intakes in high SES groups (228) but this is somewhat debatable in the UK and 
North-East England (229). Inaccessibility to fresh produce, higher cost of nutrient-dense foods 
in the UK and poorer food choices (230) are some of the potential causes that mediate the 
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diet quality gradient between SES groups. In this age group, with more disabilities and lower 
income, these issues might be exacerbated. 
Strengths and weaknesses 
Although vitamins and minerals are not abundantly present in commonly 
underreported foods, such as sweets and snacks, the inherent retrospective nature of the 
24hr-MPR might have proved challenging for some individuals in this age group. The 
challenges of dietary assessment in this age group were discussed in Chapter 2, General 
Methods - 2.2 Dietary intake assessment and food group allocation. To reduce patient and 
interviewer burden, only qualitative data on supplement use were collected. Therefore, the 
frequency of supplement use had to be estimated based on the manufacturer’s 
recommendations. Data on sodium derived from table salt and salt used in cooking was not 
recorded which might have underestimated sodium intake in the Newcastle 85+ Study. 
General limitations and strengths of the Newcastle 85+ Study were discussed in Chapter 2, 
General Methods -  2.1 The Newcastle 85+ Study. 
8.4. Intakes of folate and vitamin B12 and biomarkers of status 
Main findings 
This study found that, in the very old, folate intakes from all food sources and from 
cereals and cereal products were significantly associated with RBC folate. Individuals with 
higher total folate intake or intake from cereals and cereal products were less likely to have 
low concentrations of RBC folate. The association between vitamin B12 intakes and plasma 
vitamin B12 was weak. Individuals with vitamin B12 intakes from all food sources and from 
meat and meat products were also less likely to be deficient for plasma vitamin B12. In 
addition, higher concentrations of RBC folate were found in participants with the MTHFR 
(rs1801133) AA genotype compared with those with A/G or GG genotypes. Women 
homozygous for the FUT2 (rs492602) G allele also had higher concentrations of plasma 
vitamin B12 than those with other FUT2 genotypes.  
Folate and vitamin B12 intake and status “inadequacies” 
The median (IQR) RBC folate and plasma vitamin B12 concentration was 863 (451-
1287) nmol/L  and 232 (170-324) pmol/L, respectively. In the Newcastle 85+ Study there was 
a relatively low prevalence of “inadequate” folate intake (3.1%) and status (3.6%). The NDNS 
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rolling programme estimated that 1% of older adults (aged 65 and over) were below the UK 
LRNI for folate but that 7.3% of men and 10.8% of women had RBC folate concentrations 
<340 nmol/L. In the Newcastle 85+ Study, plasma vitamin B12 deficiency (<148 pmol/L) was 
present in 17.1% of participants and 9.2% were below the UK LRNI (1 µg/d) for vitamin B12 
intake whilst the NDNS estimated that 5.9% had  serum vitamin B12 concentrations <150 
pmol/L but only 1% were below the LRNI for vitamin B12 (74). Age, dietary assessment 
method (4-d weighted diet record vs. 2x24hr-MPR) and other methodological differences 
are likely explanations for these observed discrepancies. Specifically, the novel method used 
to assess RBC folate in the NDNS (whole blood folate by a microbiological assay, serum total 
folate by LC-MS/MS and hematocrit) is likely to give higher estimates of folate “inadequacy” 
than the one used in this chapter. The NDNS used a similar method to the Newcastle 85+ 
Study to assess plasma vitamin B12 (competitive immunoassay with direct 
chemiluminescence (ADVIA Centaur B12 assay)).  
In the post-fortification period in the U.S., less than 1% of older adults had deficient 
folate status (RBC folate <340 nmol/L) (231). In the National Health and Nutrition Examination 
Survey (NHANES) 2003-2006, it was estimated that 9% of men and 24% of women > 70 years 
old were below the North American EAR for folate [320 DFE/d (232)] (233). In the same NHANES 
edition, 19% of older adults had plasma vitamin B12 concentrations below 221 pmol/L (234). 
Moreover, less than 1% of men and 6% of women >70 years were below the EAR for vitamin 
B12 (2 µg/d) (233). Almost 30% (n=235) of the Newcastle 85+ Study participants were below 
the same EAR for vitamin B12 intake. 
Association between folate intake and status 
Folate intake from total diets and from cereals and cereal products but not from 
vegetables or fruit and fruit juice were associated with RBC folate concentrations in the very 
old. Vegetables and fruit and fruit juice contributed to 25% (16% and 9%, respectively) to 
folate intake and the relatively lower contribution might explain the lack of associations. 
Further, folate bioavailability is dependent on the food matrix, stability of labile folates, 
presence of vitamin C and folate-binding proteins and folate pool sizes (89,93,94). Nonetheless, 
there is a consensus that folic acid is better absorbed than dietary folate. Evidence also 
shows that that folic acid intake is a stronger predictor of RBC folate concentration than total 
folate intake (95,235). The US Institute of Medicine estimated that the absorption efficiency of 
folic acid in supplements or fortified food was 85% taken with food or 100% from 
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supplements taken on an empty stomach (89) whilst dietary folate absorption efficiency was 
50% (89,94). Breakfast cereals (grouped under cereals and cereal products in this chapter) have 
frequently been the target of voluntary fortification in the UK and elsewhere which might 
explain the stronger association between folate intake from cereals and cereal products and 
RBC folate concentrations. Cereals and cereal products were also the top contributors to 
folate intake (32%), suggesting that this is an important source of folate/folic acid in the very 
old. On the other hand, the incomplete release of dietary folate from plant foods cellular 
structures may explain a weaker association between folate from vegetables and fruit, and 
RBC folate. 
Association between vitamin B12 intake and status 
Total vitamin B12 was weakly associated with plasma B12 in the very old (p=0.054) 
and seemed to saturate at intakes ≈ 10 µg. The relatively weak association might be due to 
the low vitamin B12 intakes in relation to the large liver stores (1 µg/g of liver) so that 
intakes only slowly influence plasma concentrations (112). Further, vitamin B12 absorption is 
complex. Bound to protein in food, vitamin B12 has to be released by pepsin and 
hydrochloric acid in the stomach. The ensuing free form of vitamin B12 binds to haptocorrin, 
forming a B12-haptocorrin complex. This complex is later broken down in the small intestine 
by pancreatic proteases which enable vitamin B12 to bind to the glycoprotein IF, be 
recognized (by cubilin) and absorbed by endocytosis in the enterocytes of the distal ileum. 
These steps present a problem to older adults as 10-30% have atrophic gastritis and 
therefore, reduced gastric acid secretion which is essential to vitamin B12 release from food 
proteins (64). The bioavailability of vitamin B12 in any form or dose is estimated to be 40% in 
healthy adults with intact IF secretion (112). Meat and meat products, milk and milk products 
and, fish and fish products were the top sources of vitamin B12 in the Newcastle 85+ Study 
(188). However, unlike some findings (236,237) but in agreement with others (238), vitamin B12 
intake from meat and meat products was not associated significantly with plasma vitamin 
B12. Meat and meat products, especially liver [beef liver can reach to as much as 83 µg per 
100 g (178)] and ruminant meat have very high concentrations of vitamin B12 and it is 
reported that ileal receptors saturate with intakes of 1.5-2.5 µg of vitamin B12 per meal (239). 
Only 50% and 5% of vitamin B12 are absorbed with intakes of ~1 and 25 µg, respectively (112). 
Others have found that vitamin B12 from dairy products is very bioavailable (240) but also that 
vitamin B12 in yogurt and cheese is not as bioavailable as that in milk in older individuals 
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(238). This could explain why vitamin B12 intake from dairy products (that includes yogurt and 
cheese) was not associated with plasma B12 in this chapter. 
MTHFR and RBC folate, and FUT2 and plasma vitamin B12 
Interestingly, and in contrast to most previous findings (241), participants 
heterozygous for the A allele of the MTHFR gene had higher concentrations of RBC folate 
than those homozygous for the G allele. This was not a reflection of higher folate or folic acid 
containing supplements intake. However, Molloy AM et al. showed that there might be 
important discrepancies in serum folate or RBC folate concentration by MTHFR genotype 
whether protein-binding assays (such as the chemiluminescence immunoassay used in the 
Newcastle 85+ Study) or microbiological assays (generally regarded as the “gold standard”) 
were used (99). Molloy AM et al. proposed that a degradation product or a form of folate 
would accumulate in individuals homozygous for the A allele (where the MTHFR reductase’s 
activity is decreased) and bind in the protein-binding assay. Therefore, the resulting 
measured folate concentration would appear active but not be microbiologically detectable 
(99).  
Similar to previous findings (117,118,241), women with the FUT2 GG genotype had higher 
concentrations of plasma vitamin B12. FUT2 encodes galactoside 2-alpha-L-
fucosyltransferase 2 (EC:2.4.1.69) which is involved in the regulation of the H antigen and is 
a precursor of the ABO(H) antigens (118). FUT2 variants (from the allele A) are proposed to be 
protective against Helicobacter pylori infection or to increase IF production (117). Both 
proposed explanations would explain the higher plasma vitamin B12 concentrations in those 
homozygous for the G allele. 
Strengths and weaknesses 
As dietary intake assessment consisted of a 24hr-MPR applied on two non-
consecutive days, the possibility of unusually high or low vitamin B12/ folate intakes cannot 
be excluded. Even though the food groups used in the analysis contributed to most of the 
folate and vitamin B12 intake, other food sources might explain the remaining intake. 
Intakes of dietary folate equivalents (DFE) and of the crystalline form of vitamin B12 could 
not be determined because supplement use was collected qualitatively (type and brand but 
not frequency) and it was not certain which specific foods had been fortified during the 
dietary collection period (2006/2007). A general limitation of most dietary surveys including 
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ours is that assessment of supplement usage may not be accurate by dietary intake records, 
dietary recalls and other questionnaires (73). Furthermore, the irregular use of supplements 
by survey participants including the alteration of usual patterns of supplement use during 
the period of dietary data collection further adds bias to the estimation of true supplement 
use (73). It is worth mentioning that the choice of vitamin B12 form used in supplements and 
fortified foods should also be taken into consideration because of concerns associated with 
cyanide/thiocyanate from cyanocobalamin (242). 
Holotranscobalamin measures the vitamin’s active form and because it might better 
reflect vitamin B12 status than plasma vitamin B12, its use might have yielded different 
results. There is currently no consensus on the biochemical threshold to use to define folate 
or vitamin B12 “inadequacy”, especially in this population. Therefore, results from the binary 
logistic models might be different if different thresholds were used. Furthermore, atrophic 
gastritis impairs folate and vitamin B12 absorption. If available, the incidence of atrophic 
gastritis or a proxy measure such as Helicobacter pylori infection could have been used as an 
adjusting factor or to conduct a sensitivity analysis. The list of SNPs used is not exhaustive 
and other polymorphisms, such as some SNPs in the TCN2 gene (e.g. rs731991) may 
influence the folate and vitamin B12 intake-status relationship (243). General limitations and 
strengths of the Newcastle 85+ Study were discussed in Chapter 2, General Methods -  2.1 
The Newcastle 85+ Study. 
8.5. One-carbon metabolism biomarkers and cognitive decline 
Main findings 
This study showed that very old adults in higher quartiles of RBC folate (e.g. Q4 vs 
Q1, β=+1.02, SE=0.43, p=0.02) and lower quartiles of tHcy concentration (Q4 vs Q1, β=-1.05, 
SE=0.46, p=0.02) measured at baseline were associated with better global cognition 
(SMMSE) over 5 years. In contrast, plasma vitamin B12 was not associated with cognition 
(global and attention) at any time points. RBC folate, plasma vitamin B12 and tHcy 
concentration were not predictive of the rate of decline in SMMSE and attention, except for 
higher tHcy concentration, which was associated with slower decline in focused attention 
(PoA) over 3 years.  
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Comparison with other studies 
Results of folate and global cognition and/or specific cognitive domains in 
prospective cohort studies are frequently in disagreement. This study confirmed findings 
from studies which showed that folate, as measured by serum folate or RBC folate, was 
associated with global cognition or specific cognitive domains (81,82,143,244) while others did 
not find these relationships (107,144,146). However, apart from Leiden 85-Plus, these studies 
focused on younger populations. 
Voluntary folic acid fortification of cereal grains products introduced in 1996 and 
changed into mandatory fortification in 1998 might partly explain the lack of associations 
between folate and cognitive performance in some studies as it is difficult to find overt 
folate deficiency in the U.S. (146). The median (IQR) RBC folate concentration in our cohort 
was 863 (IQR:451-1287) nmol/L and only 4% (n=26) had concentrations <340 nmol/L. With 
reference to cut-offs derived from younger populations, this RBC folate concentration might 
be considered replete which could also explain the lack of associations with cognitive 
decline. The choice of biomarkers to assess folate status also deserves some attention as 
studies that did not find an association (107,144,146) used serum folate and not RBC folate, 
which more closely reflects long term status.  
In contrast with our findings, some studies have reported that holotranscobalamin or 
plasma vitamin B12 concentration was predictive of cognitive decline (107,143,245-247) while 
others failed to find an association (81,82,144,146,244,245). As with this chapter, some studies 
(81,82,107,123,143) but not all (144,244,246) have reported that tHcy concentration was associated 
with global cognition or specific cognitive domains measured over time. The Leiden 85-Plus 
Study had a very similar design to the Newcastle 85+ Study and included 599 adults aged 85 
years old at baseline. Participants were followed for 4 years and global cognitive function 
was assessed by the MMSE while attention was measured by the Stroop test. Mooijjart et al 
reported similar findings to our study. Low serum folate and high tHcy, but not serum vitamin 
B12, were associated with cognitive impairment cross-sectionally, but these biomarkers did 
not predict cognitive decline or rate of cognitive decline over 4 years in the Leiden 85-Plus (144). 
In the same study, tHcy concentration was associated with attention at baseline but not 
folate or vitamin B12 and not longitudinally (144).  
The lack of specificity of the assay used for plasma vitamin B12 may explain the lack 
of associations between cognitive decline and vitamin B12 in the Newcastle 85+ Study and 
the Leiden 85-Plus. The assay assesses not only the vitamin’s active form, 
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holotranscobalamin which makes up 20-30% of plasma vitamin B12, but also the other 70-
80% bound to haptocorrin and considered inert (100). The use of more recent and more 
robust markers of vitamin status, such as holotranscobalamin and methylmalonic acid 
(MMA), might have yielded different results. In fact, a review of longitudinal cohort studies 
of vitamin B12 status and cognitive decline found that, in all studies where 
holotranscobalamin and MMA had been used, associations between vitamin B12 status and 
cognitive decline, dementia or Alzheimer’s disease were present (248). Those with obvious 
dementia usually show no improvement when treated with vitamin B12 (249). In the 
Newcastle 85+ Study, 9% of the participants had been diagnosed with dementia/ Alzheimer’s 
disease at baseline, which might have skewed the results and partly explained the lack of 
association. However, in sensitivity analyses, when we excluded participants with dementia 
from the models, the lack of association between plasma vitamin B12 and cognitive 
performance at baseline and at follow-up remained. Very high plasma vitamin B12 
concentrations have been found in patients with inflammatory, liver and kidney diseases 
which could underestimate the association with cognitive performance (160). Therefore, 
models were re-run excluding those with plasma vitamin B12 concentrations > 1000 pmol/L 
but the conclusion remained.  Perhaps the most convincing data so far from RCTs on the 
association between B vitamins and cognition comes from the VITACOG studies (250). This 
RCT included 168 adults >70y with mild cognitive impairment and these were either assigned 
to a treatment arm (daily dose of 0.8 mg of folic acid, 0.5 mg of vitamin B12 and 20 mg of 
vitamin B6) or a placebo and followed for 2y. Smith et al. found that brain atrophy was 53% 
slower in those treated with B-vitamins than with placebo but only in those with tHcy 
concentrations >13 μmol/L at baseline (250). 
In the Newcastle 85+ Study, the rate of decline in focused attention (PoA) and 
sustained attention (CoA) was slower in higher quartiles of tHcy. This is counter intuitive as 
lower concentrations of tHcy are associated with better health outcomes, including slower 
rate of cognitive decline (250). However, this is likely an effect of terminal decline as 
homocysteine is a strong predictor of mortality in the very old (251,252) which may have 
selected more cognitively robust survivors in higher quartiles of tHcy. The rate of decline in 
focused (PoA) and sustained attention (CoA) was no longer associated with tHcy if 
individuals diagnosed at baseline with dementia or Alzheimer’s disease were excluded.  
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Strengths and weaknesses   
In the Newcastle 85+ Study, SMMSE and attention specific CDR System tests were 
applied at 3 different time points but only over the period of 5 and 3 years, respectively. 
Such follow-up periods may be too short to detect relationships with 1-C metabolism 
biomarkers (248). However, due to the advanced age of the participants, it is likely that 
cognitive decline was far more rapid than in younger populations and the SMMSE as well as 
the CDR System would be able to detect this decline over 5 and 3 years, respectively. 
Although there is no gold standard on how to evaluate cognitive performance, the SMMSE 
has a well-known ceiling effect of 30 points and a cognitive decline from above 30 points 
would not be captured (253). Also for this reason, it has been suggested that the SMMSE 
might not be sensitive enough to detect subtle cognitive changes typical of most nutritional 
interventions (254). Further, there is a well-known learning or practice effect with the SMMSE 
(but not for CDR), which might have underestimated the rate of cognitive decline and diluted 
the results (255). Cognitive function is a strong predictor of mortality. Therefore, because 
participants with cognitive impairment were more likely to be lost to follow-up due to death, 
this could potentially dilute the cognitive decline results. 
In the Newcastle 85+ Study, 28% of the participants were cognitively impaired 
(SMMSE ≤25) at baseline. Reverse causality cannot be fully excluded for any cross-sectional 
associations between homocysteine, folate and cognitive performance. Finally, RBC folate, 
plasma vitamin B12 and tHcy measurements were available at baseline only which may not 
reflect their status at other time points and lead to underestimation of their association with 
cognitive function (107). General limitations and strengths of the Newcastle 85+ Study were 
discussed in Chapter 2, General Methods - 2.1 The Newcastle 85+ Study. 
8.6. One-carbon metabolism biomarkers and cardiovascular and all-cause 
mortality 
Main findings 
In this chapter, very old adults with higher baseline tHcy concentrations were at 
higher risk of death from all-causes (e.g. Q4 vs. Q1, HR: 2.05, 95% CI: 1.51-2.77, p<0.001) and 
from CVD (e.g. Q4 vs Q1, HR: 2.29, 95% CI: 1.51-3.48, p<0.001) after adjustment for 
sociodemographic, lifestyle and health variables over 9 years. Elevated plasma vitamin B12 
concentrations were associated with increased all-cause mortality (e.g. >500 pmol/L vs 148-
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500 pmol/L, HR: 1.70, 95% CI: 1.13-2.56, p=0.011). This effect seemed to be restricted to 
women and associations were stronger for deaths within the first year.  
Comparison with other studies 
Evidence from observational studies shows that there might be an association 
between high concentrations of tHcy and CVD and/or mortality (256,257). Folate donates 
methyl groups for homocysteine transmethylation to form methionine and, typically, folic 
acid supplementation lowers homocysteine concentrations by 13-25% (124). Although it is still 
debatable whether homocysteine is a causal factor or a marker of CVD and mortality (258), 
others have shown that supplementation with folic acid decreased the risk of CVD, especially 
stroke (149). In accordance with previous findings (153,156,159,256,259), we found that higher 
concentrations of tHcy were associated with increased cardiovascular and all-cause 
mortality. There was no significant association between RBC folate concentration and all-
cause and cardiovascular-specific mortality – a finding, similar to some previous studies 
(151,197-201) but not with others (84,149,260,261). To the best of our knowledge, the effect of folate 
on all-cause and cardiovascular-specific mortality has not been investigated in a similar age 
group. It is possible that this was an age group-specific effect as all the participants in the 
Newcastle 85+ Study were 85 and over. The relatively low baseline tHcy concentration or 
high folate concentration is frequently pointed out as a limiting factor to detect an effect. 
The SEARCH collaborative group conducted a RCT to determine the effects of 
supplementation with 2 mg of folic acid + 1 mg of vitamin B12 on vascular and non-vascular 
outcomes in more than 12000 survivors of myocardial infarction (198). The study found that 
supplementation with these B vitamins had no effect on vascular and non-vascular deaths 
during a follow-up of 6.7 years (198). In the SEARCH trial only 10% of the participants had tHcy 
concentrations >15 µmol/L (198). However, 57% of the participants in the Newcastle 85+ 
Study had hyperhomocysteinemia and still no effect was observed (169).  
The raised hazard ratio for mortality for those with higher concentrations of plasma 
vitamin B12 confirms findings from others in which very high vitamin B12 intake or status 
was associated with greater all-cause mortality (152,153) and cancer diagnosis/ mortality 
(154,155). Arendt et al. (154) identified 333667 people from Danish medical registries who were 
not receiving supplemental vitamin B12 and with plasma vitamin B12 concentrations >200 
pmol/L and found that cancer incidence increased with higher vitamin B12 concentrations. 
The effects were more pronounced for haematological, smoking and alcohol-related cancers, 
CHAPTER 8 
140 
 
and during the first year of follow-up (154). In a retrospective case-control study of 25017 
patients with cancer diagnosis and plasma vitamin B12 concentrations >200 pmol/L 
measured before diagnosis in a retrospective case-control study, the same research team 
reported that patients with a cancer diagnosis who had vitamin B12 concentrations greater 
than 600 pmol/L had higher risk of mortality than those with concentrations of 200-600 
pmol/L (155).  
In addition to the excess intake of vitamin B12 (often parenteral), elevated plasma 
vitamin B12 concentration has been found in patients with liver, renal, autoimmune, cancers 
and infectious diseases (160). Excluding reverse causality, such diseases may disrupt the 
uptake of vitamin B12 by the liver, the biggest reservoir of vitamin B12 in the body, or 
alternatively, increased hepatocyte turnover/ damage may lead to greater leakage of 
vitamin B12 from the liver (160,262,263). High plasma vitamin B12 has also been associated with 
haematological malignancies (160). It is believed that an increase in the number of leukocytes 
increases haptocorrins’s production and release into the circulation (160). Functional 
deficiency of vitamin B12 can also happen concomitantly with very high plasma 
concentrations of vitamin B12 (263). An increase in haptocorrin and subsequent binding of 
vitamin B12 could lead to reduced holotranscobalamin binding and therefore less cellular 
uptake of vitamin B12 (263).  
Sensitivity analyses 
To determine if elevated plasma vitamin B12 was due to liver damage models we 
further adjusted the models for alanine aminotransferase (ALT), alkaline phosphatase and 
bilirubin; and to determine if it was due to other non-liver related conditions, models were 
adjusted for hs-CRP. Findings were not significantly different in either of the models. We 
have previously shown a U-shaped relationship between sex-specific quartiles of serum 
vitamin D and mortality in women in this cohort (29). This suggests that associations between 
blood-based biomarkers and health outcomes (i.e. survival) in young-old may not always be 
the same as in very old adults. 
Strengths and weaknesses 
One of the biggest strengths of this study is that data was from the Newcastle 85+ 
Study, a single age cohort of the very old with a large number of participants and extensive 
health assessment. The study population was socio-demographically representative of the 
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UK for this birth cohort but the lack of ethnic diversity warrants caution when generalizing to 
non-white populations. Given that all participants were 85 at recruitment, an age where 
mortality rates are high, it is impossible to exclude completely any survival or length bias 
that arose due to selective survivability. The rapid processing of blood samples after 
venepuncture is another strength of this study. The assay used in this study measures the 
total circulating vitamin B12. The use of holotranscobalamin, which measures only the 
metabolically active fraction, might have yielded different associations between vitamin B12 
status and mortality. General limitations and strengths of the Newcastle 85+ Study were 
discussed in Chapter 2, General Methods - 2.1 The Newcastle 85+ Study.  
8.7. General discussion and public health implications  
Very old adults are at increased risk of nutritional deficiencies, which contributes to 
disability, frailty and loss of physical function (68). This thesis showed that very old adults in 
the UK may be at risk of certain macro and micronutrient deficiencies, such as dietary fiber, 
vitamin D, magnesium, potassium and selenium. These findings draw attention to the risk of 
nutritional deficiencies in the very old but also the lack of age-specific DRVs. DRVs are 
generally derived from the average (median) nutrient intake necessary to meet the 
physiological requirement, as defined by a set of criteria for adequacy for that nutrient (for 
example vitamin B12 and the maintenance of haematological status) (264). If not enough data 
is available, the DRV can be derived from the average nutrient intake of a group of 
apparently healthy people that is assumed to be adequate (adequate intake) (264). Despite 
the extreme importance of establishing age-specific DRVs, this was not an initial objective 
for this thesis but could be explored in the future. The lack of robustly-based dietary 
recommendations for very old people limits our ability to interpret the dietary intakes of the 
Newcastle 85+ Study participants by reference to age-appropriate DRVs.  
For example, 72% of the participants did not meet the DRV for SFA and 87% 
exceeded the SACN DRV for free sugars (or NMES) of 5% of total energy intake (206). As of 
2014, there were 22 countries in Europe with a life expectancy at age 65 higher than 20 
years (5). Nutrition education has shown to be beneficial in changing dietary patterns in this 
age group (265). It is fundamental that the very old but also their carers/ family members 
realize that it is not too late for lifestyle changes to have benefits and whenever necessary, 
they should be encouraged to do so. However, there are barriers such as the importance of 
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fat for food palatability which makes it difficult to reduce consumption of food products high 
in fat without the cooperation of the food industry (266). Therefore, context should be as 
important as nutritional knowledge and personal motivation. The food industry could and 
should play a major role in reducing the sugar and fat content in foods, especially in CCP as 
these, along with non-alcoholic beverages, are the most widely consumed food group in the 
Newcastle 85+ Study. If food fortification is deemed necessary, CCP and especially flour 
would be good candidates.  
In line with the SACN recommendations, we agree that there should be consistency 
on how to determine the dietary fibre content of foods across the UK and Europe to allow 
for inter-country comparisons and to avoid generating confusion. For this, the Englyst 
method to measure NSP should be gradually abandoned and the AOAC method adopted 
(206).  
In chapter 4, Micronutrient intake and food sources in the very old a fifth of the 
participants had sodium intakes below the RNI of 1600 mg per day and half met the 
recommendation of less than 2400 mg per day. Data on sodium derived from table salt and 
salt used in cooking was not recorded which might have underestimated sodium intake in 
the Newcastle 85+ Study and further increased the number of participants who did not meet 
the recommendation. Sodium intake reduction and increased potassium intake might help 
reduce the prevalence of hypertension, stroke and fatal coronary heart disease in this 
population (220). Hypertension is also associated with dementia and Alzheimer’s disease (267). 
Hypertension is a risk factor for CVD and hence for vascular dementia but it may promote 
alterations in brain structure and function beyond it. Hypertension may lead to cerebral 
vessel wall remodelling and endothelial dysfunction, which can lead to reductions in cerebral 
perfusion and in the brain’s capability to clear β-amyloid proteins (267). It is clear that 
reduction in CVD risk factors, such as hypertension, will reduce the incidence of dementia 
and Alzheimer’s disease (268). 
Although it would be difficult because of time constraints, it would be interesting to 
have dietary assessment (ideally 2x24hr-MPR) on at least one more time point to allow for 
direct comparison with baseline dietary intake data to determine how dietary patterns 
progress (and potentially deteriorate) in this age group. Misreporting was estimated to be 
~26% in this cohort (211). We recommend that misreporting and the importance of accurate 
records is properly emphasized to the participants prior to the start of the dietary 
assessment, especially in obese individuals who are more prone to underreport (269). It is very 
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difficult to be certain that these 26% were definite misreporters. It would have been useful 
to confirm these findings by using the doubly labelled water method in a subset of the 
cohort. A food propensity questionnaire would allow to exclude unusually high or low 
intakes and confirm that the food recorded was part of the person’s habitual dietary pattern. 
For example, 5% (n=36) of participants had vitamin A intakes above the UL of 3000 µg-RE 
and 35 of the 36 ate liver and liver products on one of the 24hr-MPR (211).  
Greater effort should be placed in harmonising the national food composition food 
tables, such as the McCance and Widdowson’s, so that these can be adequately compared 
between countries. For example, analysing food folate with HPLC yields, on average, 27% 
lower concentrations of folate than if measured by microbiological assay (270).  
Since energy requirements are largely dependent on energy expenditure, the 
decrease in energy needs in later life mirrors the age-dependent fall in physical activity. 
However, the physiological basis for age-dependent changes in vitamin and mineral 
requirements (if any) is poorly understood. In the absence of such evidence, it may be 
appropriate that nutritional education for very old adults focuses on healthy food choices, 
on increasing nutrient density and recommending the use of supplements in specific 
situations (271). Increased consumption of fruits, vegetables, fish, lean meats, nuts, whole 
grains and low-fat dairy products should be encouraged for the general population but also 
for very old adults. Specific nutritional recommendation in this age group should account for 
the higher prevalence of disabilities (such as difficulties chewing food, buying ingredients 
and cooking a hot meal) and chronic diseases, polymedication and financial restraints (56). 
Recommendations should also pay attention to possible physiological changes such as loss of 
lean mass and bone density, fluid and electrolyte dysregulation, decline in taste sensitivity 
and malabsorption (57). In order to achieve an optimum intake of vitamins and minerals, 
dietary manipulation should always be the preferred method but if it proves to be difficult, 
food fortification and dietary supplementation can be a practical solution to shorten the gap 
between intakes and recommendations (272).  
It is very difficult to exclude reverse causality in cross-sectional associations between 
nutrition and cognitive function. That is because the cognitive decline process is commonly 
accompanied by frailty and increased number of disabilities, such as difficulties shopping by 
yourself, cooking a hot meal or even feeding without the help of others which will lead to 
decreased or inadequate dietary intake (138). Furthermore, because malnutrition is strongly 
associated with disease progression (273) and is a modifiable risk factor, we emphasize the 
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ESPEN recommendations that malnutrition should be screened in every person with 
dementia (138).  
Several different methods are used to assess/screen cognitive function but the 
SMMSE is undoubtedly the most widely used. The SMMSE offers several advantages as it is 
cheap, relatively fast (takes ~5-10 minutes to complete), has easily understandable cut-offs 
and is comparable to other studies. However, the SMMSE may lack sensitivity to detect 
subtle cognitive changes typical of most nutritional interventions (254). Furthermore, the 
SMMSE has a well-known ceiling effect of 30 points and a cognitive decline from above 30 
points would not be captured (253). More recent tools are available and have performed 
better at detecting cognitive impairment and dementia than the SMMSE (253). In summary, 
there is a need for a universally used tool, such as the SMMSE, but without its shortcomings.   
Dementia/ Alzheimer’s disease has received growing attention by policy makers and 
funding bodies but its priority is not yet similar to other chronic diseases such as cancer (274). 
The organisation for economic co-operation and development (OECD) estimated that 
member countries allocated less than 3% of their health budget to dementia prevention (275), 
an area that has the largest effect at reducing dementia incidence and related disabilities 
(274). In summary, policy makers should devote more attention to this area. 
Hughes CF et al. showed that lower vitamin B6 status and intake was associated 
with >3.5 times higher risk of accelerated cognitive decline in older adults over 4 years 
{Hughes, 2017 #850}. Pyridoxic acid (PA) and pyridoxal phosphate (PLP) are routinely used to 
assess vitamin B6 status and have been measured at baseline in the Newcastle 85+ Study. It 
would be worthwhile to repeat the analyses of chapter 6, one-carbon metabolism 
biomarkers and cognitive decline in the very old factoring in the vitamin B6 status of the 
participants. Although chapter 6 of this thesis focused on folate and vitamin B12, it is 
unlikely that a comprehensive prevention of cognitive decline is achieved by only one 
nutrient but instead by a dietary pattern that encompasses adequate supply of nutrients 
such as folate and vitamin B12. It is important to adopt a healthy lifestyle as early as possible 
as it will benefit cognitive health in later life. In chapter 7, One-carbon metabolism 
biomarkers and cardiovascular and all-cause mortality in the very old, we have shown that 
elevated plasma vitamin B12 concentrations were associated with increased all-cause 
mortality. Clinicians are trained to look for vitamin B12 deficiency, commonly defined as a 
concentration <148 pmol/L, but frequently disregard high plasma vitamin B12 (>500, 600 or 
700 pmol/L) and consider it clinically irrelevant (160). Clinicians and researchers alike need to 
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be aware of the meaning and prognostic significance of elevated vitamin B12 
concentrations. An elevated plasma vitamin B12 value should prompt the clinician or 
researcher to explore aetiologies, such as inflammatory conditions, hepatic and renal 
diseases, haematological malignancies and solid neoplasms (160). Further, functional vitamin 
B12 deficiency can co-exist with high plasma concentrations and both tHcy and MMA should 
be measured (263).  
1-C metabolism biomarkers in the Newcastle 85+ Study were only measured at 
baseline (phase 1) (tHcy was measured at phase 3 but not included in the analyses). This has 
been extremely useful to conduct cross-sectional analyses and predict health outcomes 
based on baseline 1-C metabolism biomarkers but it assumes that concentrations remain 
constant throughout follow-up. Measuring 1-C metabolism biomarkers prospectively at 
further phases (phase 2, 3 and 4) would allow us to confirm our findings and provide 
associations with exposures in closer temporal proximity to the outcome of interest. RBC 
folate is closely related to liver concentrations and is routinely used as a marker of long-term 
status (half-life of 56 to 120 days), arguably being considered the gold-standard for 
observational studies (89). Plasma vitamin B12 concentrations reflect short-term vitamin B12 
status (half-life of 6 days) and include the metabolically active holotranscobalamin (20-30%) 
as well as the inactive fraction bound to haptocorrin (70-80%). Total circulating plasma 
vitamin B12 assays might lack specificity do detect associations with health outcomes such 
as dementia/ Alzheimer’s disease. Measurement of MMA and holotranscobalamin, at 
baseline and prospectively, would provide more accurate findings (100,112,276).  
In summary, very old adults are at increased risk of nutritional deficiencies, which 
contributes to disability, frailty and loss of physical function (68). More data on the dietary 
intake, nutritional status and associations with health trajectories in the very old are 
urgently needed but until then, dietary changes should focus on increasing nutrient density. 
Increased consumption of fruits, vegetables, fish, lean meats, nuts, whole grains and low-fat 
dairy products should be encouraged. However, variation in number and severity of 
disabilities, physiological needs and context is arguably greater than in younger age groups 
and nutritional recommendations have to take it into account. Food fortification and dietary 
supplements can be a practical solution to shorten the gap between intakes and 
recommendations on specific situations (272). It would be premature at the moment and 
over-simplistic to recommend folic acid and vitamin B12 supplements to be taken by 
everyone on a daily basis, especially with concerns around supplementation and very high 
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micronutrient concentrations where a U-shaped relationship may exist with health 
outcomes. However, it seems advisable to maintain an optimal folate and vitamin B12 status 
through dietary changes. An “optimal” folate and vitamin B12 status in the very old may not 
be the same as in younger populations from which most biochemical cut-offs are 
extrapolated from but in the absence of better evidence, these should still be regarded as 
the target for dietary changes’ interventions.  
8.8. Recommendations for future research 
There is a lack of nutritional data in this age group and given the projected increase 
in the numbers of very old people in the UK (7), filling this evidence gap should have high 
priority (207).  
Public Health England released a summary of reviews which identified a number of 
facilitators and barriers for dietary changes (277). Facilitators: 1) Knowledge of the importance 
of diet for healthy ageing/ becoming fitter; 2) Dislike of processed food and preference for 
fresh ingredients; 3) Not wanting to let others down; and 4) Having clear objectives and 
being supported while achieving them. Barriers: 1) Changing food habits, lack of self-control 
and insecurity; 2) Misconceptions about their own diet and what a healthy diet is; 3) Self-
perception of being too old to change; 4) Lack of clear nutritional advice; 5) Poor access to 
supermarkets and reduced mobility; and 6) Dislike of some components of a healthy diet 
(e.g. vegetables) (277). Nutrition education has shown to be beneficial in changing and 
maintaining dietary patterns in older adults (265,277) but more behavioural studies are 
necessary to explore and confirm these barriers and facilitators. 
All participants in the Newcastle 85+ Study were 85 at baseline (2006/2007) and born 
around 1921. This cohort lived through the Great Depression (1929-1932) (which hit 
Northeast England and its heavy industry especially hard), WW2 (1939-1945), mass 
availability of antibiotics (1945-Present) and the creation of the NHS (1948-Present) (278). 
They would have been ~18 when World War 2 (WW2) broke out and rationing was enforced. 
During and after WW2 (1940-1954), the Ministry of Food instituted rationing on almost all 
foods (for example bacon, butter and sugar) except vegetables and bread (279). It would be 
interesting to understand how this period influenced their current dietary patterns and 
understand if there is a cohort effect in the Newcastle 85+ Study. 
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In chapter 5, Intakes of folate and vitamin B12 and biomarkers of status in the very 
old, we could not provide an accurate value for bioavailability of folate and vitamin B12 per 
se because of the observational nature of the study design. A well designed controlled 
feeding study to determine the bioavailability of these vitamins from all sources, from top 
contributing food groups to total intake of folate and vitamin B12 and from supplements 
alone would be extremely useful as most of the studies on bioavailability have not been 
conducted in this population (89,112).  
Epigenetic mechanisms could provide a partial explanation to some observed 
findings in this thesis, such as the higher concentrations of RBC folate in individuals 
heterozygous for the A allele (T on the opposite strand) than those homozygous for the G 
allele (C on the opposite strand) of the MTHFR gene (rs1801133, chromosome 1, position 
11796321). DNA methylation is one of several epigenetic mechanisms recognized to regulate 
gene expression in mammals. Folate and vitamin B12 are essential to the methionine cycle 
within the 1-C metabolism, being indirectly involved in the production of SAM. SAM is 
considered a universal methyl donor and largely responsible for the methylation of cytosine 
(280). Folate and vitamin B12, as indirect sources of methyl groups (281,282), may affect 
methylation patterns in replicating cells (283). Hypermethylation of CpG islands is frequently 
associated with gene silencing (283). The relationship between the MTHFR C677T 
polymorphism and folate status may be different in very old populations than in their 
younger counterparts (241). We hypothesise that with ageing, the decreased activity of the 
MTHFR enzyme (EC: 1.5.1.20) may be compensated by an increase in the binding affinity for 
the flavin adenine dinucleotide (FAD) mediated by altered DNA methylation patterns. DNA 
methylation of promoter associated CpG islands [75-100% of methylation occurs on CpG 
islands(280)] for five loci (EPHA10, HAND2, HOXD4, TUSC3, TWIST2 - chosen from a panel of 
15 candidate genes because they were shown to be the most extensively and variably 
methylated in this population) and long interspersed nucleotide element-1 (LINE-1) 
repetitive elements (17% of human genome and surrogate marker for global DNA 
methylation) are available for a subset of the Newcastle 85+ Study participants at baseline 
(n=480). 
It would be interesting to repeat the longitudinal associations between 1-C 
metabolism biomarkers and; cognition, all-cause mortality and CVD mortality using a 
Mendelian randomization approach. This approach uses common genetic polymorphisms 
(normally single nucleotide polymorphisms), associated with the exposure (considered 
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robust proxies for biomarker concentrations) to make causal inferences between modifiable 
risk factors and health-related outcomes (110). Mendelian randomization is less prone to 
reverse causality and less susceptible to confounding by behavioural or environmental 
exposures (284). However, it can still be influenced by genetic pleiotropy and population 
stratification (285). For example, individuals homozygous for T allele (A for opposite strand) of 
the MTHFR gene (rs1801133, chromosome 1, position 11796321) and heterozygous for the T 
allele have ~70% and ~35%, respectively reduced MTHFR enzyme activity (EC: 1.5.1.20) than 
those with the common genotype (CC or GG). Although MTHFR gene has several effects on 
the 1-C metabolism, this polymorphism is reflected in markedly lower folate and higher tHcy 
concentrations (286).  
RCTs with enough follow-up time and sufficiently powered to detect cognitive decline 
are needed to confirm our findings that tHcy and RBC folate, but not plasma vitamin B12, 
concentrations are predictive of better global cognition in the very old but not rate of 
cognitive decline.  
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D. Tertiary food groups used in the Newcastle 
85+ Study  
1st level food 
group 
2nd level food group 3rd level food group 
Cereals and 
cereal 
products 
(grains) 
Pasta, rice and other 
miscellaneous cereals 
Pasta (manufactured products and ready meals) 
Pasta (other, including homemade dishes) 
Pizza 
Rice (manufactured products and ready meals) 
Rice (other, including homemade dishes) 
Other cereals 
Bread 
White bread (not high fibre, not multiseed bread) 
Wholemeal bread 
Brown, granary and wheatgerm bread 
High fibre white bread 
Other bread 
Breakfast cereals 
High fibre breakfast cereals- high sugar 
High fibre breakfast cereals- low sugar 
Other breakfast cereals (not high fibre) high sugar 
Other breakfast cereals (not high fibre) low sugar 
Biscuits 
Biscuits (homemade) savoury 
Biscuits (manufactured/retail) savoury 
Biscuits (homemade) sweet 
Biscuits (manufactured/retail) sweet 
Buns, cakes and pastries 
Buns cakes and pastries (homemade) 
Buns cakes and pastries (manufactured) 
Fruit pies (homemade) 
Fruit pies (manufactured) 
Puddings 
Cereal based milk puddings (homemade) 
Cereal based milk puddings (manufactured) 
Sponge puddings (homemade) 
Sponge puddings (manufactured) 
Other cereal based puddings (homemade) 
Other cereal based puddings (manufactured) 
Milk and milk 
products 
Milk 
Whole milk 
Semi-skimmed milk 
Skimmed milk 
1% milk 
Other milk 
Other milk and cream 
Cream (including imitation cream) 
Infant formula 
Cheese 
Other cheese 
Cottage cheese 
Yoghurt, fromage frais and 
other dairy desserts 
Yogurt- low fat 
Dairy desserts (homemade) 
Fromage frais and other dairy desserts 
(manufactured) 
Yogurt- other 
Yogurt- full fat 
Ice cream 
Eggs and egg 
dishes 
Eggs and egg dishes 
Eggs 
Manufactured egg products including ready meals 
Other eggs and egg dishes including homemade 
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1st level food 
group 
2nd level food group 3rd level food group 
Oils and fat 
spreads 
Butter Butter 
Polyunsaturated margarine 
and oils 
Olive oil 
Polyunsaturated margarine 
Polyunsaturated oils 
Olive oil-based margarine 
Low fat spread 
Low fat spread not polyunsaturated 
Olive oil-based 
Polyunsaturated low fat spread 
Margarine and other cooking 
fats and oils not 
polyunsaturated 
Block margarine 
Other cooking fats and oils not polyunsaturated 
Soft margarine not polyunsaturated 
Reduced fat spread 
Reduced fat spread (not polyunsaturated) 
Reduced fat spread (polyunsaturated) 
Meat and 
meat products 
Bacon and ham 
Other bacon and ham (including homemade 
dishes) 
Ready meals/meal centres based on bacon and 
ham 
Beef, veal and dishes 
Manufactured beef products (including ready 
meals) 
Other beef and veal (including homemade recipe 
dishes) 
Lamb and dishes 
Manufactured lamb products (including ready 
meals) 
Other lamb (including homemade recipe dishes) 
Pork and pork dishes 
Manufactured pork products (including ready 
meals) 
Other pork (including homemade recipe dishes) 
Coated chicken and turkey 
manufactured 
Manufactured coated chicken/ turkey products 
Chicken and turkey dishes 
Manufactured chicken products (including ready 
meals) 
Other chicken/turkey (including homemade 
recipe dishes) 
Liver, product and dishes Liver and dishes 
Burgers and kebabs Burgers and kebabs purchased 
Sausages 
Other sausages (including homemade dishes) 
Ready meals based on sausages 
Meat pies and pastries 
Meat pies and pastries (homemade) 
Meat pies and pastries (manufactured) 
Other meat and meat 
products 
Other meat (including homemade recipe dishes) 
Other meat products (manufactured including 
ready meals) 
Fish and fish 
dishes 
White fish coated or fried 
including fish fingers 
White fish coated or fried 
Other white fish, shellfish and 
fish dishes 
Manufactured canned tuna products (including 
ready meals) 
Manufactured shellfish products (including ready 
meals) 
Manufactured white fish products (including 
ready meals) 
Other canned tuna (including homemade dishes) 
Other shellfish (including homemade dishes) 
Other white fish (including homemade dishes) 
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1st level food 
group 
2nd level food group 3rd level food group 
Oily fish 
Manufactured oily fish products (including ready 
meals) 
Other oily fish (including homemade dishes) 
Vegetables 
Salad and other raw 
vegetables 
Carrots (raw) 
Salad and other raw vegetables 
Tomatoes raw 
Vegetables (not raw) 
Baked beans 
Beans and pulses (including ready meal and 
homemade dishes)   
Carrots not raw 
Cruciferous vegetable 
Green beans not raw 
Leafy green vegetables not raw 
Meat alternatives (including ready meals and 
homemade dishes) 
Other manufactured vegetable products 
(including ready meals) 
Other vegetables (including homemade dishes) 
Peas not raw 
Tomatoes not raw 
Potatoes 
Chips, fried and roast 
potatoes and potato products 
Fried chips purchased including takeaway 
Other manufactured potato product fried/baked 
Other fried/roast potatoes 
Oven chips purchased 
Other potatoes, potato salads 
and dishes 
Other potato products and  dishes 
(manufactured) 
Other potatoes (including homemade dishes) 
Savoury 
snacks 
Crisps and savoury snacks 
Non-potato based snacks 
Potato and mixed cereal snacks 
Potato based snacks 
Nuts and 
seeds 
Nuts and seeds Nuts and seeds 
Fruit Fruit 
Apples and pears not canned 
Bananas 
Canned fruit in juice 
Canned fruit in syrup 
Citrus fruit not canned 
Dried fruit 
Other fruit not canned 
Sugar, 
preserves and 
confectionery 
Sugars, preserves and sweet 
spreads 
Preserves 
Sugar 
Sweet spreads fillings and icing 
Confectionary 
Sugar confectionery 
Chocolate confectionery 
Non-alcoholic 
beverages 
Fruit juice Fruit juice 
Tea, coffee and water 
Bottled water still or carbonated 
Coffee (made up weight) 
Tea (made up) 
Herbal tea (made up) 
Tap water only 
Soft drinks, not diet 
Soft drinks not low calorie carbonated 
Soft drinks not low calorie concentrated 
Soft drinks not low calorie, ready to drink, still 
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1st level food 
group 
2nd level food group 3rd level food group 
Soft drinks, diet 
Soft drinks low calorie carbonated 
Soft drinks low calorie concentrated 
Soft drinks low calorie, ready to drink, still 
Alcoholic 
beverages 
Spirits and liqueurs 
Liqueurs 
Spirits 
Wine 
Fortified wine 
Low alcohol and alcohol free wine 
Red wine 
White wine including rose 
Beer lager cider and perry 
Alcoholic soft drinks 
Beers and lagers 
Cider and perry  
Low alcohol and alcohol free beer and lager 
Miscellaneous Miscellaneous 
Beverages dry weight 
Nutrition powders and drinks 
Savoury sauces, pickles, gravies and condiments 
Soup (meat) (homemade) 
Soup (non-meat) (homemade) 
Soup (non-meat) (manufactured/retail) 
Soup (meat) (manufactured/retail) 
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E. Overview of variables collected in the 
Newcastle 85+ Study from baseline to phase 4 
Variables Ph1 Ph2 Ph3 Ph4 Comment 
Questionnaires 
Aids/appliances and household 
modifications 
Yes No No No  
Alcohol Yes No No No  
Chest pain (cardiac) Yes Yes Yes No 
Phase 2 cardiac subset 
only 
Cough, sputum, wheeze Yes Yes Yes No 
Questions on recent 
chest infection, use of 
antibiotics, use of 
steroids in phases 2 and 
3 only 
Dietary assessment Yes No No No  
Disability and help received Yes Yes Yes Yes 
In phase 1 also coded 
up to 4 causes of 
difficulty for each 
activity participant 
could not do 
Education and work Yes No No No  
Ethnic origin Yes No No No  
Exhaustion No No No Yes  
Eyesight Yes Yes Yes Yes  
Falls Yes Yes Yes Yes 
In phase 1 extended 
questions for falls and 
dizziness 
Family data Yes No No No  
Finances Yes No No Yes  
Formal health and social care Yes Yes Yes Yes  
Fractures Yes No No No  
Geriatric depression scale Yes Yes Yes Yes  
Hearing Yes Yes Yes Yes  
How are you feeling today? Yes Yes Yes Yes  
Incontinence Yes Yes Yes Yes  
Joint pain Yes No No No  
Key events since previous phase No Yes Yes Yes  
Living arrangements Yes Yes Yes Yes  
Loneliness Yes Yes Yes Yes  
Long standing illness/disability/infirmity Yes Yes Yes Yes  
Medication, non-prescribed Yes No No No  
Medication, prescribed No Yes No No 
Phase 2 cardiac subset 
only from GP records at 
phase 1 and phase 3 
Occupational exposure to lung toxins Yes Yes Yes No  
Oral health Yes No Yes No  
Pain Yes Yes Yes Yes 
Phase 1 included body 
map for pain locations 
Physical activity Yes Yes Yes Yes  
Self-rated health Yes Yes Yes Yes  
Shortness of breath Yes Yes Yes Yes 
Phase 2 cardiac subset 
only 
Sleep No No Yes No  
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Variables Ph1 Ph2 Ph3 Ph4 Comment 
Smoking Yes No No No  
Social participation Yes Yes Yes Yes  
Social support Yes Yes Yes Yes  
Measurements and function tests 
Demi-span Yes No No No  
Weight Yes Yes Yes Yes  
Bioimpedance Yes No Yes No  
Waist-hip circumference Yes No No No  
CDR (Computerised cognitive 
assessment) 
Yes Yes Yes No  
SMMSE (Standardised mini-mental 
state examination) 
Yes No Yes Yes  
Hand-grip strength Yes Yes Yes Yes  
Chair stand test No Yes Yes No  
Timed up and go test Yes Yes Yes Yes  
7 day activity monitoring 
(accelerometer) 
No Yes Yes No  
Blood pressure Yes Yes Yes No  
Spirometry Yes Yes Yes No  
Oximetry Yes Yes Yes No  
ECG (Electrocardiogram) Yes Yes Yes No 
Phase 2 cardiac subset 
only 
Tooth count Yes No Yes No  
Cardiac echocardiogram No Yes Yes No 
Cardiac subset only in 
phase 2 or 
phase 3 
Carotid intima media thickness No Yes Yes No 
Cardiac subset only in 
phase 2 or phase 3 
Vascular resistance (sphygmocor and 
vicorder) 
No Yes Yes No 
Cardiac subset only in 
phase 2 or phase 3 
Blood assays (no bloods in phase 4) 
Creatinine, urea, electrolytes Yes Yes Yes No  
Urate Yes No No No  
Liver function test/bone panel Yes No Yes No  
Full blood cell count Yes Yes Yes No  
HbA1c Yes Yes Yes No  
Fasting glucose Yes No Yes No  
Fasting lipid profile (Cholesterol, 
Triglycerides, HDL, LDL) 
Yes No Yes No  
Apolipoproteins Yes No Yes No  
C-reactive protein (hs-CRP) Yes Yes Yes No  
Cortisol Yes No Yes No  
Thyroid function: TSH, FT4, T3 and 
ATPO 
Yes 
(rev 
T3) 
No 
Yes 
(not 
ATPO) 
  
Rheumatoid factor Yes No No No 
Cardiac subset only in 
phase 2 or phase 3 
N-terminal pro-brain natriuretic peptide 
(NT-PRO BNP) 
Yes Yes Yes No 
Cardiac subset only in 
phase 2 or phase 3 
Neuregulin 1 (NRGB-1) Yes Yes Yes No 
Cardiac subset only in 
phase 2 or phase 3 
Growth differentiation factor 15 (GDF-
15) 
Yes Yes Yes No 
Cardiac subset only in 
phase 2 or phase 3 
ST-2 Yes Yes Yes No Cardiac subset only in 
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Variables Ph1 Ph2 Ph3 Ph4 Comment 
phase 2 or phase 3 
Endoglin No Yes Yes No  
DNA damage and repair Yes Yes Yes No  
Telomere length Yes Yes Yes No  
Telomerase Yes No No No  
Isoprostanes Yes Yes Yes No  
4-colour flow cytometry analysis of 
lymphocyte subpopulations 
Yes Yes Yes No Fresh samples 
10-colour flow cytometry analysis of 
lymphocyte subpopulations 
No Yes No No Frozen samples 
LPS-stimulated cytokine (IL-6 and TNF-
alpha) production 
Yes Yes Yes No  
CMV (Cytomegalovirus) Yes Yes No No 
Measured on all 
participants in phase 2 
and those not 
measured in phase 2 
were measured in 
phase 1 
Vitamin B12 Yes No No No  
Red blood cell folate Yes No No No  
Ferritin Yes No No No  
Total homocysteine Yes No Yes No  
Vitamin B2 (EGRac) Yes No No No  
Vitamin B6 (PLP and PA) Yes No No No  
Vitamin C No Yes No Yes  
Vitamin D Yes No No No  
Mitochondrial haplotype Yes No No No  
Mitochondrial DNA sequencing Yes No No No  
Reactive oxygen production by 
mitochondria 
No No Yes No  
Genotyping Yes No No No  
GP record review (not done on phase 2) 
Diseases-ever diagnoses, pre-specified list of conditions for each category 
Cardiovascular/cerebrovascular Yes No Yes Yes  
Cancer Yes No Yes Yes  
Endocrine Yes No Yes Yes  
Eye Yes No Yes Yes  
Liver Yes No Yes Yes  
Musculoskeletal Yes No Yes Yes  
Neurological Yes No Yes Yes  
Psychiatric Yes No Yes Yes  
Respiratory Yes No Yes Yes  
Key events in last 6-12 months 
Blood pressure check (12m) Yes No Yes Yes  
Influenza vaccination (12m) Yes No Yes Yes  
Depression (12m) Yes No Yes Yes  
Infections (12m) Yes No Yes Yes  
Medication check (6 months) Yes No Yes Yes  
Prescribed medication Yes No Yes Yes  
Consultations with primary care team 
members in previous 12 months 
Yes No Yes 
Yes 
(GP/Other) 
 
Hospital admissions No No Yes No  
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F. Cognitive drug research (CDR) attention tests and outcome scores 
CDR Task Description Outcome Variables 
Simple reaction time 
The participant is instructed to press “YES” as quickly as possible every time the word “YES” is 
presented on the screen. In total, 30 “YES” stimuli are presented with varying inter-stimulus 
interval. 
Mean reaction time (milliseconds, ms) 
Choice reaction time 
Either the word “YES” or “NO” is presented on the screen and the participant is instructed to 
press the corresponding button as quickly as possible. There are 30 trials for each stimulus 
word, which is chosen randomly with equal probability, with varying inter-stimulus interval. 
Mean reaction time (milliseconds, ms) 
Choice reaction time accuracy (# errors) 
Digit vigilance task 
A target digit is randomly selected and constantly displayed to the right of the screen. A series 
of digits (0-9) are presented in the centre of the screen at the rate of 150 per minute. The 
participant is required to press the “YES” button as quickly as possible every time the digit in 
the series matches the target digit. There are 300 digits in the series and the task lasts for 2 
minutes. 
Mean reaction time (milliseconds, ms)  
Targets Detected (%) 
Number of false alarms (# errors) 
Power of attention 
A composite score calculated by summing simple reaction time (SRT), choice reaction time 
(CRT) and digit vigilance task (DVT) mean reaction times (ms). Lower scores represent better 
performance. 
 
Intensity of concentration (milliseconds, ms) 
Continuity of attention 
A composite score calculated by combining the accuracy scores from the CDR and DVT (CRT 
accurate responses*0.30 + DVT accurate responses*0.30 –DVT false alarms). Higher scores 
represent better performance.    
Ability to sustain attention (milliseconds, ms) 
Reaction time variability 
A composite score calculated by summing up the coefficients of variance from SRT, CRT and 
DVT mean reaction times. Lower scores represent better performance. 
 
Fluctuation in attention and consistency in responding to 
correct target stimuli (coefficient of variance) 
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G. Conferences and workshops attended 
Conference/ Training Theme/ Notes Start Date Days Location 
Year 1 
Safety Course NA 05 May 2014 1 Newcastle, UK 
Induction for 1st Year PGRs NA 08 May 2014 1 Newcastle, UK 
Writing your PhD project 
proposal 
NA 12 May 2014 1 Newcastle, UK 
Design of Experiment Statistics NA 19 May 2014 1 Newcastle, UK 
AFRD PGR Conference 2014 Miscellaneous 21 May 2014 2 Newcastle, UK 
MRes. Module Clinical 
Epidemiology 
Until 08 January 
2015 
02 October 2014 16 Newcastle, UK 
HNRC 20th Anniversary Research 
Day 
Nutrition/ Poster 15 October 2014 1 Newcastle, UK 
Northeast Post-Graduate 
Conference 2014 
Biomedical Sciences 31 October 2014 1 Newcastle, UK 
Advanced Medline Workshop NA 10 November 2014 1 Newcastle, UK 
Basic Stats Workshop NA 19 November 2014 1 Newcastle, UK 
SPSS Beginners Workshop NA 21 November 2014 1 Newcastle, UK 
SPSS Advanced Workshop NA 27 November 2014 1 Newcastle, UK 
PGR Who Teach Workshop Na 29 January 2015 1 Newcastle, UK 
NUIA PGR Day 
Miscellaneous/ 
Poster 
10 March 2015 1 Newcastle, UK 
Steam A Multi-Variate 
Techniques Workshop 
NA 14 April 2015 4 Newcastle, UK 
Year 2 
AFRD PGR Conference 2015 
Miscellaneous/ 
Poster 
21 May 2015 2 Newcastle, UK 
Nutrition Society Irish Section 
Meeting 
Nutrition in the 
critical stages of the 
life cycle/ 2xPoster 
17 June 2015 3 Cork, Ireland 
Data Handling and Spreadsheet 
Skills Workshop 
NA 18 June 2015 1 Newcastle, UK 
Nutrition Society Summer 
Meeting 
The future of 
animal products in 
the diet: health and 
environmental 
concerns/ Poster 
15 July 2015 3 Nottingham, UK 
Phlebotomy Course NA 25 September 2015 1 Newcastle, UK 
Northeast Postgraduate 
Conference 10th Anniversary 
Biomedical 
Sciences/ Talk 
12 October 2015 1 Newcastle, UK 
12th FENS Conference 
Nutrition and 
health throughout 
the life-cycle/ 
Poster 
20 October 2015 4 Berlin, Germany 
HNRC Research Day 2015 
Nutrition/ 2xPoster 
+ Talk 
28 October 2015 1 Newcastle, UK 
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Conference/ Training Theme/ Notes Start Date Days Location 
Transition to Post-Doc Workshop NA 30 November 2015 1 Newcastle, UK 
Practical Statistics I 
(Incorporating Introduction to R) 
Workshop 
NA 16 December 2015 2 Newcastle, UK 
Year 3 
Analysis of Longitudinal Datasets NA 21 April 2016 1 Newcastle, UK 
MIA Summer School Biology of Ageing 25 April 2016 5 Algor, Portugal 
AFRD postgraduate 2016 
The Future of Food/ 
Talk 
23 May 2016 2 Newcastle, UK 
Practical Statistics II NA 02 June 2016 1 Newcastle, UK 
Practical Statistics III NA 26 June 2016 2 Newcastle, UK 
Nutrition Society Summer 
Meeting 2016 
New technology in 
nutrition research 
and practice/ 
Poster 
11 July 2016 4 Dublin, Ireland 
MRes. Module Comparative 
Cognition 
Until 20 December 
2016 
04 October 2016 12 Newcastle, UK 
HNRC Research Day 2016 Nutrition/ Poster 28 October 2016 1 Newcastle, UK 
FQH meeting Talk 30 November 2016 1 Newcastle, UK 
ARUK 2017 Alzheimer/ Poster 14 March 2017 2 Aberdeen, UK 
Rank Prize Funds Symposium 
Role of wheat in 
diet/ Talk 
24 April 2017 4 Lake District, UK 
XVI Congresso de Nutrição e 
Alimentação 
Food sustainability/ 
Talk 
4 May 2017 2 Lisbon, Portugal 
ICHOCM 2017 
1-C metabolism/ 
Poster 
14 May 2017 5 Aarhus, Denmark 
VIU Summer Institute on Ageing Global ageing 5 June 2017 6 Venice, Italy 
PROMISS consortium meeting 
Protein intake and 
ageing 
19 September 2017 2 Nice, France 
EUGMS Gerontology/ Talk 20 September 2017 3 Nice, France 
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H. Initial PhD gantt chart 
 
